pne
▁chemicals
▁perceived
▁48
oves
▁antigen
▁retrospective
-90
-49%.
42;
▁35-66)
85.
▁transects
Mentax
▁Cycl
CUS
▁dipyrid
▁ultr
aig
haz
▁symptomatic
▁macrosomia
oretically
▁constipated
oim
▁failures
▁orally
6-1.88;
Fren
▁enoxaparin
▁crust
Gastrointestinal
▁0.3%
▁overt
▁>40),
ventional
ercep
▁resc
▁peritoneal
▁junction
▁reac
▁optimally
▁proportions
▁underac
▁Delay
▁0.10-0.2
duce
16-1.7;
ticed
▁lansoprazole
reports
59
Las
=96,1
▁minorities
opoplite
atog
▁skinf
▁(123
▁methadone
accin
NNT
▁1.95
menorrhea
▁femoral
▁206
9.12),
tinguished
▁Vals
31,
unable
itid
tiri
inin
itiat
▁pulses
troduc
7-1.9
▁Combination
▁hypogly
earing
▁immune
▁86
▁estrogens
▁cremasteric
olpid
amph
▁ala
uppressed
TN
stead
ophysical
▁defib
Gin
ropsych
▁exud
▁tuberculosis
▁breakf
lafax
▁reflu
ucon
requent
rve
▁dogmatic
2-4
▁1.1-2.7
▁46,80
rofession
▁Fifty
▁cip
▁obstetrical
verification
tro
▁lumen
arials
▁substern
skin
esartan
roglitazone
atastrophic
eroid
lycer
.0-3.
revi
▁699
inut
-3.0)
▁grise
▁underwent
▁Limitations
-0.8])
▁Neosp
ributing
▁-5
ths
ndi
▁63-9
trimoxazole
▁smear
▁0.70
▁5.0-15.
▁6-
▁methylphenidate
3-1.00
avage
▁bioavail
▁0.23-0.66;
orrhage
equate
kf
=1.02;
eic
elstic
ticos
gestive
▁nondepressed
▁naprox
▁(38
▁1.5-4.
enures
2.4%
▁postmortem
▁395
eroids
tiont
▁Streptococcus
afl
IgA
>.0
Vio
▁Respiratory
▁40,233
=1.30,
613),
▁(28
25%.
▁Moreo
▁chlorprom
sustained
▁Dent
edocrom
▁Cumulative
8/
▁endotr
▁echocard
▁biopsych
▁3280
iaz
▁capitis
▁counseled
ruciating
ercise
▁aura
dur
▁primip
>1
fenofibrate
gatives
henid
]=2.85,
obal
BP
▁bilob
muniz
hage
▁5.3
▁simplifying
13%
lz
▁pregnanc
▁fetus
ermomet
▁dietician
Tilade
odilators
▁0.06-0.2
iazolidined
inion
▁aneurysms
reastf
▁enlarge
niver
▁cholesteatoma
▁oxymetazoline
oox
orta
<.005
ocyt
lactic
▁supravent
▁pleural
=3.
▁88%-95%).
▁IgG
▁(85.
icella
▁Individ
▁(111
Cardura
▁-0.45)
▁20-5
embran
▁hyperlipid
wth
iatic
▁1.1
▁ina
alations
COP
cery
▁Danes
assro
]=0.43;
▁ambulating
▁dran
▁antiemetics
▁regularity
▁occlusive
▁metf
raconazole
▁0.5-7.0
▁Physicians
tinoin
▁candidiasis
▁1993-19
▁Certain
▁Lach
▁99%).
715)
▁Lachman
▁gabapentin
▁Pertussis
tments
onias
oughing
▁92.
▁suburban
2-8.
▁permanently
apamide
theroscl
Bet
▁cosmetic
asu
▁1.4-1.
▁erythromycin
▁esters
▁implications
onsillar
▁1987
▁Walsh
▁0.43-1.00
-5.7).
igox
icam
▁hypercalci
Trimo
ectro
▁misadventure
leeding
▁28.
Ly
▁montgom
alapril
▁(100
ightness
▁3.3-6.
Dop
itioning
Pap
6.5
umura
▁0.2-0.8).
▁unreliable
▁airway
-2.92)
▁hypomanic
▁Blinding
▁esterase
▁nebivol
▁antiarr
▁59%-7
▁3.2,
▁metastases
▁anov
eview
sched
oclavic
orab
cerin
pore
lorh
▁79%
opaus
▁clinici
patients
Fet
▁0.026
3-1.6
▁noncancer
ransi
▁57%
▁whi
amel
ses
eration
▁Grooved
05).
forming
erichia
▁(251/36
▁quas
▁Tiotrop
econg
▁endar
requ
▁50,
▁needle
▁strongest
tharidin
6.6%,
▁dum
oprost
ddition
00-1.
ficial
ocerv
dummy
ller
orticoster
olat
taw
ototherapy
structions
▁stok
ganic
=18.
▁outpatients
▁identi
itored
▁fric
▁noncompl
▁progestog
olic
onin
effec
▁questioned
▁(14/369)
aiwanese
]=8
esthes
▁sleepiness
▁scl
▁osmotic
>0.
yretic
70%
▁delirium
▁Targets
▁67%
ractionated
▁164
▁judged
▁oto
▁eaters
43;
alan
17%
▁2.5%
▁Clof
utu
5.8%
olve
rogenism
▁1%
▁50-7
▁Testing
omile
ognized
▁povid
Nep
0,8
Ni
▁electrocard
▁0.87-0.93)
epatic
▁CN
▁inves
GADAb
MARD
=0.73;
1%-8
drox
▁posi
orotic
bout
▁93%.
actab
▁55-
▁coughing
42
-0.84),
5/10
oncent
olidined
kers
fid
esth
cturnal
apil
pai
▁rupt
▁squamous
▁nodul
▁triamcin
▁resuscitated
▁(5/
xat
immune
chosocial
ofibrate
Neosporin
▁-1.21
ALTS
antibody
▁plasmin
▁lesion
6,064
hasized
unblind
repres
tack
orre
omati
)-6
▁66-70).
Ris
▁nonm
aniti
asone
hever
hyllin
mur
▁(33
enefit
-2.95
▁ALTS
▁loosened
2.2).
tinomyc
itching
▁coinf
ypro
▁monotherapy
stay
▁modality
▁conceive
roent
ruc
▁tympanoscl
▁thri
▁1.06-1.44),
ecdot
tingu
idates
▁Cum
▁concep
▁tolerated
severe
▁8385
▁dors
umetan
abial
▁indica
urmurs
▁responded
▁(8.
▁admis
16%
clusive
angh
▁98%,
▁secretag
ucation
▁spi
binate
▁licorice
▁0.12-0.9
▁22;
▁prophylaxes
ophlebitis
▁600
romil
ixture
-1.44
▁hexa
33,
baseline
62)
▁heterophile
▁reass
actam
yroidec
onm
▁1.04-3.
=96
enati
▁Clinical
Eff
2-2.22
opar
anoth
dos
▁EI
5.8).
▁hypocalcemic
▁perin
orable
arati
rawal
▁1969
laxant
▁BM
icit
▁hemoglob
▁1977;
▁(1.58-5.
▁solu
itant
ogly
23.
36;
▁thrombocyt
▁placebo
tus
Arthro
▁bilateral
▁0.4%
ulat
▁allerg
buminuria
50.
▁baseline
amily
eptics
▁240.
▁5.5,
▁chamomile
▁0.7-0.
Vag
dwe
Mun
alized
hydroergotamine
▁0.61
7-0.9
▁nervous
▁1.09-1.57;
▁Hyst
irri
▁parity
sy
iopexy
otherapeu
lexx
▁(1).
-2.36;
=.005)
orvas
ansoprazole
▁carcinomatosis
artments
abum
iard
CAB
▁moderate
=480).
derivation
awback
▁bronchospasm
asians
asberg
lavul
=1.7
achexia
ocell
rj
▁biv
▁frac
culia
▁pharyn
eigh
nific
▁inp
eterog
2-10.
▁adip
reatening
ecreas
▁deliri
▁percenti
-1.3
tivity
oldi
pberry
gnosis
.09
▁(97%
3-0.4
▁adjus
▁40,
58).
=25)
▁<35
▁saphenof
ystos
posable
▁24.7
79
ulgar
▁Anticholinergic
tandard
▁0.66-0.9
▁Tonglul
▁26.5
promot
4-
onl
=3.0
=.0
▁1.0
GERD
etics
▁pseudoephedrine
enou
▁cardiac
▁107
bap
=100
3/
33.67,
panolamine
ronou
Vas
plor
adenomas
definitely
▁Mesalamine
▁cereb
Prinivil
8-20.
often
▁Pun
▁Aj
▁intoler
▁blad
▁3.79
▁calcit
▁unnec
ticosteroids
otype
ginate
▁clotrim
aem
,6
▁unfraction
usitis
▁40-
▁0.17-0.
adly
-4.9]),
early
reater
rimarily
5.4%
▁14.4%
=0.26;
▁0.93.15
▁Comparison
termen
▁circumference
▁withdre
▁Prot
=9443).
▁28),
resumed
81.
▁924
perinatal
▁0.93.
=1.80
2.5%)
▁thickener
▁lowmol
],0.
08)
nter
umc
▁20,000
methacin
▁Acad
▁0.93-1.
encap
bdom
44,8
▁allergy
gomery
=18.8;
▁histologic
▁causal
ferase
▁(31%)
▁-1.2
▁>32,
▁105
▁4.8
=136),
▁outlin
▁pneumococcal
78)
▁interle
▁nifedipine
▁Ultras
-0.96)
tilation
▁gland
▁palp
lawed
adrin
Mental
ovaginal
aminers
-]
lebographic
▁prostatectomy
ibro
fere
▁8.2
endence
▁(70%
74),
merg
edline
urred
▁gluc
=-0.
=10.44;
-5.34;
▁deform
▁-0.5
▁continuing
▁abnormal
▁100,
oliz
tivariate
▁glycop
reat
▁(80%;
50%),
▁crus
▁bandages
▁unscheduled
▁Benzodiazepines
okinetic
rops
▁77%,
▁(25.5
metic
upu
▁tazarotene
tified
▁80-8
▁Abnormal
3.8
lerate
uros
▁infusions
▁atenolol
▁equivalents
▁3.5%
▁succinyl
ugent
arterectomy
▁trigly
acrol
cutaneous
esearch
nivers
▁0.63-1.0
onorrh
▁transcerv
renia
▁0.26%
00-2.8)
6.4).
illary
▁saphenofemoral
8,75
estog
angl
▁dizz
9.96,
10-0.2
ounger
▁weekend
4.9%
puscular
▁14%.
omox
=93.
78,
32,
▁diffic
▁nonsurgical
▁phar
othes
9).
issi
ration
-0.5)
▁Lif
acut
>7
▁embryop
▁0.6-1.92;
3-0.2
▁nondrug
95%;
▁toxic
▁immunotherapy
▁24,
ressively
enit
▁neuroim
onidine
▁thromb
tum
▁8.3-
37.2
▁0.81-1.0
ictims
=0.68;
years
tracorp
-0.1;
▁oi
▁Exacerbation
.00
-2.3).
▁19,
▁Increased
▁0.30-63).
▁withdrawn
cessib
alys
aO
ranulomas
▁doxazosin
aturia
▁Complication
▁arteriosus
▁Incis
▁28%
iprat
▁37%-8
wif
▁postpartum
SMD
▁fluor
ardio
=.0004;
amou
▁therapy
esat
utp
roven
▁clinics
▁CFC
abases
profound
omac
▁diastolic
▁1.02
0.8
▁hydrocortisone
uscle
▁Dys
fine
▁Obstetr
opor
▁intranasal
▁2.9-
ticular
52;
leeping
veni
ulum
▁7%,
tiolog
▁Neospor
edr
4.8%
▁ibuprof
ogre
eom
▁hypothe
▁myalgias
oninergic
▁1.6%
umbersome
ytim
▁Premature
boov
▁>90%,
ticoids
▁-0.28
=1.94;
erion
▁Impro
▁1.09
tenance
Derm
=.929),
▁hypotonic
▁PROSPER
▁8.8%
▁diverticulitis
▁hypoglycemia
2-6.
iog
obl
normalities
mental
VISA
.6
▁2.9%
invasive
=16;
▁mell
dentif
,000/
▁(500-1000
FSH
▁<140
.5%
ftin
ortript
▁chloramp
▁neom
eclamptic
]=-2
sychopharmac
▁prophylac
cuff
▁5010
▁48-
▁3.6,
▁reser
▁breaths
iati
thop
▁eradic
emis
ronounced
▁insur
henytoin
▁pregest
▁oss
terography
treated
▁ambul
Dur
ensuring
0%-7
Amerge
▁weighed
▁excluding
ubitus
▁pathologic
iewed
TexCAPS
▁syncope
▁symptom
=731)
egree
gid
18),
erver
▁>140
▁glimepiride
▁1.08-1.29).
▁bilat
othp
aminases
▁lea
8,24
-54%
▁(3.
▁candy
iniz
teroids
DVT
edim
▁1.8-191).
▁(<15
▁<15%
▁agonists
-2.6
▁Hos
rG
jority
▁2007
▁VVC
▁DMAR
87),
▁hydroch
=2.7,
ticul
▁8/1000
2]=5
ensity
omyc
priate
▁(78%
▁Recall
oC
ulvin
vasiven
▁9/
▁menses
hran
-23).
eterogene
andat
▁1%-
1.7
enoc
▁alginate
vented
]=50
▁questionnai
▁ascorb
▁Wadd
▁CGIC
endoscop
testion
ficing
▁histam
specialty
angement
ewhere
▁methad
▁surrog
8-0.
▁(2.9%
6%),
88).
▁ranitidine
upri
37.
▁Twelve
57).
▁avul
▁idiopathic
▁omeg
▁160
onable
ubin
▁nitroglycer
5.3).
4-1.51).
31)
▁(84%
eteran
▁relapse
▁solely
-45.
geons
▁Reoper
Ric
▁(95%
impro
▁gonadotroph
▁lipid
gain
follicle
likowske
aggerated
▁Enures
teers
▁alar
▁1.2-
8);
▁Sulfasalazine
omorb
▁4.91-13
ulants
▁(55.
structive
-1.28;
efle
ociated
▁dex
comit
genase
▁vulv
ulan
epten
ocom
Low
▁ingred
usive
▁measurable
▁multiorgan
▁Ghan
cises
llent
leas
holinergics
▁uterine
=.259).
idem
henic
Cu
orns
sis
mpicil
=5144)
vac
romy
otas
ervatively
▁1.58
▁curricul
7.2%,
▁introducing
ergics
▁emph
▁postco
sac
lorprom
▁abstracts
▁17.7
oporotic
-0.43;
▁tic
▁<3.0
traum
rectly
,427
▁tantrum
▁hepatore
ifornia
hri
▁chlorthalidone
▁47
▁(10),
sient
ixteen
lipidemic
▁100%.
uervain
nee
▁hematologic
corb
▁terfenadine
▁intracerebral
▁seve
zop
ruptly
▁(10.
50-0.7
▁resection
▁elliptical
▁64
▁nonexperimental
elod
▁Statistically
▁esoph
ytoin
aleplon
ynec
isox
ainment
RP
ropyridine
▁Chlamydophila
Nor
▁subcutaneous
▁sulfonyl
edent
9-
oag
hydramine
1-137.26).
▁antimicrob
<.01,
▁diat
Vitamin
sform
ucos
▁Fibrillation
▁defiant
▁2633
tilizing
nds
▁pts
omery
8]
enoh
▁0.016-1.7;
nogr
▁postin
-18.5).
SCU
▁0.4
▁78%),
▁costeffec
▁0.40-0.97;
▁Across
▁iat
▁MCV
▁salbut
erif
=5.78).
▁phenomenon
contin
icab
▁microor
carbo
otherapy
orts
▁sne
anine
ulid
▁1.47
ppos
▁12.4%;
▁adne
41).
etor
acqu
-6.5
picil
▁1.17-1.6
▁1.02-1.2
56
▁0.21).
▁extensor
odified
=944
energ
▁Iberog
agus
3,
=605)
▁0.94-1.69)
▁steroids
▁45.7%)
▁fremitus
asily
usor
▁31,
0.9%,
▁Topical
matory
-2.8)
ofenac
chond
pretation
Compazine
ommended
(6
cad
600
thys
▁dosag
▁0.2%
vestigation
▁immunosorbent
trained
▁encom
▁Indonesian
linked
inant
▁homocysteine
▁MMS
▁12,
-1.7;
EIB
tates
tussis
▁regulate
oose
=0.85;
▁88
arboxylase
lafond
=29)
▁79.6
▁orgasm
▁circumf
xpec
▁4.91-137.2
erally
▁2.21
▁48.
▁psychosis
Trim
-15.8)
ectomies
GD
ledgeable
▁clop
tox
▁demands
▁30%;
▁>5
▁1.08
▁308,
▁teratogenicity
▁2.0-3.5).
▁tig
neph
coun
54
roglycer
▁Drawer
ertussis
oxaz
▁chorion
▁0.36-1
▁unrelated
▁premenstrual
59)
▁Neph
▁purul
radi
▁conceal
▁(50%)
echn
trum
lexa
viewer
3)
=33%
vit
▁118
vage
▁treadm
temperature
orbid
swe
▁antihyper
▁Candid
▁Hypocal
vasc
-1.30).
▁89%,
8,297
▁dereg
dell
izophren
▁thyroidectomy
idit
xaz
gular
4.5).
▁thermomet
erably
▁anticholinergic
izophrenia
▁termination
▁endocervical
▁lozen
▁PCO
cerated
▁ineffec
henazone
▁thos
4-0.53;
1-0.77;
▁Fink
troin
▁TPOAb
ildenafil
inite
▁aids
▁SG
▁withd
▁superficial
ervised
atency
▁noncon
gory
ethas
nop
Nut
lampsia
▁quantif
▁bucind
feren
▁Postmarket
venou
vastine
▁0.4-1.0
stern
alities
3.0%
▁2.61-2
12-2.
4%-91%).
exidine
130
horts
abo
▁carbo
otoxicity
▁unl
▁CHD
-57.6).
ipop
weren
oos
sor
omagnesemia
<1.
urit
ezetim
▁physici
▁20%
2).1
emotherapy
▁200,
inase
▁colposcop
=12,60
▁(10/12
▁48-2
▁copper
367;
idec
asan
▁glyburide
esicl
▁Trog
100.
xamin
▁nuts
▁Thirty
▁doses
▁deoxy
inatus
▁15.2%
olones
enyl
onergic
86.
▁regimen
9-1.
▁3.54
▁64.
110
▁9/100,000
▁sulfam
▁inaccurac
3.1
▁Sexual
alanc
enro
-0.20).
▁isometheptene
hange
88;
trog
ainen
▁Magne
atremia
-31).
asou
oric
iotrop
=.52).
▁neurotrans
troduction
-21.
uven
▁hypertro
dosing
tine
Cyl
esq
meas
▁Gaviscon
▁lowmolec
=27
▁metop
▁285
▁descriptive
▁RENAAL
monitoring
▁gynecologists
▁slows
▁Ischa
▁Commit
Wen
▁intraepithelial
▁colorectal
▁sulb
Wou
▁7.7
▁nonresponders
pharyn
torchid
▁POC
▁<25
Mel
443).
tervi
ripip
]=3.5).
▁plaques
▁1.16-7.0).
=92%
▁mup
emoline
▁Lactobacill
▁48%
▁danazol
othyroxine
otland
▁231
▁12.5%
▁0.04-0.6
▁0.24-0.99).
▁rehab
▁abnormality
▁styloid
▁262
omethep
▁Headache
-4.4
▁immunoc
▁0.93-1.6
agitis
oidec
andinavi
leu
entific
ystoscopy
▁0.21-0.4
▁allergens
060
▁pentox
▁adrenal
vestig
▁examin
ialty
▁nephropathy
▁glycos
thall
▁Surgery
83;
▁80,
66-10.67)
-26.97).
=.042
▁hypert
CABG
5%-9
quite
▁20-4
=7.4%
onb
esare
Eac
3.6%
▁screened
▁Biop
▁yeast
entoxify
ognitive
erately
▁>27.3
iscon
▁(18.9%)
LG
eroph
▁annually
paro
alve
alaz
▁approx
54%
▁neutropenia
▁ticl
▁flaw
Sig
▁SGR
onstrates
▁emes
▁356,222
=3]).
.14).
]=4).
443
omplete
▁vulvovaginal
97-0.97)
=97%),
16),
reener
74).
428)
▁187
▁syncop
▁283
6-1.8
▁1.35-7.41;
▁calcified
▁myoma
0.0
ewly
omagnes
nts
▁hypertri
▁successive
▁Helsink
usu
-3.8
▁mite
kwhe
olut
obacilli
oriation
▁35
▁adherence
▁probe
]=5)..
▁reflecting
▁(8-12
▁withdrawals
▁enzymes
▁0.36-0.70).
▁postnasal
=20
ramadol
gestin
▁(383
▁-2.78).
▁budesonide
3-1.9
=2.0-3
esign
utional
akenings
▁adolescents
iminary
▁compartments
▁recommending
metab
▁4.2%
-191).
tracep
hether
▁heel
0;
iparo
0)
unw
12-4.
alat
arly
▁Gyn
gion
▁topically
▁cardi
eurysms
-1.07).
otonsill
guably
▁(>14
-9.
▁76%,
▁bacteri
4-0.86).
scopy
▁provoke
/2
otine
5%-
ultic
esom
▁(35%-5
3.0%).
ignant
▁phle
▁neurogen
oconstrictive
ulvovaginal
Wo
▁prevention
▁erythematosus
onale
▁(60%-7
▁pharmacokine
▁hydroly
COMM
▁1.05-1.6
▁-0.03).
ohort
=62%
▁metoclopram
▁Investigators
▁intrau
stimulating
=.004)
Given
▁ea
roxyz
▁cardio
▁33%,
-2).
aynaud
chotherapy
oncl
ophen
anoma
lycop
atropium
▁Estimates
inkers
15;
=-6.59
acis
oros
▁endobronch
resented
ypass
▁quinolones
▁antis
▁choles
▁throu
▁0.28-0.60).
(>
atisfaction
▁readiness
▁cremaster
▁McIss
bation
crease
▁46
ospitalization
cardiogram
▁24,52
=.94),
▁1000,
▁unspec
icyclic
yroidis
▁0.27)
lavulan
▁assis
▁Lojander
▁athl
▁instruc
▁0.2-2.
▁kep
▁(89
OPS
roate
▁(151
▁0.61-0.75;
▁8.0
paction
terq
tiv
▁enlarged
▁(83%);
▁(>9500/
▁0.38/0.81,
osu
▁airflow
otiv
essarily
▁bromoc
ucralfate
▁Metformin
arrhy
glyceridemic
oxif
▁admission
ircum
▁counterirrit
▁onetime
yotherapy
379;
0.5%
▁rabeprazole
6.89
▁3.7%
-57).
butamol
▁5.5).
▁Aspir
<3.
ousre
igorous
▁uncontrolled
lH
▁interm
8)
=6.6%;
▁detrus
utic
▁0.29
▁0.21-0.43;
uidel
▁16.1%
rowing
93%
▁1.08-1.2
=75)
▁metr
molar
40-2.09);
▁counseling
80;
alves
ergy
▁472
▁ques
▁unresponsive
convulsive
=1.32;
tract
niotic
2.6;
▁ppm
=23),
klist
erican
feedback
▁2.25)
▁unmed
usually
racla
▁0.08-1.34).
▁characteriz
zulf
▁Protection
hydro
=.0055)
edti
ospor
▁increas
confir
▁2758
alce
etical
▁2.06
▁63%,
utab
▁uncontro
edema
▁fluoroquin
▁11,
oglit
▁differentiate
▁workplace
essi
romi
▁negatives
ifesty
2-1.0
prehensive
acto
tutes
lamp
▁Arter
▁Measure
▁1.4%.
-1.12
▁corticoster
▁95%.
▁(1/
lour
estants
fficiently
vigor
▁6.5%,
odol
9);
yphen
arnett
▁0.65-1.02).1
mograp
▁nitrof
▁nondiab
▁sulfasalazine
-5.3
53;
▁radiculopathy
▁monoth
▁192,478
ilad
,448
=0.5%)
▁resis
ospices
inizing
▁expensi
45.
▁35.
▁rhinovir
ynd
▁47%-4
hydration
▁lact
epakote
▁45.
▁McMurray
interm
▁6-36
2-2.22),
urgical
▁operative
▁hypertensive
▁(466
▁oxyc
▁0.21
75;
72-41.8)
▁spiromet
ocla
oec
▁>190
▁psychoph
▁uv
gestimate
▁metic
▁raspberry
ticholinergic
4.8%)
▁exposure
▁washout
▁scarring
.1
coital
▁enhances
▁cellulitis
▁89)
▁postnat
7-1.0
▁>27.
=0.26
-20.70
rowth
gestion
▁confirms
▁anticon
▁endem
muniti
▁obstetricians
onber
▁1.3
▁nonas
▁neuroc
▁Aler
avir
inafine
▁0.24-1.5
hyster
ypne
▁(1672
thar
exercis
arti
zod
▁satisfactor
▁insulin
osocial
▁0.17-0.9
▁glucocorticoid
▁meperidine
acervical
hyroid
ratic
idated
erog
▁1.12-1.8
▁1022
tropl
=27.
pasmodic
versity
▁1.05-1.2
▁triad
risk
▁(86%
-0.97
67.
ilmed
▁92.5%
ibri
minute
oterol
▁Successful
▁hypers
▁0.34-0.73)
▁endocrinology
▁rigor
ypoth
▁dysuria
▁disti
relaxation
▁sprinkles
.03
dly
avoid
=80
Breas
otec
▁PEFR
▁prostatitis
=1.11;
=2.16;
▁1985
nable
riene
▁0.63-1.07).
urth
▁thrombophleb
▁suspen
▁adjustments
▁rheumatoid
athy
opidogrel
ospitalized
▁Spl
▁arthroscopy
kly
ioedema
-5.4)
isil
▁alp
▁Bacterial
propan
▁donors
2.4)
chl
ytolog
epar
agnetic
foll
40.
xual
ulsi
acious
ctional
orvastatin
▁-50.89
▁orlist
syll
mpac
accination
athere
cetate
acell
▁coli
▁0.84-0.97).
▁0.22-0.88)
▁radionuclide
espite
▁antiseiz
▁92%
reening
ocolitis
vastatin
▁exten
2,0
adings
dati
bou
▁providers
▁(-0.23%
▁157
52).
ffectiveness
ttor
resen
▁(4.8%)
vered
=141
-45
adual
Fur
metazoline
▁0.36
iphasic
afet
unded
▁82.6
▁27.6%
▁hyponatremia
▁Ghana
▁subse
▁echocardiogram
tinue
LNG
paration
▁disimp
otor
linician
rgan
▁0.34-0.5
iopathic
sents
▁drank
ignific
atisfied
2000
▁pancreatic
▁19
▁glomerulopathy
▁affects
orkp
.0-3
teinuri
assic
sop
▁warf
aucasian
▁-0.01).
▁ventricular
9)
quate
tropen
▁amn
▁concuss
▁regurgitation
ecess
fficiency
comfort
▁Depend
▁infection
15
▁Compl
acerb
=5.67;
▁angiotensin
blood
-0.71).
▁noncep
▁Indo
siu
▁0.58-0.71).
erned
ystat
oic
breaks
tients
resection
▁1.33
(5
▁MCI
▁microenc
▁ptsd
).4
imms
▁strang
tie
▁LRs
▁interp
ifylline
▁<105
-26.
▁capsa
▁nebulizer
=1.4;
▁recove
reatest
22;
▁>38.
▁concentrate
ellet
▁Asthm
▁quantified
4-0.20).
▁caloric
▁methyldopa
▁nys
=.26
xid
tentionto
acturing
▁RRR
87.
tamin
▁anticonvuls
▁phototherapy
aicin
▁CRP
▁sequentially
mitted
rine
▁recommendations
]=0.9
lafaxine
cere
2-0.
calcified
plored
sules
▁ADA
iazine
▁hyperbil
ocuses
▁(74%-93%
cisely
=33
Lon
-17)
▁etre
▁unplanned
▁pyr
▁Levels
racin
350
gnanc
elogram
▁intrauter
istop
mpair
▁immunofl
▁hyperplasia
▁0.7;
ymptomati
▁transcri
60%
nders
▁DCA
▁crut
nv
▁24.3
=2.26
▁attendant
▁anhy
farin
▁hund
▁concur
enac
epla
ypn
▁intracranial
▁aminotransfer
▁amit
▁relie
▁Wors
ostc
-95%
ilif
-11.
Vioxx
procedure
▁71%-86%).
adia
mild
AFA
ingococ
▁200-400
▁itrac
▁Significant
elsink
ventil
▁citing
▁pectin
▁nigricans
umbos
4060
istar
choth
irub
▁encouraging
artere
asian
▁treatab
Wa
▁membran
teran
erated
▁epstein
▁urgent
▁forceful
▁malignan
▁repor
▁coen
7%)
▁outpatient
▁0.38-1.33).
▁448
66-10.6
sate
utr
▁appointments
orc
▁researchers
otension
▁dosing
heterogeneity
▁endotrach
▁tast
dil
DLI
▁griseofulvin
Abilify
lipidemia
5-0.79)
▁(278
▁nortriptyline
=78%;
▁3.3,
roiditi
pici
▁1989
▁postdi
hicle
elati
▁71%
322
▁lactulose
completely
▁Benef
▁cryptor
▁0.14-0.
ocomp
rorrh
1.8%
ventions
▁parac
▁antip
ranul
▁2002).
osely
pation
tity
▁curretage
onsensus
▁diverticulosis
▁blac
bating
lyam
romyc
▁4;
rosy
alb
vou
-0.29).
▁enrolled
▁elderly
▁0.03%
positories
▁methodologies
eutic
▁grading
abumet
tivator
▁Graphical
0-50
▁enlarg
glucomannan
▁syndrome
enhy
inging
oxy
▁fluoridation
omipramine
chlorothiazide
▁Inh
▁7.8
ranial
inalysis
▁infec
highest
imentation
-3.65;
PCR
▁decreas
▁Caucasian
▁thrus
▁remis
▁0.2
ophor
▁doxy
ACI
▁perioperative
olus
▁epidid
raspin
ximum
7%).
▁depres
▁cesarean
cholesterol
efazodone
prothrombin
Demer
▁1.63-4.56),
▁gonadotropin
tology
ashing
5-7.
yler
▁perihepatitis
ialists
▁urog
98).
▁antibodies
vations
enyang
=.36).
ithou
▁gestational
ophageal
▁considerably
▁Ajoene
▁comorbidity
▁pyridox
▁insol
▁ottor
▁SCS
=83%
▁therap
ifferen
▁casted
Rou
▁ank
▁56%
oml
▁infecti
idism
5%-50%)
▁careg
eroc
bly
ighing
▁ventil
ycological
4.5
4.4%
▁contribut
tosis
ffected
]=1.37;
kner
▁86.
possi
▁1.07-2.
ifteen
duci
▁pyridoxine
3;
▁1.15-3.
62
exCAPS
▁venous
▁antiseptics
itiated
ffers
PV
▁bronchodilators
▁(94%
▁>1.
▁Improvement
crip
acitrac
▁hemoglobin
79,
752
▁71%-86%
entering
▁diazepam
112
Less
enid
▁untr
04;
▁merit
4.8
Pant
▁gum
resistant
▁PPIs
▁2.1-3.7).
iscip
arket
osocom
▁epste
▁equi
▁1.4-
ulfameth
coprotein
>4
eep
uspec
urely
▁3.1-10
▁secreto
antoprazole
▁2.8-10.9).
▁infected
▁mild
3.7
opram
7%,
▁posed
▁glomer
▁workup
▁amoxicillin
▁rehydr
▁crucial
▁hepatorenal
▁chlorp
hydrated
▁postdiagnosis
646
824
centr
bute
racyc
▁27.5%
▁pemoline
▁Hyster
▁uncomfortable
itrus
▁2.4-1
amaz
003
▁ADAS
▁sildenafil
▁oxym
holics
ingd
ulfill
piration
▁unpl
racon
▁Tes
thir
▁macrosom
zith
▁gastrointestion
itri
▁5.11-21.23).
wife
▁genital
▁nonex
ulair
-3%
▁8.2-2
▁85
▁64.6,
▁coinfection
erbating
prevalence
ecreased
▁2.10-3.7
kets
▁>70
▁sulfate
GI
▁3.9-10.
identi
00=
reates
▁77-97),
▁erad
0.9)
▁asthma
inusitis
otrin
▁massage
quartile
.007
Women
48)
▁titration
3-1.40).
▁poten
>2
▁1/30
▁transpl
/9
Pil
▁minut
arents
▁ceftri
▁acan
▁0%
roma
aul
ionuc
▁tT
chitis
atella
▁32%,
venting
▁3.48,
oppler
elanotic
▁4700
▁hypogon
▁benzylamine
▁criti
▁Neosporin
itoc
xen
7-1.1).
▁0.013-0.
26).
▁Ninety
▁disadvantage
edul
ormality
bivolol
▁migrans
▁ingu
▁1.1-3.
▁proving
ocusing
▁refl
quenti
roduc
9-1.3
▁altered
lemental
tram
imitations
▁leukotri
▁9.0
▁weekly
▁spann
eride
ezing
▁>1.5
acerbations
10.9
▁saphenopopl
ulsive
▁2.6
elical
▁(32.1%
▁68%
mnipa
-0.94)
▁Fract
rogen
sychotic
▁99%.
▁Estim
sicl
▁herni
▁Cuban
▁estradi
▁chances
▁4
▁47,88
Nip
redom
ocomprom
ermined
]=0.42;
earches
▁wounds
▁3.22
1,5
▁LVH
▁Factor
uation
▁noncoated
eason
ocytosis
titudes
opulation
▁bactere
▁DT
▁Higher
▁threefold
▁43%.
▁Egophony
▁addiction
olitis
▁classroom
randomized
sibly
▁2.5-4.8);
▁behavioral
8-0.87)
utures
▁4.2
obic
▁17,67
=68
alap
▁Nons
ourc
umarate
]=1.16;
▁differing
▁(5.8
Ter
contro
tenatal
▁toge
bral
=637
aric
▁endoc
▁disorders
▁0.04-0.1
▁exceeded
50),
icitly
90
▁Guaifenesin
478
uished
▁0.7,
=9%
▁consultation
▁improvem
9.
▁recurrences
▁progest
▁ascer
depend
hronic
tee
=73
▁indapamide
ainag
▁acute
acolog
dence
onri
▁hypos
-2454;
▁Chin
absorption
66).
▁spuri
=96%,
▁postmort
9%)
▁144
cence
31%
▁300
▁perfusion
ovarian
▁avulsion
▁prelabor
▁Psychiatry
occur
3-0.19)
ervous
igric
▁antifracture
▁conization
▁subscap
ortriptyline
agonists
▁<10
PCL
▁Tricyclic
▁formoterol
▁<3.2
▁0.76-1.30).
amad
rents
rehensive
▁(24
-1.1).
▁11-8
▁(89%
▁characterizes
00-8
=2.32,
=4.
▁Malign
▁noreth
▁prospectively
alamin
▁immunized
=0.65;
1-1.5
▁colonoscopy
arterec
▁Chronic
▁-3
▁glenohumeral
4.6
vealed
alidone
=3]
▁overestimated
▁pillow
-7.03)
▁122
ritation
5%).
▁cutoff
89,
6,094
▁diast
=.04)
▁95%)
artum
▁0.04-0.16;
▁methion
suc
▁0.17-0.91),
aminophen
ripty
14,300/
eem
plicit
undice
ryon
▁(1.58
105
ceride
arres
▁faulty
▁(90%)
▁(15%
fec
▁Lymp
11).
▁286
steo
gard
;.
eterm
9/1
Ep
5-0.9
▁pylori
▁organic
▁1.4-3.8)
▁hyposensitivity
=.01
illow
ghly
▁Lovastatin
▁withdrawal
▁fasci
5).
▁41.
▁nitroglycerin
▁0.88-1.5
gic
76)
icability
nw
isab
redis
▁(4)
-2.7).
-63).
▁<0.1
▁vaccin
▁cis
ourish
=0.88;
utrition
▁beats
wit
▁PVCs
unif
ontro
▁bupropion
▁lans
<.001)-
alent
▁2.8
27.
▁5-3
471
aftin
▁3%
ranian
▁responsive
itour
urve
seven
parenteral
▁grou
unctivitis
hydrate
▁overwe
verestimated
▁newborns
▁0.01-2.92)
entral
▁chest
▁63.
▁clamp
▁underg
▁0.01-0.4
atigue
jalain
avors
8%-9
uloma
▁newborn
curring
▁EE
▁8.6%,
antamine
▁Ebstein
▁microw
inologic
▁conjunctivitis
▁42.1%
ephropathy
ritish
ollicis
▁comorbidities
cised
yclob
▁pois
4-0.74).
▁splenomegaly
etiapine
▁cros
▁0.05%
ecret
niz
▁invasive
ominal
127
▁anticoagul
▁8.8
▁lacked
▁nervousness
▁antiarrhythmic
riple
▁microwaves
=0.80
▁especi
=176;
ISE
EMG
120
orazine
(3
Cer
ogist
strogen
irb
▁dermatitis
▁cranial
ridine
▁estr
apolate
oal
Ri
▁6.4
▁HLA
▁0.71-0.85).
=7.3%
uations
-0.86).
erlikows
▁alarms
▁albuminuria
lyce
▁postoper
inergic
▁(76%)
▁admissions
▁Bowel
pasm
luen
▁opioids
omnography
▁microorgan
▁estolate
elv
5-1.6
▁6.97%
edron
-3.
estis
hial
=6),
uscit
yograph
zal
▁nonce
icar
▁Systolic
▁arterial
▁volunteer
idog
yroid
▁1.40
amethasone
adene
=.042),
=-2
trial
▁gonorrheal
14)
▁2.66).
volves
entag
usiti
▁2492
eberry
aple
▁(28%)
▁Pooled
rition
henhy
▁douching
▁1.25-1.68)
olot
zymes
nesses
uthor
hia
luor
ichlor
=1.52;
▁Autoantibodies
-1.26).
▁zalepl
urettage
▁circumcised
romot
ranol
▁nondiure
▁Attack
▁prodrom
▁trazodone
ipients
fet
renerg
▁NVAF
▁0.88,
▁195
▁0.72/0.83,
8-0.9
▁stab
▁6.7%.
aerobic
▁(769
intensity
▁plaf
▁145,
-1.6)
odipine
enopathy
▁fumarate
enoid
lected
▁esophag
isedronate
▁synthesize
=18,24
▁dentures
redients
▁UTIs
chedule
▁30/70
-5.
▁1686
PTT
4.3
55%
▁Tenderness
7.6).
naliz
▁synthesized
▁NEST
oliti
valpro
▁Pravach
▁5.4-
otensive
▁erythro
onr
ecular
iddie
2-
ifyll
▁psyllium
tious
7.4%
tionated
dum
=1.41).
▁pertussis
▁cumulative
ovir
hospital
=884
measured
▁(69
asmo
letes
strat
▁effus
owor
brel
▁unvaccinated
breastf
▁tabl
26-5.
inear
▁matur
5-4.9
-89%
mated
=11.
▁173
ezafibrate
▁cumb
▁colposcopy
liximab
▁shou
▁toothpaste
▁AGA
]=37.
▁seroconverted
▁titr
50,
owork
urf
.2
▁quinac
0%-33.0%).
3.4%
▁10.0
▁36%
inov
▁atherosclerotic
micro
erception
▁unfractionated
astoid
9%-9
ABA
▁diagnosed
Ure
▁effor
28)
ucom
acup
▁disturbing
▁aler
romal
▁hypopig
59).
oarthritis
▁nonan
▁PEG
▁abuse
loroace
▁Urea
▁Amlodipine
inister
▁preex
▁predominantly
893
▁lifelong
▁splinting
amphetamine
▁-30%
▁97.2
▁0.64-0.86).
▁optimizing
60-0.8
oddlers
=61%;
▁Nutritionists
▁Britis
unster
▁0.87-1.
▁1.11-1.
▁accid
▁215
▁159
▁pater
▁refr
9%-7
ostp
tinop
hc
olter
▁Symp
ereas
▁doxycyc
▁diagnosis
▁15-
nose
uminal
ypocal
▁Abnormalities
psych
faction
loro
onegative
gnan
=0.4;
▁oils
lactams
olem
▁peripheral
▁Varonen
▁1.47-2.91;
ributable
▁amou
onogram
ferases
eeding
▁aggression
efore
▁tuberosity
cortisone
NIDDM
▁132
▁influenzae
Prin
erotic
▁confounder
▁unst
▁latent
enopausal
▁angioplasty
▁1.17
zyd
loride
embolic
▁drin
tipated
▁laparos
▁nonasthm
ubo
excellent
▁(61.
=90%),
alpro
arately
ranscer
artan
=.02
CRO
Lut
▁protec
57.
▁Groo
oriasis
pear
3.8%.
▁febrile
ubes
amins
plet
rofurantoin
ections
teinur
iomet
abilitation
▁zol
▁nimesul
▁biological
Abil
ausation
▁27%.
90).
▁Improved
10
▁supplement
▁0.83-1.18),
alked
=1.7;
cetonide
versal
-83.
alop
▁antifr
▁Dop
urated
oxazole
ulted
rush
▁1.72-2.
150
administered
▁Fifteen
▁Varicoce
quine
▁Practi
lux
hoth
Dut
23;
Great
:1)
nti
▁carbohyd
▁(30-50
▁nasopharyn
tations
noid
nh
iditi
ooking
estant
100
ganization
5691
6.0]).
▁1.2-14.
▁consumed
Gord
▁nabumet
▁13,44
▁7046
▁preprandial
ucr
▁pneumon
longed
▁Petersb
▁240.9;
▁eith
luenti
riad
spectively
▁1.05
pig
▁suctioning
▁colectomy
▁blu
▁40,000.
▁Summarized
trattera
2.1
anb
56%
▁Clom
▁sponso
▁creatin
▁neoplasia
=.027).
ingf
tering
▁1068
▁balanced
onsistent
hieves
▁cate
▁81%
17;
▁Lum
essors
hanghai
▁Postmark
3.2%).
▁glycerin
▁LR
blind
▁1069
▁3.1
▁ARBs
llul
comycin
▁abstin
▁exclusion
▁Subcutaneous
▁survival
▁1.75
38),
▁1.4-1
edil
LLHA
adjusted
▁39%
45).
azod
36
=0.44;
▁preeclamp
▁47%-49%
▁lymphocytes
Naf
sod
▁163
ivary
▁10.8
uetiapine
51/367;
▁scabbing
]=1.31,
9.2%
907
entration
uloxetine
FIT
VV
cholesterolemic
ducts
laints
=0.18
▁beverages
uplex
abapent
udat
depressants
▁1-
▁panels
1)-
okers
entire
▁121
▁expulsion
6,19
▁encompass
=.007)
▁Cheilitis
▁misuse
▁Unli
▁surp
.09)
▁7.2
etermined
atally
lants
▁Synv
]=19.4;
▁nonhyper
pwor
esting
▁identic
otransferases
lical
xate
▁8%,
istere
▁Reasonable
▁Pneum
▁fungus
▁chlamydia
ymm
▁unav
▁2.6-4.9
▁(71%)
▁yor
▁complaints
▁compound
limb
▁perimenopausal
pectively
▁22)
▁aripip
▁150-
▁subur
▁3,
▁antipyretics
▁therapists
<.0001).
15)
myograph
▁detr
▁serol
verf
itoring
-0.44
▁retrospectively
▁>70.5
▁0.02
Vi
▁nonsystematic
▁fortyyear
=2.95%
onventional
1.3%).
▁viruses
▁irritant
▁microvascular
▁severely
issed
95.93
inished
5.2).
▁experienc
▁anem
-20.43
andomized
xal
tihyp
ardias
▁Surve
rimeth
4%-49%).
▁(-0.02).
▁diarrh
dren
foration
▁agon
onatal
]=1.7
]=2.5;
Nation
-65
▁0.01
]=-3.65;
enogr
▁167
▁knowled
Spor
▁65%,
▁expressive
roxyzine
iscons
vular
ilvadene
tention
2]
▁oxymetazol
▁chlorthalid
241),
▁multinational
▁0.9-3.
▁99%
07).
1.9
intile
▁reviewers
arag
▁experi
▁6.5%
ameth
OSCOPS
gophony
=.002
▁evolved
1-2.9
09)
otam
terac
1-10
12-2.67),
astine
14).
▁immunos
▁3.3-6.9)
iph
▁intrates
amole
0%.
▁spinal
▁23.8%
=24.6).
▁minoc
epe
artic
neon
▁theref
=19.5),
5-0.8
▁nonp
▁exudation
▁deformities
ecessary
munos
▁inh
▁evacuation
▁laxative
halic
▁1.5-2.
▁48.5%
▁tho
▁noncalc
▁kinase
<.0005)
aracter
.0;
Sle
elstein
nur
▁1.1-2.0)
▁546).
▁somn
6%);
apul
great
-90.
venile
▁1.04-4.9
umcis
urethritis
=1200)
]=0.66;
ordings
▁Tram
7.3
▁pressu
▁nontr
▁motivation
▁Wash
ibrill
▁bronchodil
▁lifel
PDs
▁antichol
▁542
▁0.74
Bacit
▁nont
▁ripening
etab
▁263
ilu
viding
shaped
orporated
otre
nitive
=2.0-2.85).
▁weightb
asoph
quely
leepiness
ipening
rox
Relaf
erable
emand
▁electros
▁generaliz
▁angelica
ydroxyz
▁sacrificing
▁77-9
yment
respectively
ickness
▁tightly
olyp
curate
harmacologic
versed
laxis
▁adolesc
▁Fluc
onsmokers
▁climb
▁Loj
those
▁macroad
mly
▁837
▁1.5-1.
ionizers
▁MIC
ronchodil
yogr
inases
▁1.52-9.
▁0.11
28%
unotherapy
others
-8
atical
▁0.
emicade
stance
▁Myc
ildh
▁enzy
▁intraven
▁HA
aramycin
akly
▁blinding
▁rigid
▁infertile
algias
▁protr
oran
▁2004
▁115
▁162
▁excori
osin
.47
▁16,
▁969
▁24%,
▁therapeutic
▁neuropathy
aq
▁treating
titch
▁biopsy
▁unrel
▁initiation
LADA
bitive
▁restraint
-1.25)
▁wides
=9.1).
8/0.
▁microscopic
cytosis
▁135
▁spanned
▁morbid
inog
osth
20).
▁remedy
sues
ysu
CTs
vacc
Ram
-5)
etaz
▁60.6%
mastine
ersom
apin
ronidazole
▁terf
▁Individually
duction
ibb
▁unmedicated
▁Checklist
onstr
▁nicotine
▁subarachnoid
▁1.11-1.5
▁Tuberosity
-1%;
825
5/
epa
-1.21
esive
▁(25%
▁51.
riate
51
=274)
itn
▁vulvovagin
PLs
utination
▁optimiz
ingul
tivities
ecretory
▁Varico
-74.
▁outc
▁posttussive
▁sequelae
2-2.
pharyngeal
▁69
alemia
▁fluconazole
▁Belgian
▁0.58-0.98).
cic
abit
▁1715
ceptionally
▁diagnosing
▁pyl
drug
ingiti
▁prostag
amphenicol
tut
▁Imple
rofes
]=50).
irre
▁124
▁ketoac
▁pretreatment
▁malaise
▁14.5.
▁10.75
6-7.0).
▁cauter
8.1
▁laparoscopy
-125
sparing
▁Nutrition
ylurea
Far
bri
▁lengthin
▁13.3
stim
▁97.0
Bride
irmed
009
laxes
▁wort
▁4.76
inly
etable
guing
▁2.4
sychi
-2.33).
reac
lamed
▁repl
▁7.0%
idox
sul
▁4.0,
vidone
▁sensitivities
iters
ogic
▁inges
uine
-96)
rhage
opies
esit
lif
▁0.9-1.7).
5%-8
yin
▁findings
enzap
▁nonrespond
iride
▁flaws
orin
isapride
▁Raynaud
ranspl
berosity
▁thromboembolism
iteal
▁antep
Tas
glycem
-2.4
thrombotic
anol
disp
brom
rela
▁cessation
▁<60%
▁ValHe
▁enl
▁0.02-0.23).
resect
.002
oneal
▁23.
▁5682
▁indometh
24).
]=8.1;
▁nondiar
▁corp
4/
▁canth
opharyng
ycol
▁Ginkgo
ataf
prove
▁tended
iology
▁1.5-4.4]).
isits
astric
-2.8
▁enalapril
▁Uni
-1.
uran
oscopically
ewor
▁tuberos
quo
riginal
▁20%.
▁2000
orbitol
▁malabsorption
▁duoden
▁malabs
▁5.4-12.8)
ectoscopic
▁Brazilian
▁1159
▁1.44
epressant
irone
▁stopwatch
▁54%
▁caraw
oD
-=0.
uke
tection
ecl
erro
▁cog
ifamp
sons
4-0.54).
otons
370
eaked
viated
zheimer
ostati
ective
ELT
▁Reas
▁decar
12.
▁Sle
yoc
tiss
▁(1)
chlorprom
0-2.3
8-1.29).
unil
rres
▁clarithromycin
effectiveness
▁900
8%,
exin
▁(25
▁stres
80-5.37),
▁70%
pidemiologic
detection
▁immunoflou
Lop
▁3300
▁formulations
=0.99,
=16.
lorth
ypo
nge
▁0.13-0.3
exy
▁Milk
odopa
▁fenoterol
▁295
rinologic
ulliparous
selec
▁5.4%)
▁0.70-3.
andful
▁toothpastes
▁dyd
▁3).
▁dehydration
ipulation
uding
▁epid
▁Weight
▁nebi
▁13%
▁vitro
-5.3).
=342).
▁0.60-0.87).
2.1)
=1.05;
terl
▁edema
elec
▁chec
isode
Prav
udge
=-5
▁glyce
redi
▁dau
pact
▁allyamine
8,241),
utine
▁DMA
rotein
cne
gestog
▁38%;
▁tendons
vents
▁methylmal
ximal
▁Alarms
2.8;
petent
▁0.48-3.03)
9%-4
▁hepatotoxic
ndy
▁devel
dif
ervical
▁outweigh
▁immunocompetent
▁556
▁chills
▁21%-54%.
]=6).
-79
▁colicky
knowled
edules
cinoma
-0.94
▁Theore
tensives
▁propion
Sen
ommend
▁DMP
▁hepatotoxicity
37)
ysf
ingent
Ear
entia
▁unif
auter
iating
▁nutritive
entil
olp
owere
▁0.44-0.9
▁21.2
=4.7;
▁6%,
aR
=9.96,
eritis
▁0.07-1.47).
onglulo
astat
otrach
▁(315
<0.001).
7%.
▁pren
unctivi
pectedly
Ps
▁15
positives
▁0.7-0.9),
ewed
18,
hilis
▁noninser
actobac
imiting
▁adoption
opa
▁exudates
referred
4-0.9
▁GAD
▁niacin
oderate
▁nonh
▁nonantib
1).
▁impinge
▁128
▁18,5
0]
▁25
2.8).
nf
▁establ
ndro
acti
statitis
▁0.21-0.8
acipran
▁824
▁90.9%,
=93
imeth
-1.94).
▁subscapular
rigly
▁homeop
▁bronch
▁antipsych
▁lithium
sia
▁psitt
opathy
▁infli
▁1.04-1.0
▁postcataract
tening
▁cardios
▁unmet
uln
proteinur
▁65%)
orsened
whe
▁statin
▁refractory
uscitated
ostterm
chological
8.8;
990
inist
cqu
enome
bjec
lts
▁INPH
74
9,
▁perfor
▁insertion
ocervical
Singulair
4-1
▁ultim
RIPO
icros
▁1.38-3.98)
▁endo
ehavi
hyd
▁tendenc
▁questionn
▁scabb
ogonad
▁prodr
▁0.24-0.9
anem
mesalazine
▁poses
Mas
]=1.2
chondroitin
26%
ducting
▁Statin
▁chewing
▁excising
▁2%.
numb
terograp
eliri
▁(50.0%)
▁(10/68)
▁(41%)
▁Registry
▁progn
▁22%
▁(5.1),
astrop
redic
10-0.5
▁dysph
urther
ressed
▁42-7
▁lymphoc
▁HR
▁defibro
=.01).
▁Assessment
tbooks
▁encephalopathy
▁Chlam
▁preeclamptic
▁Fractures
▁corresp
▁12,500
▁1.3-3.7)
ffici
▁hepatic
chann
acral
tenuation
0.9;
ysuri
▁569
▁VTE
▁anoxic
▁privi
5-1.02).1
▁sonographic
FCA
▁0.71-0.9
cture
▁NESTOR
=16%;
leuk
directive
▁0.23
eous
ptococ
tigat
rounding
▁perox
▁Pn
ysm
=-1.88
6.89),
inh
essenti
▁lifestyle
▁superfici
ifestations
▁-23.21
oxycy
andi
▁Exacerb
ividualized
adication
▁NP
venox
▁(11.2%
▁suprac
▁midw
ohum
biased
olposcopy
zoles
onstrat
emetics
deficient
▁sting
▁pediatric
ylc
-11.2%
▁2002
endom
ollowing
▁purpos
▁1.04-1.07),
▁adequate
▁veins
cestry
▁29.7.
▁18.
oride
▁naftif
Wound
gur
Lach
ezaf
▁diarrhea
lliptical
▁2000.
onver
eud
citated
▁(15
▁(83%
▁plotting
▁0.43-1.00),
▁dyslipidemic
▁0.36-0.
▁glomerular
opress
▁consistently
▁uter
cesses
efulness
▁nonantibiotic
▁amniotomy
▁FOBT
▁staging
▁renal
▁71.
6-0.2
▁hysteroscopic
behavioral
▁weigh
ophilic
unb
terol
celes
adio
-0.94).
▁oxyqu
andidias
7),
▁fatigue
▁(95/108)
tension
▁fibri
▁miscarriages
lamydial
▁norfloxacin
67).
70.5
endation
▁679
monary
▁juice
▁proteinuria
▁nonorganic
disc
▁valacyclovir
▁modeling
▁Gavis
=3.01;
▁13.7%
▁paroxysmal
▁(30
▁7.9%
ovirus
▁supplemented
papulopustular
-5.6
19.
▁clues
▁VAS
itrate
=.009
Vene
ndrome
epine
ecox
▁(9%)
▁800
prednisone
electas
ndoscopy
criptions
edd
getabl
aintained
-8.7),
▁practition
Eig
iologic
▁hospitaliz
]=25),
troviral
▁(64%-81%
▁acri
9-1.15),
centered
=6.
bduc
hle
▁51
Nati
▁ValH
▁2437
▁angin
ulati
▁hypertrop
7.5%)
want
▁uvul
▁chemotherapeu
lderly
▁prevalence
oqu
00).
▁Mini
-1.04
onglul
▁imprac
▁interferon
ooxygen
ifam
essity
▁200)
cq
sic
itiate
▁isometh
▁0.09-0.2
lment
ammography
125;
ysterectomized
ashimot
phosp
ytosis
▁23.2%
37
opsy
▁pant
▁(7.
trover
6,
▁SMT
yspl
▁offspring
▁enamel
ilade
ostin
apitis
▁streptococci
>5%)
acts
=52%.
▁444
iases
▁deteri
▁unbiased
thical
ooperative
▁Pravachol
parous
▁noncephalic
hir
▁0.88-1.54)
Mi
▁0.97
▁adulthood
▁Abstinence
▁Helsinki
▁augmentation
▁0.7%
▁reticulocytosis
▁Hydroxyzine
▁spas
▁Fourteen
oustic
1-4
▁examining
▁preoperative
sone
▁resectoscopic
▁sunb
tary
▁Asthma
▁0.43-
▁carp
▁GER
8-7
▁commercially
aratript
iclof
▁chlorpromazine
igorating
▁microinvas
245)
▁perc
▁advised
▁hypomagn
▁imaged
▁nonbreast
onoc
=2.35;
▁angi
▁(12/99)
bulizers
atation
,45
frequent
0-2.
1.6).
2.2
erbations
heny
emical
urvivors
mpact
▁(5/110)
▁(0.0
▁Complications
80-
▁byp
▁1.84
▁multior
▁3.6
-1.29).
▁colore
▁(86%)
llet
▁Carolin
▁methodolog
▁statistic
llular
ptoc
3.5
▁<2.3
▁sedative
▁CU
▁20,2
standardized
▁brainstem
▁antithrombotic
929
ronchial
▁Neuroimaging
▁indus
2-1.
▁contraction
geab
ofiltration
omethasone
▁2.9-6.7).
tics
▁1.11-1.58)
▁phary
eavy
HOPE
▁synovial
matur
wes
50-0.
4.4
▁(75%
actating
6.97).
▁35.8-74.9)
hritis
ABL
▁(98%)
ications
TIs
roup
=1.55;
▁584
▁2.4%
▁enuresis
▁guidebo
gester
▁14,8
405
tinate
▁progestogen
alicyl
▁gast
▁intolerance
arying
▁socioec
▁wheez
iscl
osteroid
▁47,8
▁0.88
designed
▁(79
ronch
ditional
▁26
▁tobacco
-5.9
orh
elukast
▁lactob
inum
=.5
prot
▁hydrocor
0.22
-13.7),
▁(67%)
acental
versally
prising
aloxifene
abies
atig
▁randomization
▁52%.
▁Criteria
▁Gibbs
▁Medline
mpic
nac
onatre
▁<0.
0.9
%-
ecac
utoanti
taining
▁36.
riath
muran
gorithm
4%-14.7%)
nerable
ibrotide
nent
▁anemia
▁Beresf
allop
4%-8
operating
Gas
▁997
80.
▁microorganism
▁postscreening
▁sugges
ptan
tigation
bstr
▁anemic
comyc
erapeu
hro
zithromycin
asot
thox
akness
▁sutures
arctions
amip
NHAA
▁anticonvulsant
onvulsants
▁0.75%
etting
▁dysp
▁transfusion
26),
▁constip
▁5%.
▁1141
46
▁recog
▁cytochrome
epak
tivar
▁cep
▁itching
4-13.
▁bicarbonate
9.0
ustain
ultin
▁Intervention
arbon
-56.89),
▁birthwe
gredients
6-4.
93,
ozygous
▁gastropl
-20.
MDI
▁hypothalamic
▁brace
▁155
▁ovaries
loroth
=0.0
erbate
rious
▁triam
sych
▁ethical
4,
yretics
orrhag
▁atypical
41);
▁chloroth
apulopustular
▁0.36-0.62;
traven
▁42%;
▁desaturation
IDD
▁evid
81%
elogr
leven
responsive
plif
uloph
▁Thiazolid
iopath
=108)
ympanos
alsartan
-0.91
10-3.7
▁3.79.
nei
olac
▁heal
gd
aldosterone
▁gonorrh
viou
onization
▁struc
tolerated
trogen
▁42%).
▁unlimited
▁Medicare
▁campaigns
ormi
plified
ndere
=933)
▁epic
ultures
ropath
kp
▁satisfact
▁nedoc
idis
feron
=1.20;
▁endoscopically
ismuth
▁thistle
▁psyll
▁fewest
veraged
▁counterirritant
7-7.86).
ometri
▁Nip
▁Validity
▁(0%-4%)
azepine
▁triage
▁disclosure
▁1.17-1.68),
ipit
=64.3%
▁ally
ipon
yu
▁0.40-0.9
▁selective
acran
▁meaningful
▁Extr
▁thromboembolic
34%
▁nonhyp
▁gastro
roxypro
▁drinks
blad
omip
▁glycer
▁Endometrial
▁303
▁resear
▁Allergy
▁57.2%
eys
0.70
pil
12),
ithrom
▁3.8;
▁pree
olates
▁2.8-10.
pst
▁0.71-0.8
25;
▁Alend
3,7
ussion
alant
▁40-60)
▁dysf
▁declin
oled
alif
orming
Hos
▁95%
▁glucoc
lutic
▁35.8-74.
▁leuk
8,
=9;
ongit
cretion
▁surround
▁intraep
andin
=2.4;
▁(87.
▁Monitor
=.046).
eeth
▁Ure
ervations
cB
▁radiolog
▁rof
▁32%.
▁endarterectomy
Va
▁miscl
umcision
=224
▁ECGs
icade
▁1.5-7.1])
estril
onch
onou
stant
▁autoantibodies
ouris
rhythmia
▁intramuscular
▁NuvaRing
▁triath
owm
6-1.44
▁1.0-1
▁79.
▁chlorhexidine
aginal
osme
lobulin
]=25.9
rative
▁(3/1
ribing
▁0.67-5.9
▁predictive
▁(76
perim
59%
eady
▁chas
▁electr
netic
5.4
oxin
zid
▁obstructive
sue
plasty
ortive
antr
▁(5
▁recurrence
▁decreases
alantamine
▁0.05
▁predicting
▁(88%).
electasis
▁2990
▁exercises
methot
inearly
▁64%
ials
▁Interestingly
▁20-
structed
ycline
▁0.17-1.04
▁exacerb
CDC
▁cardioselective
▁liquor
=1322),
▁withdrew
636
ophary
roved
<.01).
ophle
▁prostatic
fth
mia
=1.45;
occurring
▁Atyp
▁antiem
iated
▁476
abeprazole
▁unc
▁Copenh
mpres
▁enlargement
▁nex
▁2005)
▁255.
▁1032
levis
1000
7/0.
rete
pain
▁unrecognized
interpret
estin
essation
onf
inti
fou
▁1.03
▁injec
ressions
cination
▁twent
tively
reinf
▁DVTs
tand
▁usefulness
▁Vanderbilt
▁0.12-0.96),
=1.6
▁1883
▁investigated
-6.0
plann
05%);
▁0.97-2.3
comparative
▁necrotizing
68
▁promp
isor
▁31
▁Impairment
amcin
▁attribut
50).
natre
▁1.25
encaps
aprox
Gon
cinomas
▁0.84-1.
idesp
oretic
▁electrocon
38
sulf
▁Consensus
▁lacks
▁0.58-0.7
▁dexameth
72-41.
ionuclide
arad
▁0.70/0.
▁peppermint
osphate
alati
▁contractions
▁abus
93)
2.5%
ovar
▁3.6%).
earned
▁Manufacturing
▁PPE
▁1.6
EPD
61;
umoc
▁Clos
▁<7
▁pruritic
▁morb
rental
▁colitis
ogues
4%
ergic
=6.7
%),
-10.
▁0.77-1.1).
30).
tilage
▁secretagogues
▁outwe
tien
erousre
=.2
-3.41)
90,000
-1.47).
▁hyperc
▁DCAs
thic
thov
duced
=2.0-3.0
2%;
=7.1).
▁Tylophora
56),
▁6.8%;
romaz
▁expens
=1.30
▁disor
▁amnesic
▁hepatoxic
itho
Season
▁prevalences
▁4.8-13.
=16%
▁AFCA
abilizers
29).
▁osteoporotic
atholog
efine
▁tubes
tate
▁82.
▁-0.7
-0.7
▁miconazole
-1.58
▁bladder
=116
▁1.03-1.
zaf
▁celiac
rimaz
▁napro
▁medroxyprog
]=0.68;
▁levod
▁68
elsinki
01)
peci
▁ketoc
]=5.33;
▁angiogram
gthening
.05
xig
▁91
▁gath
▁outbreak
idespre
8-4.20).
▁0.05%;
▁POCk
=3.2).
162;
▁1.5-1.9
▁Ade
isol
eresting
1%-
thermal
▁250,000
ecid
osteroids
▁21.
▁Osteoporotic
onococ
onorgestrel
▁uvulopharyng
66
▁esophagus
▁tenderness
▁Infants
▁phleb
▁(30/30
▁1358
uterine
2.66
=1265)
▁Atarax
▁nonhypertensive
71).
▁telephone
▁tantrums
oak
8.3-9
Ga
elodipine
nife
26-
inPrep
gical
▁0.04-0.7
erich
menopausal
flammatory
redominant
monly
quan
9-5.
▁23
ucosamine
tisone
▁30.
▁receptors
arted
▁nonco
onpro
rein
▁Cen
5])
-0.79;
▁metronidazole
boem
irw
▁95%-9
▁0.12-4.1
▁mycoplasm
oligo
chitect
▁52
▁antagonist
▁0.34-0.9
cystic
idoca
▁cess
▁Hysterectomy
▁3.0-1
▁chal
▁6793
revent
▁preval
▁26.
▁psoriatic
giotens
onably
▁1.04-1.40).
10),
929),
rogr
▁(82%
medicated
2-0.99).
▁0.65-1.02).
▁0.10
▁sonogram
=5.8;
icant
▁hypok
tith
uris
▁deterior
iousn
3-
▁incorp
▁underpowered
▁Addition
▁Statistic
▁4).
▁nasal
mortality
righ
103
▁elevate
ingl
74.
▁0.71-1.0
1)
]=0.2
▁hirsutis
▁88%-92%).
56)
▁0.30-6
=5.5;
Cas
▁bottle
traceptive
▁29.4
▁ottorhea
▁comparis
culosis
▁0.69)
▁HSV
▁snoring
=2.7).
alainen
▁dextroam
uped
ausal
▁norges
2.8)
▁polysomnogram
opril
ovisc
tivat
▁defici
itro
armacok
▁1441
▁3.34-6
▁premen
▁urodynamic
26.1
HF
opharm
actat
eptene
▁901
▁(21
▁(3.12
▁hepati
▁outcomes
ecoxib
reated
eath
ashim
▁<10.
▁abductor
▁coitus
▁Recommendations
thas
▁homogeneity
traceptiv
▁smo
ueti
▁cerebrovascular
=125
▁osteo
election
oram
▁17,671
▁erosion
78.
iliz
▁levoth
etrol
▁focal
determined
▁6.2
▁2.5-8.
omnia
▁eti
▁61%
depress
671
ventable
▁guidel
▁measu
▁encop
-1.90
▁tenden
/0.7
roes
nded
enef
epir
▁11-88
roi
unti
ulfasal
ingful
3-2.42)
▁reten
▁antioxid
unip
92%
▁Reason
▁iden
agl
-48%
▁46,
urine
idespread
aration
-5
▁transaminase
▁zoster
▁formulation
▁350
ularly
rement
Nys
eved
reati
erative
▁nonblind
esearchers
▁(6/
ailed
▁0.9%
▁ovulation
=9373)
▁-0.52
▁colick
1-14.5
heat
ershirts
]=0.3
vand
▁trimester
▁Enuresis
erbation
ransl
=92%,
▁spikes
inerg
initis
opres
rimoxazole
▁qualitative
▁medit
viat
▁Theref
ofem
▁623
=1
ctal
=5.
▁cancers
rays
bivol
▁53.9.
6,1
▁Relative
▁indicators
▁8-1
▁43.
roscop
-1%
odality
DV
▁Opin
estinal
UPPP
▁40,23
▁Antise
▁musc
osyno
/110)
-400
▁cann
facture
▁valsartan
▁1.15-1.9
carotene
atterns
gests
ilot
▁84%.
death
▁rG
▁meningococcal
ampl
Lac
▁ari
propanolamine
▁4.6%
0.5
▁vertigo
61%
abep
lina
▁tread
66,
aghula
-50),
38%
kness
▁91.
3.6).
▁tubo
▁ventilation
=44;
▁achie
▁dyspnea
▁tru
▁8.2-23.
=2.34;
▁conditioning
3-9
isin
.09);
▁colleagues
▁rofecoxib
clinical
=10).
3-1.76)
=.024).
iratory
inolone
gol
tran
OBT
panol
▁pirox
surgery
ndon
▁marketed
▁alprazolam
▁13-2
▁surgeon
agic
-1.86).
57;
ediatric
ilepsy
▁tinidazole
▁(85%;
utrin
apol
eal
▁overweight
▁0.40).
▁Mank
entered
bati
ilep
▁flawed
anding
lucosamine
▁Staphylococcus
-3.3
▁urine
lephone
▁petrolatum
ricyclic
▁(4-6
fond
timalar
chemia
83.
▁allyl
therosclerotic
orac
▁trauma
51;
000),
▁aerosol
▁insul
▁dreams
iccoated
udoephed
▁validating
-32.6%
-1.69).
▁transec
roh
▁incompletely
▁cyc
▁syndromes
▁hairy
nity
>0.80.
▁Oste
▁84%-91%).
▁Intranasal
ioxx
=1.50
odology
biotics
fibro
ndag
elanom
stratified
▁75%
▁hysterectomized
-0.91),
3-2.7
lococcus
atew
altep
▁measuring
▁ionized
9.6%.
▁clomiphene
▁1.42-6.76)
probable
▁panic
▁15,8
gges
wedish
retro
▁thei
▁1.66-1.8
clin
▁0.2%.
▁0.5-0.8)
▁65%.
▁Azithromycin
nique
▁preparations
▁Overf
=7.
orrhe
romocriptine
▁IBS
aning
▁(>1
▁75%,
▁0.45-0.71;
▁noncalcified
7-1.4
▁17,25
▁28.9%
▁(32.
yphilis
▁orchiopexy
▁deposition
▁>55
▁<100
8-4
689
▁ethn
losp
▁0.04-0.
▁2/204
6-2.
▁protime
▁Hep
▁biwe
324)
▁biopsies
▁Sixty
=47.67;
▁18.9%
▁0.55-1.38),
▁arteri
ussia
ajor
▁FEV
▁14-
▁caraway
▁10.3%
▁thyroxine
mselves
jun
erid
aliz
▁classro
cM
▁Orthovisc
▁tantr
ovas
omnol
lw
erenc
ategies
▁intractable
▁imipramine
▁93.5%
▁Hamamel
5.7%
33)
eful
▁25-
▁prodrug
▁textur
olal
ingoc
acerbating
▁decarboxyl
▁trichom
▁9.2
▁poore
emale
▁indet
=96,193)
=.0001).
▁0.4-1.
▁expir
.003).
Sporan
▁63.1,
-1.92;
ithromycin
▁lipids
holin
▁exces
▁56%;
ungus
▁(122,471
▁5.6%
▁tricyclics
▁thrive
▁>60
▁metrorrhagia
▁predispos
ucind
▁(18
dip
creatic
▁knees
-1.67).
91
ighest
lpro
itript
▁16/
/170)
▁>1
estioned
▁tendonopathy
▁povidone
pidemiological
roic
fies
uctive
▁PV
loroacetic
10,
pul
▁appr
otrim
82).
retin
andaging
▁piog
▁Beta
▁antibody
▁Cardiovascular
▁pum
=59).
▁152
methotrexate
6%).
trolled
▁Committe
aifen
otoxic
▁92
dine
ocused
▁-7.
etely
rease
▁0.55.
ganism
visc
endronate
▁formulating
=1560)
▁chloride
▁1993-1995
asciitis
acteria
thim
cool
idab
piratory
▁adenoidectomy
oniz
asses
usate
orion
-20.6).
▁10.5-1
▁0.497-0.9
inorrhea
▁2.1-3.
ingitis
-45)
eace
shaved
▁Formal
20%
VTs
onu
▁>36
▁corti
ewis
ylitol
<.05).
giotensin
okeless
phenid
arriage
xag
>5
ynecology
▁nonrigid
acted
astropl
rising
roch
=0.23).
adiazine
enohumeral
atistical
astatin
▁0.62).
-70).
rochlor
tib
▁trended
=.25
▁pituit
lations
33).
▁assessm
▁Highly
iculopathy
-0.67.
1,2
flexxa
▁Proges
▁mycopl
-5.1
ielding
▁nasopharyngeal
▁EST
amis
6.4
oneg
▁0.5-7.03)
▁26%
agnes
▁rehy
veil
eris
=24;
acule
▁1.31-3.32).
giti
utritionists
▁kidney
▁internists
▁86%
▁aPTT
=2.36;
▁1991
▁medicated
1.4%;
▁sprain
34).
Son
chit
otenti
68;
alue
ticulocyt
opathologically
▁400-8
ondyl
▁immunosorb
ulfam
▁awareness
-0.84
<.010
2.1%
areness
▁(<7
▁1.4-10
▁Butenafine
titute
.06).
/324)
erab
▁isp
▁rur
reslow
xon
▁Pengo
▁1298
-2.2
itness
suited
=2).
idere
-0.20
adon
-13.16),
▁0.64-0.8
intention
▁extracorp
▁hemochromatosis
astatic
welling
▁958
▁anemb
cium
▁graded
timum
rri
eatoma
▁suppressive
50/
=4.8
versing
▁22%,
vasi
geable
arized
▁24,529
▁pooling
ounts
=82%,
epress
=.26).
]=2.1;
5.5
=0.74;
▁IUD
otran
toth
riately
▁(42/170)
throu
=33%,
terns
cogn
pam
leen
▁leukocyt
▁subj
tiveness
▁1213
ipi
▁0.35-0.9
tron
▁(52%
▁>32.2
▁3.34-6.0
▁confounding
9.6%
▁29.3%
3-4.56),
67
▁0.45-0.7
▁regurg
▁Adolescents
=4.8),
▁urod
▁predom
fice
11),
▁0.2,
▁saturation
▁MEDLIN
uor
▁rotavir
▁Twent
▁bacteremia
▁-5.2
densed
vidu
▁measur
roxetine
erotherapy
▁concomitant
17,805
efs
terog
tant
▁29,
-1.11).
inb
ageal
▁Exam
▁131
enom
=12.8).
=126),
▁gris
-0.93)
0.15;
▁interrater
▁Heal
▁levam
vascularization
uctur
cognitive
ostur
▁twof
domyoly
-0.8]
cinolone
▁randomiz
ellation
=.09).
▁96
vuloph
acology
austion
bable
alit
▁Bish
ithin
▁insufficient
▁408
▁sumat
utamic
▁reminders
▁292
▁(19/108)
▁poorly
▁(19%-4
▁drawback
▁Significantly
isopro
ovement
veri
▁mitigated
=26
▁Mep
10.
▁(87.5%)
▁bruit
iure
ifically
<.001)
<.0001
]=3).
▁rated
▁chlorh
▁ceftriax
▁(101
71.
▁2.6%
▁0.54-0.81)
▁46.2
reign
▁phos
eospor
oxical
yot
imepir
-2.4),
thac
3-1
specificities
▁electromy
ressing
urosemide
▁<5
66-1
▁clonidine
79,6
ioly
esul
iasis
miconazole
▁dihydro
66%
levate
bear
▁(45%
▁siz
muscle
=1162)
▁lymphad
▁0.11-0.20).
nda
idid
4-0.20
apazole
▁addic
▁tob
distal
ecrolimus
52.
00-800
erating
esicle
aRing
▁acyc
anization
▁predominant
▁unpleasant
▁moderately
▁Blind
=7.8%;
=125).
icating
▁3.34-6.07)
ribonucleic
85)
atars
ceeded
▁dietary
▁13.
▁Mortality
24,
▁hamilton
3-0.3
▁urinary
▁unscreened
ostomy
▁progres
23),
upraspinatus
hort
acranial
-86%)
inuri
lso
-0.81)
niques
▁543
acetic
ellbut
kine
ucate
endations
▁rotavirus
Ring
43
erestingly
▁5-2
▁Risedronate
927
▁immunogenicity
▁cosme
▁252
▁titrated
▁opio
triglycer
▁unin
▁Regist
▁47,22
icu
.50
ewb
asound
Roc
liad
oconstriction
▁electroc
.8
fric
iglit
tomati
▁immunocom
▁slowing
3.9.
glyceridemia
▁Concentrations
gnos
onors
=89%;
irms
=0.62;
▁abdomen
cessively
▁bism
motic
lucos
arable
▁>27
▁equivalency
,)
▁sertr
ptiv
▁lactul
▁strokes
dule
ersh
▁piroxic
▁unpredict
iscar
ipri
700
atosus
ultaneous
0.80.
▁Rare
35)
257
▁0.06-1.2
▁36.80)
▁Valsartan
▁thromboc
]=0.0
▁Included
▁substernally
6.7%
2.1).
▁bradycardia
ologis
▁0.4-0.8
▁punched
▁Contro
verwe
=2,
▁65%
rocy
9/10
ctur
=8).
oene
amoxicillin
,881
ropioni
▁gon
▁Tend
▁dihy
▁rectal
80-1.0
▁ANC
▁(>95
25)
▁decreased
▁irreg
atl
0.65%
▁dermatoses
=87)
▁antihyperten
▁significan
ifics
428);
▁osm
reata
inish
=2.0-2.8
trod
▁NV
ocioec
isod
▁clinicians
=3),
▁116,0
▁subsc
▁Esch
▁Attributable
uir
onates
=615)
▁Chang
anip
ctomy
▁OB
]=10)
▁VA
arrhythmic
LSIL
▁crosssection
▁institutes
▁65.
▁correspondingly
acheal
urement
▁psychophys
▁WHO
riptan
tential
▁allylamines
bograph
opharynx
▁bip
ilet
3.7),
uppression
matched
▁citrus
▁delive
▁agglut
Fro
▁progestogenic
uble
osity
▁ipecac
▁170.15;
▁-4.59).
▁endocrinologic
-3.7
waiting
▁Dival
emf
▁18.3
oughts
itely
icits
circum
5.7
▁inpatients
.07
▁4.91
mipramine
▁10,000
-2)
avach
War
86).
▁eliminating
).6
oall
fy
▁encopres
▁Comparative
▁illness
-7.1])
▁placental
amphenic
umat
thyl
ificantly
ifluc
Ban
urgitation
▁hyperand
ystolic
▁pretest
▁homework
▁chlorothiazide
▁hyperarouse
▁refill
etero
histamine
gA
LV
=14.
▁10.71
omnogram
oconstric
igorously
▁elevation
▁95%-97%,
Fu
malonic
▁OC
-4.20
lid
63
▁pulsed
30,
▁hypothal
-224).
▁ocular
▁-1).
Benz
opharyn
cts
3-1.1
=0.93,
▁fluc
▁vasoconstric
▁bioch
=1.07;
▁7.9
▁conservatively
,825
▁glar
valuated
lase
▁reductions
▁administer
distant
afine
▁incubate
advent
terin
(1
loralphenazone
▁UT
▁134
disabling
endons
assess
▁incorporated
orized
▁sulfa
▁hetero
▁tibial
Actos
▁Sonography
▁transplant
▁therapies
emide
yno
▁11-220).
40)
▁(14/
oice
ascular
8%-7
blockers
ersb
roa
romocript
▁hyperaro
umbar
▁(5.
▁endocrin
uctured
axatives
1-2.
thri
cising
molec
5%),
▁tension
▁(3.4%
▁2067
▁0.72/0.
60-0.
=19
lebitis
▁pneumonia
▁cefixim
inidazole
cet
-1
ariate
▁Antimalarials
▁1.2-2.7).
ermat
▁MICRO
▁disord
3-6.
▁toilet
2-9
opop
citon
▁diphen
orphine
<.000
▁ductus
sulfon
4.6%,
▁103
▁syphil
▁1%.
▁hospitals
pasmod
▁prescri
ondroit
▁disting
udies
onatremia
8.
=.043),
haled
▁dys
actu
iclopirox
ongestants
phosphonates
▁Meper
▁whit
▁bicarb
enough
vaR
-3.34)
ggest
lk
0.
yx
-97),
ultiv
▁macrocytosis
▁mitig
▁prodromal
legiline
▁alanine
vox
=27).
▁64%-70%)
▁caff
hild
▁Cyclical
▁0.42-0.99).
▁unt
▁myoc
▁(1:
▁1500
▁Stopp
tipation
▁ispaghula
▁2779
jand
alation
elography
▁anat
]=2.1
anthosis
▁splen
▁conducting
idoc
isphosphon
5-1.02).
ulner
▁exercising
cohort
▁supplementation
enterologists
▁restarted
▁Unpublished
vices
4.3%
95.
ocl
misoprostol
sufficient
enoxic
▁isch
▁Troglitazone
elief
▁practiced
▁1/2000.
▁40,000
21%
copro
hemolytic
▁prophylax
enceph
▁cleanliness
▁referral
Od
iovas
pletely
eperidine
▁weakened
▁Surg
tazole
VCs
▁cyclospor
6),
ixim
tratified
▁Norvas
▁glom
▁2.10
▁TMP
damine
asten
mnip
rthro
▁0.67
162)
iffic
▁oste
▁ket
▁superficially
VAF
phor
regn
ostn
3-2
bend
olute
=0.50;
▁atrophy
▁(35%),
▁1.4
steopor
=.005
kne
epart
-36
▁Manu
▁0.38-1.3
apular
▁Hypogonadism
▁diath
1.1
▁0.83-1.
arbonate
ulmon
▁10.4%,
opig
-1.44)
▁suicid
▁mobilization
ertional
assing
▁Screened
],0.10-0.52;
Cop
▁chos
▁obese
▁-5.27
-99%),
▁impotent
▁compati
▁concentrated
aired
▁shaved
pati
kep
▁stimulant
▁fiber
sical
▁osteoarthritis
etric
▁nondi
▁evaluations
gies
▁575
stion
yprog
▁glimepir
acological
nine
plifying
(=
▁occurren
▁Gin
-0.8)
▁exter
▁HOP
atox
▁6796
enox
approved
8/0.81,
]=0.22;
▁pulmon
▁myop
▁1200
▁captopril
▁(20/324)
▁96%
▁139
99%
catar
.8.
urgh
▁unre
erred
▁thirds
▁Infection
mpression
ulomas
▁sulfonylure
liti
weigh
▁(75%)
mentation
lycem
ndian
▁curren
<.1
▁Wenyang
▁Cutaneous
▁underactive
▁-4.5
▁direc
▁10.0%
▁0.497
▁percus
henous
otients
▁Mayo
iopr
apazol
▁antiat
=.03)
▁compartment
▁Scand
▁2.82-14.58).
strated
viewing
▁1.42
lod
esart
▁Thos
▁(46
ticoid
ufacturing
ystere
=1250
ologically
erw
reptococcal
▁microencaps
▁1.38-3.41)
▁0.63
▁(41.2%
lum
▁grain
ylor
237
amatic
urvival
▁diaz
orag
▁dival
=0.59);
toxic
▁(34.
ecies
▁lis
▁(72%)
dres
ghout
▁(14/36
▁inhibitor
isur
<.001,
osened
▁encephal
etwe
herence
signs
epression
ormly
7%),
ternatives
FEV
thyroidism
bronchodil
oprotein
ovulation
elvic
▁labial
tensity
etrolat
▁Nineteen
▁embryotoxic
▁coac
threat
▁0.44-0.98;
yclovir
cision
ylind
▁fossa
▁58.01;
9.5
▁discussing
9]
▁contaminated
▁myopathy
pectant
▁0.48;
kle
▁Munster
imenop
ominant
▁conclud
orities
7-1.8
▁fath
▁examination
ictive
iln
▁contributing
ickets
▁ribs
▁colonization
▁hydrox
▁breakth
▁thres
▁persists
exor
▁mucosa
▁1.3-4.5).
▁Extracorporeal
plem
605)
▁leve
Aj
▁arous
idined
▁arti
▁Nug
acteris
ooper
ransf
▁revac
Wor
ramad
erous
▁bradycard
▁343
▁1.07-2.8),
xia
iq
▁Positive
▁controll
▁aspart
roxen
=2)
epending
▁nonsur
=.049).
lele
▁countri
ehy
chon
.005
ocardiogram
olester
▁encour
teer
Ral
▁resec
uating
▁infusion
▁suicide
=4.92;
2.5%;
=1.5-1.9
=15;
-0.9),
▁1.17-1.98),
1%-5
▁-0.14;
▁temperatures
▁expiratory
▁Framingh
▁indef
▁fibrillation
▁absorpti
▁spirometry
▁hygi
tured
=21
xative
▁investigat
▁presch
▁29.
ctionally
▁49%
▁Postpartum
-2.24)
uat
▁0.6-1.
▁(60%-70%),
▁0.4-2
enation
ipoph
fus
orrh
▁clindamycin
ralfate
▁idiop
▁Increasing
ussis
36%
calcem
chlatter
▁neurobiological
▁1573).
,790
oidance
ototh
▁epidural
▁noncompliance
▁anesthesia
ohns
▁hypokal
etent
pensi
▁Calif
resu
▁(820
ormon
ardiogram
▁Modified
chie
inemia
▁nonsolid
-1.11),
tam
glyceride
▁nonprotein
▁15.
=7
▁rea
zyl
/367;
001).
ronically
hile
241
▁sediment
▁alop
▁depressive
▁metabolism
▁70%;
▁plac
prednis
orary
ASA
50
-1.8
▁adhesives
▁desatur
tropenia
rotal
kage
▁transi
=0.66;
▁cytologic
▁0.25-0.77)
▁dalteparin
tolic
▁aerob
-93%)
=3.43;
olerated
Fam
,52
▁olam
SGR
▁nitrofur
▁adoles
▁185
vertent
▁differentiated
rinologists
=44,825),
-1.69)
anuts
▁20.5
▁bacteriuria
▁discharged
▁transit
▁20,15
▁Diab
icl
▁dysplasia
▁raises
SOLVD
▁0.00-1.44)
▁meper
eha
anag
▁lumbosacral
01
1%-69.6%
▁-7.9
▁Omnipaque
▁3.5,
ocard
▁8.
▁413
▁immunob
▁1050
▁earl
▁0.42.
▁ergotamine
=1.06;
icor
bate
fti
proh
<0.01).
acul
reased
otherap
▁dementi
ghage
controlled
hag
]=1.
isks
entricular
▁antipsychotic
▁pregnan
iciency
▁injur
-69.6%
23.3
71,
opathic
=0.98;
▁Disease
▁-5.14
▁Impair
▁interestingly
hibiting
-3.8)
tos
ppro
▁metere
9.9
▁1.31
▁hypokalemia
=1200
▁Preventing
▁sensi
▁17.
▁sheath
acists
▁sertral
certainty
atm
utro
▁(8.45
ipec
▁adop
pran
▁betameth
▁6.6%
=.003)
▁adenomas
acch
▁ketorolac
FITS
lasm
hormonal
▁popcorn
stick
95)
▁50-
<.03)
2.3%
istamine
lexxa
▁excep
perat
oDerm
induc
-0.97).
chlorpromazine
▁Clin
▁(22
NSAID
earn
▁hyperlipidemia
alac
▁(58%)
▁shedding
orse
▁consc
ropat
mep
ometritis
▁(1.6
▁methyl
▁painful
]=0.46;
erms
tiated
<.001);
urp
245).
ilitation
▁sulfad
ecu
64%
-8.1).
▁23/
▁10%
▁ablative
Effexor
▁-4
roublesome
3.9
ORs
▁oxyquinoline
▁preventing
onfusion
▁diazep
55.
hion
▁mL
▁doubled
reast
atitis
▁Rules
▁suscep
agulant
▁77%-97%,
▁Bacitracin
▁5804
▁cac
▁Irbesartan
auses
▁cheilitis
▁fatig
revis
▁infections
▁11.
enting
▁1.1-1.
ects
▁Polycystic
▁Isch
▁painfree
pleasant
▁223
▁escalating
11-2
▁micon
tas
esqu
alosporin
▁testosterone
Pravachol
▁menstruation
oiding
▁37%-86%)
▁milder
▁AFFIR
yod
ordination
icarb
ruri
▁glycopro
▁hyperventil
reakth
▁esophagitis
▁Tanner
pilot
65%
-7.6),
dinary
nai
▁minority
17,
▁nigh
isolated
xys
ixation
otonsillectomy
▁physi
▁0.47
▁creatine
=0.9
▁supportive
utches
gag
oncom
▁textbook
ollec
▁0.04-0.62).
▁Overfeeding
363)
ocytop
toacous
armful
terase
lyp
labor
1-1
▁0.45-2.
ilm
formin
ucin
trospectively
▁endpoints
etus
▁pancre
▁(56
▁unrecogn
cautery
endoscopically
thou
ypoc
elste
tinguish
-1.00
ndet
▁placenta
▁coated
igit
tentially
-1.12),
▁(10/
oscler
▁39
nual
albumin
▁443
yog
erase
▁(27
88%
sure
utc
▁Seventy
▁(3),
amisole
▁Interpret
ydrop
▁dimethyl
aibo
▁UTI
▁25%
▁ectocervical
5.1
tropine
12
34-6.0
▁0.38
icc
uced
onment
ysmal
WHI
lusive
2-0.9
=.036).
-49%
ioprine
▁inaccuracies
▁radion
▁blisters
ustry
▁Adoles
▁biofeedback
▁holidays
itripty
8%
eigned
obenz
asic
▁polycys
▁237
610
individ
lati
▁nyst
▁ovules
▁benefic
fered
anovulation
mro
ospic
▁Lef
eclin
0.3
▁Farr
▁complic
▁(57%
▁0.5-7
▁pimec
▁(43.
▁8.5,
pac
reness
tisol
stres
▁nitrofurantoin
induced
traception
=1.0
▁439
NNH
▁individualized
enon
▁omeprazole
antam
mpir
terc
▁0.86-56.89),
henyt
gthin
ulab
▁Inhaled
▁intub
▁propensity
fam
▁Bronch
▁examined
hemo
▁cys
imso
▁primiparous
ifici
moderate
▁Fib
9-2.3
inam
phine
08).
▁acy
alospor
AISE
▁Acet
-2.20).
irths
▁angiop
▁medically
▁prein
odiazepines
▁sedimentation
▁vegetable
▁rhabdomyolysis
0),
.004
Ox
rations
glucom
roal
.26
▁3952
tros
icell
1%;
thost
etast
witch
▁-95.93
idur
edocromil
holic
▁aspec
▁(39/18
omoc
edtime
-1.4
=24%;
60;
]=1.6;
4-0.5
▁465
▁nabumetone
▁nef
▁nimes
▁logis
▁Osgood
▁podophyllin
▁mucos
▁83%,
▁indeterminate
0.7%
natremia
▁participant
ariatric
▁immunosupp
gesia
49%
otrans
▁crosso
▁phenot
▁appoin
tency
▁cyclobenzaprine
ruritic
▁2.5-5.6),
34)
-0.9
▁116
▁1.29
atedly
▁mec
ymph
mr
▁shoc
▁abortive
▁mefloquine
▁Guidel
ystag
enase
▁mildly
eces
onre
▁suppos
rician
edures
acking
rilling
atectomy
=97%
▁sonnei
▁Clomipramine
uod
etary
hly
=6.7).
▁Lact
ollic
▁27%,
▁expen
posit
58;
trocon
thc
19
▁22.
therap
plained
▁fallop
trophin
▁suppositories
▁suffici
definite
iewing
18%
▁(10%),
sants
astol
aprine
▁(71.
=1.70;
▁Patient
dation
trimester
omnogr
Motrin
▁certainty
▁Obesity
▁discontinu
▁attenu
▁appendic
ransco
BM
pab
▁Headach
sence
▁47%,
▁(0%).
▁ambulation
▁pitocin
▁(51%
emophil
▁bumet
▁melanom
▁lactobac
ystatin
LDL
▁Apnea
ABG
▁57-2
▁(41%
▁withou
▁coaches
acorp
▁-1
▁1964
aigns
▁diabe
▁ey
▁crutch
▁(25%-5
▁pneumococ
8,755
thetic
▁Haem
=1689,
▁facet
▁seated
▁renovascular
icient
edro
lash
ecrol
cific
▁aqueous
▁juices
tihypertensive
▁compu
▁incub
Celex
▁neurologic
▁acids
idate
ADC
licting
▁Intrapartum
]=0.9;
▁interviewed
▁Penhall
▁nipple
▁aPT
iphene
centag
benef
▁unspecified
arazine
sitt
reliable
▁cryogel
▁acromioc
trac
▁5.6,
▁capsules
SAIDs
▁imaging
seudoephed
▁euthyroid
eriv
umor
hone
]=25.96;
▁regardl
▁itr
▁hyperpl
ocic
kth
itial
▁(>
▁retur
▁151
utoantibodies
april
Vasot
▁Neuropsych
cill
hyp
pooled
xati
=24
onservative
olectin
▁inquired
▁<232
erologic
▁Nonsmokers
▁Antimal
▁undergone
icide
▁85%.
▁(72
ulfa
zap
5%;
abap
▁bact
titi
▁hemorrhages
▁Experts
IDS
▁respir
yphil
oscopies
oac
utoff
ameters
onuc
entab
▁immunoglobulin
995
.4%
▁fibula
▁amph
▁colostomies
avastatin
▁37%
80)
emfibrozil
▁epicondylitis
rbes
=47.
ercises
▁18%.
▁clot
▁softening
▁cumbersome
▁sild
▁cardiolog
▁744
salt
henhydramine
=192)
▁spor
0-3.
hylax
reval
oxify
▁forc
athermy
▁anticoag
ularities
▁28%-3
▁hemorrh
▁85.
1;
▁1.95-2.54).
▁correlating
ueb
004
arv
▁intervention
=0.5%).
,888
▁earlies
3.10
-12.2).
▁unsc
ophila
insertional
▁40
▁themsel
▁25,
Pet
eremia
▁(9%
3-1.18),
▁anter
usual
sulfamethoxazole
▁fertile
▁insufficiently
empted
▁consecu
▁specif
▁(35%
▁>19.6
▁500,
▁Lymph
▁symptoms
▁87
▁cefixime
CU
▁769
7-0.61).
olesc
▁>2.0
aution
0.01).
▁cyst
▁unselected
iome
"-
nly
▁16.7%
▁gemfibrozil
▁levamis
upd
erad
edis
sso
(9
▁AFCAPS
DOR
irically
vig
luv
rised
lowering
▁bromocriptine
▁(1494
antib
2,684
Bactro
2.2;
tration
▁quitters
▁unreported
ucas
upation
udd
vaccination
▁GADAb
-21.23).
levated
iological
oxacin
▁computerized
aros
=824
▁fibr
vivors
▁remed
▁(278/43
lebograph
sodium
ospitals
20
curacies
alain
▁relieve
▁87%)
▁nip
tice
▁6.3-41.
uerv
broadly
▁0.90/0.96,
syst
-3.0
▁Duct
▁77%.
▁dermatolog
48,
romog
isodes
]=2.
▁0.6-1.9
aral
▁uncon
▁39,
sink
]=63;
athro
Wit
▁exercis
glycemia
▁Metronidazole
▁guinea
▁0.22-0.8
0.3%
▁diagnose
▁capillary
▁produc
7-5.
WOSCOPS
retrospective
mple
=2245).
▁(34.8%)
▁administered
heum
proced
itamins
ondary
opi
▁SWEET
▁sati
3-1.40
▁Interventions
ulosis
teras
▁excision
▁690,000
emory
ulide
-2.0
sibility
erl
uled
▁cigarette
ogmatic
ibited
▁requir
acteriz
▁(26%
▁(32,
▁subtherap
▁141.7
▁106
ansi
▁concealment
weden
▁urol
=69)
tinence
▁longitudinal
anaflex
-1.15
getable
gam
variates
▁evaluates
▁methodologic
cline
▁<2.
▁accoun
avings
▁27.6
▁stripping
▁syno
▁gastric
21;
vial
uspir
oconstr
ervain
upun
▁HER
akened
hid
amining
roimaging
43.
itonsillar
vocal
▁valerate
=43).
▁recruited
▁(59%
andina
bic
▁attain
▁trun
▁Unusual
▁557
Imur
▁amput
lexed
1]
▁undergo
tute
▁228
terv
erapists
ephed
uncture
▁upright
-66)-
39;
▁contex
▁clam
▁458
4.
▁57-245
promazine
▁ence
▁effici
eac
▁0.86
=25
▁discontinue
▁adverse
-2.41;
ysicians
thors
▁infr
-3600
inoline
/6
iets
▁revaccin
iseofulvin
▁acutely
naproxen
▁98.9%
ocor
▁poisoning
▁0.48
hers
ilab
▁activator
SRI
▁47%).
▁sulfonam
Blocker
▁orthopedist
▁dramatic
▁enures
omies
▁Terbinafine
▁3.2%.
imag
▁instrumented
▁Cure
▁EGD
▁exclusively
▁conti
gab
cove
ipitor
▁streptococ
ycles
resence
epartum
oil
.5).
▁82)
]=13
▁salivary
▁hyperglycemia
ermatitis
BEST
ablets
mpicillin
=.8
ewer
68)
▁816
15.
depressive
UPP
▁(0.
▁particl
▁AFCAP
ogas
▁mice
ampin
entoxifylline
▁27.
▁radiologic
▁dropout
▁701
olace
idural
vening
onazole
▁abrupt
=50)
▁2.9-16.0]).
thromb
▁inq
▁(24%
idyl
umentation
▁23.10
atifies
sions
▁8.4
▁radiograph
▁appendicitis
▁17.8
ransv
amination
joene
▁18.3-42.4)
iflucan
udation
▁80-
▁overn
tribut
imens
ctive
▁1.1-3.8,
▁commerci
▁Transi
▁elig
▁etiologies
▁rhe
nausea
vip
ramingham
▁1.0-12.2).
enzodiazepines
osexual
▁spont
actul
▁saff
imepiride
▁institutional
▁duvet
▁rupture
onis
▁4.91-1
=21.2
ootb
▁8.3
oquine
▁hypothy
▁drops
osite
▁tenoxicam
▁Nystatin
▁0.58
▁ecological
-3.77).
timulating
▁(700-800
umol
3.15
borns
ressin
▁jaundice
mg
tihyper
HDR
onat
icti
onograp
▁Buten
▁cohosh
glycopro
▁Evaluation
▁areat
▁exacerbations
4.20
▁malign
▁0.19-0.6
<.01;
▁surveys
robi
USP
▁(3.2%
▁sonne
▁illnesses
hiscence
▁endog
erature
▁10
▁1.4-101.6).
▁psittac
1-
▁>1.7
=3057,
▁Tests
1%
▁51%,
▁excor
ualized
isom
▁temperat
acit
▁Unp
idne
▁rhinitis
▁(300
▁(150
▁aspirin
77)
▁(49%
▁irr
RM
oxap
▁87%,
▁puls
aund
▁Hypog
▁55%;
▁777
▁aluminum
▁coag
timis
lom
)],
▁71%-8
▁lymphocyt
amnionitis
.0).
tinal
▁42,44
]=-3.
▁arthros
trose
▁35.4%
▁symptomatology
ulin
▁analyzed
4-0.7
▁-1.64
385
▁0.55-0.84),
ichever
artate
▁cesare
▁dair
▁psycho
▁grades
tionis
▁67
▁1.8-19
=0.3;
▁pati
▁hypon
▁pump
=4.87),
▁statins
arice
ults
oprim
▁(1/19)
hemoly
▁Toler
=90%
▁defi
rachial
onar
▁arou
7.2
asmodic
▁Stopping
=2.95%;
edges
terr
grounds
munication
osporins
▁(21%
8;
ribed
▁Hb
▁ensuring
▁pretreated
▁arousal
▁(10/1208),
phosphon
fortable
▁booklet
renergic
▁20-3
▁acromi
ibul
▁diure
▁behaviors
▁antibiotic
diabetic
▁achieving
roth
▁refract
=.03),
ulm
▁peaked
▁(2.6
hisc
arit
drome
▁nonanti
=9.
teral
,8
▁Leu
orice
oxic
pioid
urul
58-5.1
pled
lite
▁fibrates
marized
-3.03)
▁Asi
ryonic
▁varies
811
0.10-0.5
▁vulgar
brovascular
▁noncompliant
=115)
▁preexisting
axative
relating
infold
amamel
▁(44
▁employment
▁unadjusted
▁Gynecologists
▁allergenic
xicity
hical
elative
30-
▁telev
ocript
▁0.2-1.2).
▁epidemiological
▁urtic
▁qualifying
▁<4
▁ofloxacin
respon
.1,
=17
▁hypothesize
▁Lisuride
▁breastfed
-2.32;
▁hamil
.5.
▁sulfadiazine
▁posttreat
▁17.1
-20
Bec
▁gou
▁manipulative
econazole
inkl
▁protim
.1;
icting
-1.64
▁HIV
eptide
▁<45
cob
3%),
kew
gths
▁enam
▁thromboph
seudoephedrine
mopress
▁instr
▁89%-92%),
▁Framing
-0.0
▁1668
▁hinted
Lax
=2.0
threatening
=937
▁>8
00.
thep
=-0.9
ukin
▁Notably
▁cyclooxygenase
▁peanuts
▁favorable
▁6825
▁tiss
▁shaft
=0.64;
▁inferi
ophysiology
▁postt
thirds
athered
ergenic
oclavicular
▁10.4%
=37
atadine
▁0.80-1.09).
▁Corp
ogr
5%)
mol
manent
▁serology
▁pooled
1-13
▁Detect
▁scanning
-1.53).
fant
▁0.76
dram
]=11),
▁amplification
oep
0-2
▁microal
[9
8-13.
edoc
▁426
aternal
▁speeding
eliefs
ociet
ifestyle
<.01)
▁sputum
▁polymyx
3.3
▁selec
ysteroscopy
=2.23),
fication
▁minocycline
▁multim
▁durab
onical
▁80.
cab
ocrom
▁furos
▁12/1
409
▁postnatally
▁598
▁0.23-0.7
siv
RCTs
▁682
reduced
▁empl
Tro
erpl
orcement
erap
efl
6,222
▁24)
exercise
-14
▁calcium
=-1.8
▁interleuk
▁adnexal
▁becl
erbin
▁psychopathology
=.002;
3.3%).
1.6%,
ntim
▁androgen
rimazole
▁Insufficient
tati
▁vasoconstr
▁goiter
▁excluded
▁77.8%
▁Mild
▁aripiprazole
yclics
▁femal
▁mycological
▁nosocom
69.
▁36
]=19.
4-0.6
CAPS
80-5.
▁Sti
eredit
<.0001),
proic
▁clom
floxacin
oroth
porting
▁excisional
▁AMA
▁(4%)
=24.
Prep
osoc
▁0.1
ophysi
-14.
▁1833
erogenic
▁Cens
▁shampoo
▁ratios
▁316
adrenergic
OSCOP
taneous
entu
26)
▁Mesal
onv
▁suicidal
acidosis
▁experimentally
▁weakly
▁4.9%
inating
onj
144)
▁0.84
▁2.43
▁chronically
inj
▁suicidality
▁68.
(2
▁bacterial
erability
-0.8
▁electrolyte
▁Misuse
=.003).
▁triglycer
ouching
ialis
▁attenuating
alyses
▁4.4
▁dyspepsia
▁encouragement
]=14
80-5.3
▁plasma
▁mitral
▁451
▁orgasmic
▁Subgroup
▁2.61
amine
yoma
▁strictest
ransth
1%-6
=11
dose
▁antisep
omated
1),
▁revascular
thma
▁supplements
▁948
/170
▁parat
educ
▁questionnaire
▁(64%-8
▁32
▁interleukin
uitary
▁crying
LGA
Dem
7-0.82).
Cen
Pun
nited
oys
▁controversy
Mu
ooled
diagnosis
▁(5%
gop
ohnson
▁prolact
emop
▁Calcium
ironmental
iol
osynovi
▁tizanidine
▁tas
antially
sychosis
mented
▁1.40-2.0
▁acet
bial
noth
pment
BG
ymptomat
94
cate
▁formo
borrh
▁pentoxifylline
ryp
▁cohos
▁pharmacok
evel
▁infus
plas
orazepam
▁menis
-23.21
valproex
ophil
▁leukocyte
anation
romycin
▁<2500
▁precordial
trihex
otranscobal
▁0.25%
2,000
lavicular
▁neutrop
lti
▁grains
▁5.5
▁drinkers
▁156
▁upt
▁arthral
▁0.66-0.96)
osid
▁aspl
▁anecdotally
▁magnesia
▁bedrooms
▁1.4-101.
irtazapine
AFASA
acic
▁nondiarrheal
▁221
▁(500
apill
dv
yti
▁shortened
/2000.
▁endarterec
=78.
=16).
001
lacebo
atop
inm
uenti
ampicillin
estos
▁olive
espec
urab
▁nefazodone
▁compro
aract
▁1.5-2.3;
▁0.4-1.06).
63;
ifl
hlam
reptococ
vasculariz
▁1.53
=166
erobic
▁40%;
idered
resist
/20
▁uncomplicated
SOA
▁saphenopoplite
▁kidneys
▁teratogenic
▁ECMT
▁surger
▁243
▁2.03-2.7
▁56,790
-41.
2-1.30).
quiring
araz
iotherapy
▁17%
nalap
ualization
splenic
uas
▁SOAPP
8-1.54)
ophy
ibromyalgia
▁(63%)
57,
dentified
uconazole
▁48.9%;
▁pedis
ludes
ilv
cancer
ardia
▁bronchoconstr
95%
chondroit
ofloxacin
8.1%;
bution
▁mainstay
▁5.
▁misad
▁unk
Tap
▁0.7-1.
uestionnaire
▁1.61-5.34;
DHE
keli
=1.24;
isuride
akote
▁(4
▁(6
▁69%
▁Functional
NHANES
▁concussed
▁somnol
urtherm
acuation
ravent
bination
▁endp
roim
irrit
inyl
epth
azarotene
▁28%-38%).
▁1.8-1
udative
nq
osorb
acor
▁ralox
.0,
atherm
▁therape
▁fash
▁senna
▁nodules
0.10
myocardial
ecall
llo
▁Detran
uprof
inetic
atati
reec
▁labialis
oated
lel
▁sunscreen
rength
▁tolmetin
▁cryotherapy
8.2
emoch
enterocol
.003
▁etaner
,828).
bth
▁breasts
7-1.6
ightn
oftening
-41.8)
uretic
<3
=1.3;
.1).
ignancy
]=1
▁diatherm
▁2.8%;
represent
▁pharyng
uitable
▁recalled
▁Caps
erli
▁(3%).
=2.6
▁retested
uati
▁glands
▁discus
firmed
▁gonorrhea
actable
▁modeled
▁malignanc
▁protectant
vate
▁63.5%;
/0.78,
▁enti
▁adiposity
▁chloramphenicol
oglobin
Vasotec
accine
▁Pantoprazole
sistent
▁multination
▁ligament
▁upri
▁radiologists
40
▁(158
=2.7;
screens
▁Intr
atologic
▁incontinent
▁48-224).
▁Grap
orbit
3-0.8
▁oin
disciplinary
adac
ticulocyte
orrhagia
oplacental
▁Tio
-2.78).
venti
▁induc
verview
▁4.0
aer
▁cuto
ervational
▁sertraline
▁1.2-1
0,
eron
innish
▁3.9-1
imus
▁irrig
antif
Lamis
▁betam
idazole
▁transvaginal
▁serologic
▁pregestational
ozy
▁docus
icil
opath
▁ovarian
▁Valpro
ancomycin
-25)
).8
▁heterozy
cillary
pregnant
▁confound
centration
-4.98).
ypnea
tainment
ymphad
titution
gis
▁LN
riag
nce
POA
▁68.3-9
▁4.8)
=.003),
ormities
▁relap
▁(99%
▁Comorbid
nisol
▁treatm
cellent
▁hypoxic
yclical
▁confi
oniazid
▁lesser
▁reliably
▁12
▁noncomparative
▁34%
arcinoma
400
▁21%-5
15).
echoc
oniasis
usal
▁efficacy
ectos
stetrical
▁fulfilled
▁oppositional
omiph
▁umol
4.6;
enh
rated
tual
laqu
inp
▁teen
▁42-78
mune
▁indomethacin
4-0.1
Tis
259).
▁oflox
iners
▁4.7%
cephalic
▁necro
retroviral
▁Eliminating
▁Criter
ndm
-8,
▁angiotens
▁sensitivi
etw
urant
▁duodenal
icare
▁Therapy
tives
entox
actors
▁(208).
-0.62;
tiomet
]=12.5%;
▁1.22%
intment
▁Ramip
▁irb
rals
▁Tsumura
▁<80
/100
▁equivalently
53
▁(167
iterated
forti
▁ovulations
ternati
vals
ecent
ateral
organism
spectr
▁(80
▁protoc
uou
ayle
▁(278/
evere
▁41
being
-3.41);
4.7)
ternative
▁curret
aid
▁bruising
▁metocl
2-9.12),
▁10.7
oddl
2.8%
108)
Both
nures
,80
▁echocardi
▁dehisc
uple
▁serum
▁queti
▁ibuprofen
=135
▁aspartate
▁(10%-20%).
▁opioid
▁227
rimro
taint
esu
mast
erance
arrest
.04.
consuming
▁sti
ylureas
▁268
nually
yqu
Ey
▁tympanoscler
quiv
6.9
▁412
▁BV
▁titrating
▁CALM
therland
▁levonor
0-23.2
ithro
=0.72;
▁antisp
▁revas
▁progestin
▁virtually
▁Annual
▁stepw
353
-1.54)
▁inflixim
▁births
]=10.67;
▁transth
▁meb
choph
▁disorder
▁electroly
-13.
▁genetic
▁adren
▁(49.8
▁Transbronchial
▁NuvaR
studies
0%
▁NNH
adver
▁bacter
▁theoretically
trau
▁metformin
verus
▁methylmalonic
▁0.19-2.3
▁flashes
blin
7.8%;
.04
sulin
▁Respir
terit
enam
-4
=60)
ultis
tet
Bis
▁Doses
▁Compre
▁transf
veral
ifte
ordial
orrec
rounds
▁vesicl
achex
▁20,75
2.5).
▁0.97-2.32;
trophil
▁(4.7%
-3.3).
▁sunbur
trav
mined
ioniz
▁Benign
erious
rept
stetricians
fung
parations
8.4%
ulv
elan
▁spine
buride
▁initiative
▁hypnosis
arox
ilators
gues
)...."
▁561
=0.59)
ostil
▁LEEP
endon
inic
▁<0.7
▁metopro
▁0.13-0.65;
▁0.63/0.
tap
.01;
econd
lith
▁Unlike
▁Routine
▁discriminant
atly
eated
▁hydroxyz
▁(17.8%
▁microscop
ulfasalazine
▁30-
urgery
▁optimistic
arative
▁1.31-3.3
▁percussion
idw
/200
havi
▁Lescol
10%
▁ValHeFT
▁papular
▁pyel
4]).
ughage
3-1.63).
retory
▁42.9%
▁absorb
=.05
70.
xtro
▁49
oplite
▁oxycodone
]=0.83;
ysic
oriented
ispanic
sati
▁Propion
epako
ecati
▁standardized
cti
ndones
rimes
▁OD
SMR
8.1).
excep
eab
omnograp
otrex
terview
▁toothpast
▁excised
▁Lojand
▁thrombosis
ouragement
▁fluv
▁47,888
▁1.2-14.7)],
▁superv
sychiatry
=22
5-5.
=6.9
extur
▁interr
8-3
ldopa
roxy
leukin
8-2.0
▁Mast
-50%).
▁focuses
▁suspicious
▁0.70-1.02).
dihydropyridine
.8;
thros
▁beli
▁Nystagmus
idality
3-0.
▁juvenile
▁88%-9
AFP
ensur
▁bever
elded
ydoph
nted
▁fum
▁topical
▁obstructions
▁Achilles
▁Parents
▁preeclampsia
Hep
imental
Duc
▁1.35-1.7
tenu
▁glycemic
▁99.9
▁Evidence
▁Antib
78
verag
asured
Ou
oloft
yet
ffron
▁witnesses
bograp
▁enhan
77
▁fulfill
65).
190
▁suicides
▁(114)
▁6.6
dullness
▁impaction
=63).
▁alum
▁(90%-100%
▁<11
72%
▁sprin
9-0.8
▁11%
▁amputation
1-5.3
siveness
otransferase
=1.6;
roac
olon
▁ather
▁saturated
▁incarcerated
astas
=.1
nec
leptin
▁25,927
ysfunction
▁97.7%
abetic
failures
8,2
▁gend
acterized
-1.79).
/43
=0.1
abolized
arbose
imentally
▁Identified
NBS
roges
ilitary
adjust
▁precurs
ocro
▁rheum
▁unsuitable
ardura
▁Finnish
=0.59;
6-56.89),
arjalain
▁1.9-4.1),
▁nonsk
saf
ication
▁0.43-2.
arjalainen
TOP
.0.
▁donepez
ariz
umur
rmy
▁20-45)
▁chloramphenic
37;
=4
=2]
▁azathioprine
igid
.9%
▁293
leared
strum
unblinded
▁80%
orly
▁Almost
▁unchanged
▁97.2-99.6%
azilian
▁1.61;
▁5-
▁mesal
gesterone
antibiotic
4-0.98;
ALUE
▁pelvic
▁0.28-0.89
▁hypertension
93;
olerance
adjustment
▁insid
erested
▁adenoid
ductive
Schlatter
▁bone
265)
NHAAP
▁31,5
▁transient
orbidity
theros
,608
▁ticlop
▁absorption
42).
▁fathers
▁40%,
1%,
opul
eech
enomas
ubse
molality
ioed
razole
chil
=7.9
7%;
▁-0.6
orated
▁4.6
▁osteopenia
▁(0.49
-89).
▁Shan
ACA
▁doz
inety
▁prol
.06
▁0.25-0.7
▁nonmil
iglitazone
-91%).
▁systematic
▁6935
yon
iatrogenic
▁adre
▁Injury
▁(2),
▁genotype
oluble
anemic
▁0.5-
tigated
ABHS
2-1.2
ximab
▁nig
▁subc
▁2050.
ostic
=3.5
▁substudy
26.7
ylinder
arginal
orsening
Gail
▁Lon
elstick
inaf
uft
▁85%-9
ucoc
-0.38;
▁5.3.
▁gains
iphen
▁cisap
▁1.45
ipant
ctos
alp
▁(67
9038
▁Hypocalcemia
▁eccent
romat
▁ideation
▁hypocalcemia
oephedrine
▁97.09).
anlin
ticent
6.4%
▁indefinite
▁normo
ropathy
-245
▁23,1
▁0.49-0.
▁1.19-7.6),
86)
7.4
urret
▁1.12
etrospective
▁psychological
troph
▁PGA
▁13.9
▁recommends
uited
minant
98;
oriti
▁microhem
2.5
yste
▁fever
▁tremor
ypon
▁osteopen
parathyroid
▁aided
▁asthm
▁cerebro
diure
toly
▁endotracheal
tissue
ilateral
▁relati
-3.7).
epti
▁cartil
▁209
▁girth
ergon
Tes
▁1.38-3.41);
enosis
▁<150/85
▁0.79-0.97),
▁raloxifene
10)
▁intermittent
aspberry
Bres
troll
01.
ardiz
onsequent
▁pyog
omly
▁Muns
3.5%
▁limiting
otyp
▁adenocar
tranasal
▁hemorrhag
11;
▁randomized
▁0.23-1.
tatin
▁feather
exia
Fir
EI
erosis
▁contraceptiv
▁hypern
ainst
prac
79,600
▁1.30-1.73).
▁nonhormonal
erythro
▁etretin
Relafen
aucas
ameter
▁-1.6
olidays
urpos
INR
compl
▁1.11
▁89%-9
▁inherent
/19)
▁Insol
▁pate
▁anticonvulsants
adders
▁distort
ablish
▁orchiop
▁atel
▁feeding
▁116,
▁postinj
▁Medication
▁endoscopies
▁EBVCA
2/1
▁malab
edion
tular
▁insom
▁tonsill
▁Rates
chiti
reto
3-8
alig
▁Omnip
▁2.7
▁0.82-0.9
nurses
acupuncture
cg
dominal
owing
ptin
osmolality
▁Colposcopy
receptive
ghter
gli
]=12;
6%.
▁hyperch
ronid
79)
iotom
▁ini
▁70-
▁consistency
agulable
▁stomach
▁189
▁0.98-1.26).
▁0.78
Bef
rinted
icondylitis
70
▁(42.5%)
▁disim
axone
▁64%-7
▁strains
6-
Nine
▁sensiti
▁(<25).
▁musculos
=689
▁(140
tionn
▁asthmatic
▁(29%
▁pyogenic
sat
▁(1
▁<1
▁throm
▁ib
adequate
▁adipocytes
▁Serologic
▁zolpidem
▁Abn
anidine
ctly
corrected
▁(4.3
▁8.28-20.6).
ometers
▁1.5-6.2).7
.05).
▁variability
ublished
asting
ulant
androgenic
gth
itab
hil
vei
teroscop
azolam
▁guidelines
exact
▁0.45-0.79;
trated
vived
azone
▁stap
▁prognostic
cetic
nati
▁keto
▁extratesticular
vedil
▁diverged
histamines
olicy
obilization
▁progressive
▁dogmatically
▁polysac
ologic
▁filmed
-23
istam
parin
ezetimibe
▁extrates
▁metab
=1.90
ospitaliz
▁bipol
▁0.70-3.35)
▁Reviewing
9.4-57.
rue
bent
▁aq
ochromatosis
▁gonadotrop
▁cramps
▁confus
rusor
tg
onven
▁-50.
Hashim
enteric
▁antithrom
ukocyt
uric
oppos
▁copp
triglycerid
▁sucralfate
▁surf
82.
▁85%-95%).
▁0.0%-33.
▁(71.6%
▁125
talian
ulatory
unab
plin
▁psychomotor
pant
▁managers
▁alm
▁wake
timal
▁tolmet
estim
▁(2.5
▁bab
pical
▁Lumbar
ldop
▁mononuc
▁dox
]=2).
astroes
▁progesterone
Morbidity
stin
▁24,5
isterone
▁distinguishing
▁Meas
▁classifying
ourinary
obacillus
▁thyroidec
lammatory
▁infre
exce
llow
▁97.2-99.6%.
mall
▁accurately
-57.
anagement
acteri
=0.05;
etri
]=0.
▁13.9-15.8)
▁escitalopram
PID
39%
renting
epos
leepin
ysi
kowske
tebral
▁Thi
=89%
▁Pain
▁Anticoagulation
orsemide
=19.
▁(47
▁MICR
-2.85).
ayc
=0.37;
ufacture
▁1.1-7
ancom
otonia
▁inguinal
Pent
utn
▁rheumatic
▁jum
▁LD
inities
▁cachexia
▁preso
elano
▁orchitis
▁suppression
omiphene
▁glycem
▁8.6
rhe
yce
idays
ysici
▁0.74-0.9
▁Lumb
▁sorbitol
▁uncovered
▁Holotrans
ulti
rganization
venty
lamines
enteroc
=.0008).
▁1.46-7.5
afil
▁birthing
96%
ympanometry
uam
▁medicines
ighly
1-5.
inement
genic
ordance
▁gastroes
▁Schedule
ollowed
acorporeal
▁>90
arcerated
ikely
ITS
▁tacrolimus
associated
2-3.
=18).
▁medication
thallium
-57.9
▁27.7
CEP
rican
rch
ceful
Strattera
riti
▁subdural
ulari
ocellular
ceptiv
pable
orsal
▁cruc
▁4.93
▁penc
▁entericcoated
expressed
lyamine
beros
=1.3
▁specialty
▁antecedent
ypically
▁indi
atome
romo
IDs
▁respon
citalopram
erolog
otri
acycl
▁serot
▁polysomnography
teinu
▁Barret
rictest
ictory
-2.54).
87).
85).
LTS
▁pillows
▁speculation
ystol
4-2.99;
▁Angiotensin
▁unmetab
34-6
▁nondiabetic
▁myocard
valv
▁levonorgestrel
imec
<.010).
aner
etf
▁plas
variate
▁11.5
vov
0.10-0.52;
aroten
isabl
<.002
wab
BMD
▁righ
▁(69%
▁Varon
▁dissemin
monit
▁satisfactorily
▁musculoskeletal
Sul
▁gonadotrophin
228
reatic
ortan
▁vaginal
▁limb
▁therapist
▁radiographic
eryth
ycin
▁89%
▁0.77/0.
▁improves
hrop
argest
▁13-
▁3.3-8
giline
-3.6).
8.9
stitute
Imuran
ostop
epressed
▁epididymitis
▁satis
▁decu
tenan
ormonal
▁compou
▁VISA
▁0.87-0.9
entage
breastfed
ophleb
▁23.6%
796
aifenesin
clavul
icillin
▁98
▁Metoprolol
▁abdominal
▁expense
ideline
▁naprosy
▁2.21-14.56)
ixte
struc
▁reflects
-99.6%.
,1
vated
▁Pentoxifylline
roub
nderg
ronchosp
aliti
▁prematurity
▁orl
▁Simvastatin
▁biofeed
▁neith
▁irregularities
▁40%.
litazone
ryop
ellul
▁250
abd
tolog
9-0.9
536
▁oxim
6-7.0
mop
▁schedul
ormations
tazapine
dayc
-6.59
▁hypercal
-0.23).
▁enroll
orbic
ilies
▁compres
=6.0
▁prolonged
entilation
▁0.80
dized
▁24-
▁lipopro
lec
▁Hosp
▁alre
▁oxytocin
rivastine
74%
/0.
▁triglyceride
trop
▁(6),
▁Diabetes
▁(25%-50%)
▁evac
SRIs
urol
▁noncontrast
▁59%
▁assessed
5%-4
-0.92;
61.
centi
lre
upational
actobacill
eneral
uloc
iclop
▁wheat
▁emergency
▁fruits
▁<.0
-1.09);
▁midt
▁benzodiazepine
▁neutralizing
▁1.44-2.9
-1.99),
▁46%;
▁mothers
▁7%)
▁elevations
▁nonlactating
dary
▁1140
owever
OLVD
9%;
uterol
]=14.
▁multid
▁mebendazole
orably
▁popc
▁3.1;
▁elevating
▁1.8
lyb
ttage
▁goit
1.3%
▁sustained
▁glybur
onop
▁1.38-3.9
▁corticosteroids
▁scor
▁70.2%
oxide
▁(78%)
sally
ylon
▁(2.
4),
▁1.8-18.
>3.
▁cefac
horter
primarily
▁caffeine
ubgroup
yb
=.06
rhythm
▁Haemophil
▁0.86-56.89
▁27.2%,
apidly
valvular
▁1:30
aminosalicylic
▁impulsive
ylori
▁recal
16;
=.25)
-33.
individual
vail
arious
25.
iscal
=-6.5
irr
▁cortisone
itl
▁(82%).
Ov
eet
▁miscarri
▁4762
ecd
either
Wellbutrin
▁(25%)
adol
amuscular
iotics
alges
curately
▁yi
▁immun
▁vulvovag
nol
dinburgh
▁INR
onsored
▁impairment
6-1.
aride
▁1.04-4.94).
▁-0.22
▁Hepatorenal
luoride
ophag
iclofenac
▁macrocy
▁0.56-0.94).
▁26.2%,
izoph
▁1.42-6.
▁embolus
▁heavier
▁NSAID
pap
▁Biopsy
▁publ
▁Combined
sver
▁Ral
5.5;
-0.87).
▁ward
0%).
▁Nipple
olated
kwheat
urray
ipheral
particularly
ysteroscop
▁centers
]=11
▁naftifine
▁cultures
▁321
0.75
▁surveillance
Difluc
▁158
=.047).
▁luteal
▁acar
▁resistant
▁0.2-2.3).
▁15%.
▁(34%-49%).
ignificant
▁Revaccination
=91.4%;
▁(7
biologic
▁splenectomy
hieving
ergen
▁nonsignificant
▁Elev
▁fluvastatin
oxicam
▁AFF
thmatic
28;
▁explored
▁pharmacokinetic
▁(5/1
=2.9%
▁fibrom
▁unpleas
alamic
▁2.41
osup
quas
▁remin
thalidone
▁3.34
enorrhea
irations
▁diseases
nalys
▁rath
▁amin
lements
▁MHI
▁poorer
vary
palp
▁(74%-93%)
▁2763
teri
▁97.
▁sleeping
7-5.7).
amelis
trapartum
▁(75-81
diz
▁isom
58-5.18)
▁counterir
-0.82).1
▁522
afloxacin
ortal
▁0.42-0.9
▁differenc
-4.5
-20%).
▁conductance
-6.4).
▁advant
▁cited
▁Euf
▁magnesium
▁persis
▁54
ardial
odium
-1.66).
ofen
cult
necessary
ocomial
=18
▁hys
▁bloc
significant
ndivid
confusion
-0.85)
onti
▁stric
powered
PST
sib
▁noncal
▁predic
002
36),
armacy
ffecting
erone
▁construc
▁glycosyl
▁2/20
▁1723
verestimate
=.3
▁1.52-
ucan
▁85%
cessf
▁Splenectomy
vervi
▁uti
orges
▁mane
▁systemic
▁6-3
athology
nating
▁usef
ircu
yuria
▁pertus
sist
unar
sting
▁0.13-0.2
▁cyclosp
▁scro
lance
tinoids
amomile
▁4.
▁>78
▁histamine
▁mathematic
oeph
▁bey
phenazone
7%-
▁8636
▁19.2%
donal
▁breat
trogens
▁increments
▁25,92
▁hyperten
interquartile
=1250);
athyroidism
tenti
=12,
Norvasc
asber
idating
▁nonacute
2-1.86).
▁disab
▁2.1
903
ertro
60.
12).
▁1.4-3.
▁80%).
62;
▁4.32
orit
elanoma
▁Toddlers
▁competent
enzae
▁BMD
idy
ycolog
▁hep
riam
▁1.3-4.
▁0.70/
cetaminophen
yyear
▁658
itary
=98)
ocrin
▁ae
=.005),
▁thiazolid
fis
▁reduc
hyll
▁0.2-0.5)
8-3.0
abul
▁1:
▁restrain
▁spray
<.001]
▁1.09-1.5
67%
initi
inser
▁regimens
]=1428);
▁0.71
▁0.17-0.44
▁(60%)
-3.7)
Seasonale
curs
armacologic
▁qualit
▁multinod
inted
▁dumping
▁flunarazine
▁Vene
▁antidepressant
bolism
▁12%,
13),
allenges
▁depress
▁deter
▁breas
ticoster
coin
eant
isoprostol
entations
emaf
9-0.
▁18%
▁Antibiotic
▁Thirteen
]=8.4).
▁kneeling
cest
▁descriptions
/30)
-4.5).
▁communications
itazone
▁(122,47
/1
▁nonfatal
=-2.38
ciitis
▁dul
mally
uage
typically
GADA
▁consciousness
HSI
▁etan
35;
▁fibromyalgia
▁coit
006
osor
3.21
rinology
cum
enor
▁Lyme
esized
▁Gibb
▁pharmacy
▁fulfilling
]=0.39;
▁workups
▁clus
ispos
pread
ulfas
itives
▁abst
anomet
italized
inosis
▁procal
▁Hys
idation
▁heterosex
500
ichloral
▁inappropriate
>8
▁COPD
onor
jour
▁0.71-0.91).
▁Thiaz
osam
▁1.07
xide
9-7.
4.8)
▁nonsurg
istologic
4%.
-1.63).
▁rab
▁0.93-1.67).
▁shor
ABR
▁inheren
▁guideline
apent
▁CABG
▁110
▁0.06-1.23;
▁dissection
edative
▁breastf
Lor
▁uterus
utinely
onded
▁(85%)
=85%;
veh
▁unil
▁awak
ergotamine
▁Remaining
paral
=0.71;
.1,2
ithout
▁antise
opne
▁coping
▁47,228
ousn
emetic
▁89%;
▁swabs
▁rosiglitazone
entrate
ease
ript
▁hypocal
▁comprising
▁diaper
▁Adolescent
revoxyl
accurac
dayclinical
erbil
▁Statistical
▁biof
iopex
▁257
00,000
actation
▁6.5
▁87%
onchi
3.7)
microb
▁1.36
-20%
cerid
accharide
▁myc
treatment
87;
▁42,448
▁chasteberry
002.
fecoxib
▁ketoconazole
41;
-14.9%
]=1.2-10.
endazole
21.
▁pravastatin
▁(11
-0.75;
verg
terized
novascular
▁43
=111;
▁HOPE
▁(90%
▁hexacetonide
▁tear
▁primrose
rele
xant
▁membranes
hythm
▁0.36-10.36).
21
▁salb
▁microin
▁99.2%
▁isl
▁cefaclor
▁vals
▁nonlact
▁11.2
9.7.
Lact
otrexate
]=5
▁hospitalization
lasty
-1.88
=.17).
▁fibrosis
valine
▁positioning
ydia
ighted
Rif
lamydoph
tiative
▁abstr
▁Retrospective
tism
eractivity
▁heavi
▁nonanemic
▁ruptures
▁Unl
USPSTF
▁sclerotherapy
enzod
39
▁anes
ibroz
=31)
▁63%
unog
past
▁Exac
ubl
]=0.56
urologic
▁5-25)
ecolog
olger
▁lorazepam
gnancy
▁papule
endic
azole
▁epst
▁psittaci
▁Stimul
63).
tsc
hydrates
vedilol
▁norethisterone
llip
Even
▁undet
.3-42.
DCA
7-2.9
▁valproate
]=10
808
BSS
1.6%
enters
▁reflec
▁37.
0.44;
brile
elet
entive
5.7%)
thos
▁Invent
bse
adenopathy
ollicle
asal
umbers
▁nondiarrh
emog
▁Infarction
iately
▁35%
epiride
irf
usation
▁20.2%
3-1.67).
▁Aerobic
<.05
▁(20
▁Evalu
=.043).
abdomy
irts
coh
77%
▁880
ulfid
30)
utwe
utri
ilk
42.
hey
]=4
50%
=16.2;
5.8)
2;
▁multis
2-5
posures
▁nonster
=689,
Fif
acid
epr
▁trichlor
-0.38
7;
efficacy
edited
produc
▁Mixture
▁Rarely
▁palatable
▁>3.1
5.5%
▁unm
▁incompet
▁perinatal
=2-4
cellular
entamic
▁nylon
▁1.8-45.2).
sensitivity
asonable
osart
297
tionto
=-1
lym
▁widespre
▁2995
▁mycologically
hazard
cry
,5
▁tenos
=.2)
▁stepp
2.1;
65
poin
=5.5).
▁transcervical
▁(82
▁Antim
urations
▁innerc
ducing
ozyg
onan
releasing
▁obstruc
esiz
usp
erand
▁DS
STA
amisil
▁mefl
▁buprop
▁quadrup
▁incontinence
obac
▁granulomas
▁sampl
▁polysomn
ocyte
stetr
athyroid
▁594
▁pellets
neonatal
8.8%
yridine
olence
▁352
▁1/200
.3;
▁thrombos
rospective
▁perih
aryngop
27
1.8
▁temaf
▁96%.
▁participating
▁0.0
ronidazoleor
olines
▁subanalysis
>5%
mou
▁testoster
administration
▁(12-1
tiqu
0-1.2
estry
NV
▁atten
▁volunteers
81
▁(3%
▁menopausal
ofib
4%-14.
irsutis
estive
oskeletal
▁intract
irthing
▁17
OAE
▁polymyxin
▁0.20-23.21)
▁mupirocin
▁schizophrenia
▁referen
ipol
2,478
taz
▁Myocardial
▁intermedi
▁nul
=112).
=255
atib
▁determines
=2.0-2.85)
<1
ublesome
-1.34).
▁Wiscons
=0.5%
noring
▁477
39)
▁30%,
▁preserving
▁mirtazapine
▁(43%
▁antihistamine
▁9610
▁650
idosis
initive
▁normotension
▁chew
▁-6
▁gly
7-0.91),
▁<.05).
▁1.1-7.0
▁(49.
▁4.7).
hinPrep
zetimibe
▁SSRI
enoma
tigations
ificant
ogenicity
▁Lifest
▁presentations
▁Behavioral
8.9%)
boovarian
▁Coza
▁flora
▁trichomon
▁78%
irds
IUD
▁68.4%)
borrheic
oxid
▁inducer
▁1.4-5.
lusions
lafen
87%
soc
fat
anov
▁0.70/0.9
munob
ptine
terval
icides
opam
7/344)
▁habits
adition
ptococcal
apanese
▁physiotherap
▁hepatitis
oxygen
▁prostat
▁american
51/36
▁141.
rocyte
▁confinement
apine
▁Copen
=0
zulfidine
▁angiography
chial
▁Cooperative
rificing
▁accep
laint
▁19%
▁MRSA
▁awaken
▁communicability
▁112
Arthrotec
▁coni
▁47,1
tancy
ecations
medy
istency
androgen
1-1.9
▁bronchosp
4.4).
▁calories
▁0.09-0.38;
4%-
lerotherapy
▁dropp
▁56
▁noninf
odophyll
<0.
onog
thi
▁181
▁Targ
5-0.99;
▁183
▁Varicella
eresf
itati
▁lipophil
roups
aic
.0
▁Wah
eers
ght
▁bronchial
anate
ycodone
munity
opositive
LU
ticar
lorper
▁deh
98%
opri
quival
▁licensed
tia
▁anesth
▁(266,064
2]=57%
5-1
▁itch
idazoleor
▁colic
ginn
▁clamping
▁>3
▁caregi
▁3.54,
▁Brickner
=63
ylam
▁Hispanics
erly
ecis
▁exce
▁Lik
ortend
otally
▁1.3-1.
▁2.1%
▁acti
▁cystitis
3]
▁anec
TCAs
=2-45
▁plasmace
▁HS
▁cital
▁Thes
37),
efac
▁GAB
eplon
6%
ripiprazole
irteen
alar
▁infants
rth
3.7).
-14.5
▁PD
Ck
ticl
-70%),
7/34
▁tissue
1/36
anent
▁gradi
=.04
arbo
▁tol
▁779,600
],17
=.005).
▁decubitus
▁(71%
85%
▁(28%
-1.23),
▁serological
32-526.
▁scalp
iometry
▁leukocy
nre
▁(23
▁departments
7.7
ABGs
biological
lud
▁underw
▁substud
▁blacks
ergone
idneys
▁fractions
ropsy
▁waking
▁diabetic
lives
ormalities
ching
▁8-
▁1990
=.2).
-8.0]),
reasts
afood
▁Alzheimer
iphenhydramine
LHA
▁investigator
tivation
▁plasmacell
ritable
5.2;
▁disch
▁antacids
81;
olec
otions
=3.3;
▁Alm
▁2,
aep
▁TCAs
▁triathl
▁multiparous
▁buproprion
ancel
-1.40).
▁0.18-0.87)
icond
▁Pregabal
lained
emiologic
nition
=5),
▁dilat
▁elicits
ufficient
ermination
ypas
=167)
=.92
▁3339
]=13.9;
plasia
▁5.4-1
▁vaginosis
▁enhanced
▁seafood
]=15).
▁horiz
▁35-
▁leukot
abular
pnea
median
.0-1
umors
▁47%-49%.
▁exacerbate
▁Infant
▁gout
▁stapled
▁subd
RIP
ucial
▁langu
92;
▁saibo
invas
6-56.89
tratif
=11.7;
rhea
▁aspiration
oiditis
toms
illectomy
▁8.28-20.
▁5.4-12.
imbs
33%
ecurren
▁recipients
▁90%
▁208
▁fluoroquinolone
-96
▁Nys
eit
▁curettage
▁0.89
▁18%,
▁paral
inste
=6.4
▁sensitivity
▁Hear
▁kic
walking
comf
=12,603
stol
-54%.
parative
▁psychotherapy
4-1.0
5]
67)
odds
▁maker
▁Nyst
0/0.
nacipran
otassi
fecox
=13.1
uco
▁distur
apule
ormone
▁hyperbilirubin
▁deviations
82;
=1.70
▁molecule
▁(0.14
▁heterose
▁salm
inment
ditionally
valent
64.
yclo
▁Reduc
▁electrolyt
▁43).
=.007).
10).
480
▁1.57-7.86).
▁influenz
▁assesses
iuria
=1250).
edin
cef
1:
omat
-2.19)
▁Bri
▁appendix
urbinate
-7.4
Ost
revox
▁dozing
mip
▁saibok
efi
▁3/1
▁(4-
rojec
adenoma
roer
osocomial
▁12%
▁Acne
▁170
=2.8;
ralizing
▁1.13-1.63).
▁Prac
▁(81.3%).
▁labored
achyp
▁0.34-0.99).
▁uncircumcised
onent
ymptomatic
▁(11.
▁nati
▁qualitatively
▁immunogenic
44,825),
ipocytes
OPD
opre
▁lipop
-9
43%
eith
▁determination
▁11.9%
▁421
▁16.7%-8
=88
yzine
eves
▁280
▁-0.6);
▁1.5-6.2).
olesterol
▁7957
ertensive
sment
rofur
-2.76;
vain
tensi
▁hyperthyroid
tician
▁palat
astases
spective
ionine
▁hypera
40%
quor
▁ine
ondro
▁adenopathy
▁Pati
nipa
-83.3%).
▁paradoxical
ubsequent
▁prophy
▁homoc
▁perone
▁cowork
tite
levi
-1.23;
=48)
▁seb
▁feigned
▁wearing
▁Tann
ounting
▁freez
▁crutches
▁Epid
roxet
=.06).
copic
choc
2.3
▁3
▁differen
natal
▁harms
▁(10.8),
▁positives
▁>7.
thal
▁Subsequently
▁Warfarin
▁Waddell
andatory
▁handful
etformin
▁erratic
ersen
▁infan
▁lifest
▁alend
]=6
gthen
65;
▁hypercalciuria
unl
PGA
▁LDL
romyalgia
artment
▁Sod
▁detrimental
traep
tioning
elon
Hear
▁Tolerance
osus
▁ossicl
actin
sian
=112
itrof
WBC
133
tric
inkgo
pretations
amazepine
7-2.
1.
▁dropouts
conducted
▁48%)
▁0.48-0.9
umbered
remasteric
▁propran
▁defibrotide
▁electrocautery
diagn
iotomy
ezil
4-31).
▁(2
enof
▁estrad
ultation
dul
▁(42
70)
=0.8
▁490
▁ure
▁<.001,
rosem
▁197
▁conjunction
xC
▁0.1,
▁Neuropsychoph
▁4.32-526.17),
▁33-
,44
=1.13;
reli
▁Endomet
▁auditory
amous
▁Veterans
▁irbes
uaifen
lementation
6%,
▁laboratory
▁Trials
69
▁9-
561
▁arrhythmias
ogroup
headach
▁1513
asmod
VH
Cro
hypertensive
▁lymph
▁elastic
ipecac
▁Progestogens
▁ambulatory
etters
=90)
GH
bered
▁implants
2%
▁ethnicity
30-6
ranolol
rimar
relate
▁testic
vasive
▁statewide
43).
NID
▁8.6%
tire
ternalizing
05;
ulopust
▁stenosis
▁-20.
▁stimulus
▁uvuloph
▁nondisabling
2).7
Norm
▁discl
▁(1.2
▁14
▁acne
▁polysaccharide
▁Pregab
▁trog
niqu
cysteine
▁tine
▁HRT
abas
oxine
ithium
▁myocardial
▁1.11-1.90
▁Aspirin
ondylitis
cribing
▁discom
4.6%
▁sha
=464)
chom
▁intentionto
▁duod
▁(62
▁Osteoporosis
▁definitive
▁coadm
abolic
▁dextro
loral
▁TDI
▁buspirone
▁favorably
▁idi
idance
10-0.
▁quetiapine
iazepines
▁cavity
entory
ttom
▁externalizing
=-57.
macule
▁Computed
neumococ
▁Readjus
ucc
6,7
oquin
5.14
▁20)
icep
▁remind
4-8
mortem
andardiz
▁calcific
▁supra
roergot
7.10
▁citalopram
-0.88)
▁Steroid
▁amnio
▁hypogonadal
unv
▁metat
enem
holinergic
ynvisc
eati
▁metatarsal
PIs
▁Ostenil
▁[9
▁perception
pecul
oagulation
▁numerousre
▁streptococcal
▁tolerate
▁nutritional
▁86%;
uthyroid
▁Autoantib
▁5.35
ilol
▁expectant
erlin
▁Lamis
eim
3-1.19).
-1.78)
170
-24.3).
ndex
▁308
henof
bies
erim
▁(8
▁buc
nists
▁(43.2%).
▁vulgaris
pecif
▁(40),
▁Outcome
-2.
oler
▁(69%)
ramide
tapering
imazol
▁kneel
▁Swed
▁Psy
holog
▁55
=1.4
hana
▁4723
▁revaccinated
▁arthralgias
▁postterm
onopathy
heter
▁4328
=91.
▁11,42
exC
cisional
adually
-1000
nosis
HOT
▁Pant
.001
▁2000)
athl
6.7%,
bogr
▁electrod
adm
5.27
▁professionals
vors
ystic
rinolog
spir
versible
acterial
embolism
▁(247
ffus
▁unsweet
lyl
oxet
▁toi
-23.2
▁anembry
▁>32.
▁cyclosporine
rozac
umented
rogesterone
▁enoxap
itone
addre
xap
vertebral
reactive
▁0.0),
▁Nim
▁clomiph
▁hypothyroid
▁distress
arenting
oidable
tinine
aprosy
▁neurolep
▁verap
▁0=
▁20.
▁pulmonary
▁276
▁Risk
▁Stratified
-1.58)
▁reveals
elev
▁exch
nst
tiou
atas
inute
illn
▁(17.
traction
Bere
orvasc
▁16.7%-83.3%).
▁1.05-1.7
iffere
▁299
▁cephalexin
rhag
▁OAE
▁hypogonad
=7.9,
-3.1).
672
macy
otroph
onstriction
retable
uprasp
plants
16)
velopment
▁1.80
▁bedro
22
▁2.47
▁Stro
▁proximal
5-0.77)
orst
8-1.58).9
2.6
athic
positor
azodone
]=1.1;
▁inflammatory
▁cruris
▁exhibited
▁48%.
9-0.6
6-1.30).
bolic
iotens
▁magnes
echan
idoxine
rogly
▁tetrac
▁progression
analyses
▁43%
okel
78).
▁psychos
loth
ribonucle
afety
▁acquir
eav
22%
▁otitis
▁sweats
▁95
▁isoniazid
MCI
▁80%-90%,
-4%
opecia
abal
uded
ermint
ullness
▁0.18),
▁sut
▁unexpectedly
ricians
odilation
01;
entures
▁Worsened
▁expenses
ciclovir
=3.7
oes
▁phri
omf
7.8%
-76%),
▁nonspec
▁7.7%
bulin
atex
▁averaged
▁PROSP
▁2)
▁enox
gely
gether
▁Atar
oreal
examin
▁qid
▁diar
elone
▁percutaneous
Spect
nephropathy
VT
sition
▁Abdominal
▁powered
mation
retations
▁antid
▁investigators
▁febri
▁plafond
ecurrent
▁bleeds
oneph
=39%;
=2.2
▁(50%
▁treatments
/24
▁Detrano
▁egophony
▁carcin
691
▁111).
ytop
▁Biopsies
ightf
4-1.7
orati
▁douch
▁Practice
=-1.
lun
▁breathing
centage
Vir
ematosus
▁widespread
17).
▁Capsaicin
eel
▁Scale
tch
▁extrac
▁2%
▁retest
ertus
=7.3%;
▁renders
▁Examination
uin
kapp
iptic
▁79%,
leptic
▁dizziness
=0.8;
onse
osk
stracts
udesonide
ultination
ommendations
Ol
sule
▁Corticosteroid
motor
▁identifi
▁(99
▁419
7.10)].
coagulable
edications
5)
tiat
35),
RSA
▁1.38
▁(5.7%)
-2.3;
▁unnecessarily
strument
copres
acchar
200
ionate
▁splin
▁1.02-1.25)
▁3.9
5%
iteria
▁achieves
IDNT
▁1.3-3.3).
istering
▁-2.54
▁elective
onac
▁77%-8
▁cumbers
DNA
▁>2000
CRP
-0.71,
98),
▁solids
▁favors
▁Belcaro
▁0.24-1.51).
oanti
▁fluorid
vad
manently
▁quinol
idemia
oxicil
terans
,4
opathology
▁distill
till
000
=8245)
smoking
▁reversing
▁beneficial
,-1.
ripe
Aid
orat
Rev
striction
▁42,
▁ciclopi
ameron
]=0.89;
intens
<5
▁NPH
▁(1.5
lator
▁176
=2.38;
▁1.6%,
▁spirometric
4.3)
4-0.52),
Dif
▁lowm
▁9.7
fad
▁differe
▁2287
▁expec
▁(0.5%
▁erythrocyte
▁20,5
jalainen
ulou
▁oxygen
loph
RD
▁budes
Nu
dere
▁(1990
▁3.5%).
▁pharyngitis
▁0.84-1.12),
▁revaccination
acill
▁heartb
mpro
▁fertility
▁12.0
▁(4.6
merc
rosso
▁(39
▁42;
Dys
imazole
▁methionine
-0.74).
▁morn
▁avoidance
▁Empiric
>0.8
▁verific
▁incu
tul
99
bog
▁cetiri
▁anteced
▁melano
▁edem
enop
inesterase
idon
ochemical
▁textbooks
▁hypoventilation
olor
inat
▁50%
▁NSAIDs
▁Initiative
olerant
onomic
▁ischemia
aparin
yptor
Vand
▁Resp
▁optimum
dosed
▁uncircum
arb
-3.32).
▁(2.9%)
iopl
ifenesin
▁sucral
▁clu
]=0.02)
tiem
▁0.09-0.
005
▁Pioglitazone
60).
rtic
udates
▁(68%)
(<
ucts
▁conges
▁infarct
▁endpoin
▁endobronchial
veloping
riptyline
=143
▁1960
vem
▁bacit
▁paternal
▁308,755
▁concordance
oglobulin
▁feat
▁vagin
▁decub
▁vitamin
tici
,825),
1.7%
▁ibup
everity
1.8%).
▁2.0-3.
▁(85%
hangh
ulonephritis
onad
4-3.
tbook
▁cryptorchidism
cog
rophilic
▁competence
▁5-33).
▁standardization
542
alor
ethoxazole
▁benzodiazep
▁(32,684
▁multinodular
▁capsule
urrences
1.8)
▁impai
▁tet
▁0.50-0.78
regularities
akage
▁reproducible
494
eresford
▁UPDRS
▁citrate
▁1115
▁Achill
▁(1450
CNBSS
agnosed
▁Orthov
▁hematoma
5.1%
▁46.
▁knife
6-6.29).
lusively
40),
heumatic
renc
▁diagnostic
17
▁hypoglycemic
ethop
5),
▁unsaf
▁3.1-1
▁3/1000
▁acrivastine
▁lisin
▁disimpaction
ndice
mokers
escol
▁maturity
8-2
odin
ifed
▁underway
85
ackup
unm
reig
▁morbidities
2-0.8
▁Desquam
▁subarachn
aind
▁Polyp
apaz
6-7.
chizophrenia
ytologic
▁(19%-40%).
entere
▁antiath
]=40).
▁immunof
▁scarred
▁dissem
3.21)
▁1.66
▁unipol
orrhoid
alking
erbinafine
▁chlamydial
botic
▁sulfis
=2.0-3.0)
▁0.81-2.1).
anage
▁7.
erq
-0.4
athological
▁2.5-
asionally
5.0%
▁(3/
ortic
▁vag
exer
directed
entif
▁Postp
isole
Tre
▁Alendronate
=.4).
▁nonorgan
vailable
▁Bangl
ausing
▁(1.
▁depressed
osolized
onography
turns
▁hypogonadism
00/
jec
=3.1
ominantly
▁ejaculation
entile
▁inadequ
illance
8-2.05).
▁41.5
idn
llb
linici
▁hepatocell
▁Readjustment
▁migra
▁neop
▁thrombotic
=.03).
0%-4%)
▁smokel
7.0
▁bleeding
▁16%
▁dydrogesterone
Lovenox
nk
iminished
▁hydrochlor
reaks
▁0.57-0.9
▁FT
sied
azin
agnosis
▁1.04),
▁itraconazole
▁13%;
▁234
▁6,
eduction
adenop
ehavioral
▁Hib
Au
▁0.5,
▁(16.4).
▁Vand
partic
isition
yloid
actob
deri
fasting
]=5).
1.9%
opc
covered
sage
olution
uice
=32;
prandial
▁47,150
▁Luteal
▁Obstet
▁(34%-4
1.2%
thl
▁5.7
romazine
▁92.9%
▁1861
▁elas
,000),
nisolone
▁7.0%).
kag
▁neurorad
▁388
▁Coch
▁Combining
=80)
koc
dac
aparen
=26).
loqu
enicillin
▁ND
▁(440
▁urinalysis
lamy
▁>0.8
▁Tissue
▁931
▁fibros
▁preven
etion
breastfeeding
ofold
▁Impressions
6.76)
odiaz
ounsel
therapeutic
<.004
iciar
Mur
▁efficacious
▁excl
idious
▁Fet
ubjec
▁percentile
▁penile
usag
▁deox
dap
latter
43)
▁1.45-4.9
epin
▁polye
iotensin
Dos
92
▁23,
▁rales
▁stimulation
ABH
urett
ayers
▁(10%-2
=.818),
▁ciprof
.0)
▁bilirubin
▁prelab
aparos
▁10,730
xio
▁diap
▁discriminate
▁Fram
ihyd
orizontal
ococci
gested
osure
8.1%
▁2001
ractions
vach
ereg
▁1.61-5.3
onectin
▁86%)
cicl
mmol
▁retic
olol
▁antire
inkg
-4%)
▁Diphenhydramine
▁ciprofloxacin
▁empiric
▁55.
▁0.24
▁shampo
vicular
29;
erioration
igns
arkers
berog
▁nodule
▁predictor
▁duplex
Mort
▁Advancing
▁Incontinence
lth
▁660
yoth
95-2.
3.1).
▁Hysterec
eplacement
▁tympanostomy
▁masked
omiting
oam
-0.99;
paris
▁resect
▁brush
=29
▁60-
itiative
9-15.8)
utlin
umetone
▁hypotension
▁voiding
potassium
.01).
▁Scoring
▁noncontr
uctural
▁remission
adder
Rimso
edle
,730
Bactroban
▁1000-1200
▁formul
▁lute
hostility
▁testos
uates
compliant
culos
7-9
ronchitis
bdominal
▁plaster
▁occurring
▁9.7%
▁Melanoma
=0.4).
437)
bulatory
▁136
-0.70).
usively
▁2.72-41.
▁orresp
euvers
epatorenal
compli
orti
Priniv
▁0.50).
TG
▁0.49
▁Somatic
▁positional
▁rick
▁crosss
▁noninvasive
ukot
ibia
▁Epidemiologic
▁89%-92%
▁cured
Arth
▁0.41-0.77;
▁18,8
▁effectiveness
urements
ustion
onstric
resec
alform
omes
palpation
▁swab
▁preinj
utaneous
▁impot
asmolytic
▁0.90/0.
anic
amol
asti
▁colposcopies
603),
erol
▁2.4-17.10)].
▁41.3%
aseline
reefold
▁guidebook
▁UPD
▁1.19-2.41;
olycystic
Tar
tiar
Gro
bability
ipos
▁68.3-90.
riminant
munications
roen
erience
lactin
▁nonl
=0.25;
▁trend
▁383
▁miner
-9.4)
1-3.
publ
2.7).
60
prodrome
▁(31
luenz
imult
yces
hic
▁Roch
▁modest
ophage
▁defects
▁manipulation
▁hydrophilic
▁metron
udin
ceal
▁Theo
▁psor
oad
-3%;
tino
▁tympanometry
chosis
▁1.57-7.8
▁carotid
vation
▁constipation
▁coronary
▁Alzhe
=1.24
rolog
ilir
xyp
▁bronchoc
▁1243
OAb
othiaz
9.42;
▁chlor
▁paroxetine
▁hypothes
kid
▁regained
▁indome
567
roscopy
▁4.5
boph
ulitis
▁divalproex
▁0.12-4.
instead
71;
ourage
-3.5
infection
▁fulmin
147
▁70%.
7.3%
pecific
venous
▁parental
especially
achypnea
02
oraz
▁preterm
▁macroadenomas
751
-4.8);
amic
▁(92%
▁Subjects
4.7%)
804
▁5.1
sess
▁11-24).
calor
▁ESR
omycin
2-2
▁(95
▁glyc
,7
560)
▁lorazep
pingitis
osphonates
,13
ogast
▁titers
▁GERD
lated
▁rul
▁Progesterone
▁carbamazep
lled
▁wk
adian
▁Absolute
▁Lute
viations
rhythmias
▁poin
teroidal
▁Laser
resti
▁painf
mong
▁reasonably
▁actinomyc
▁(7.4
▁tox
lline
alene
haped
POAb
▁(6/109)
vegetable
olesterolem
ibrom
▁0.36-0.6
sou
2,6
2.34
ylert
▁10.
oures
3-0.1
ehold
-7%
enous
▁inadequate
▁Simms
-84).
acting
▁kidne
▁retin
omach
hepatitis
▁312
Celeb
▁mamm
ceptions
mpt
▁contac
▁PROS
tsd
▁jaundiced
▁episod
▁bacitracin
▁4.3%;
▁hyperthyroidism
▁4.1
ledges
▁interc
letion
stress
ermine
▁adul
▁schizoph
438;
ipartum
buterol
▁suscepti
▁attem
onucle
▁GE
▁practitioner
▁0.05%.
▁chlam
=25.
97;
utb
▁enrol
▁malar
14,
▁Comprehensive
▁specul
▁reticul
▁menorrhagia
▁dermatos
timulant
222
▁intentionally
trib
Celexa
▁58.0
uising
▁21,
▁endom
luence
rofloxacin
▁extracorporeal
olesterolemic
bercle
novial
▁crackles
▁6.65%
▁Inventory
▁0.2-1.
▁51%
▁absc
▁manufacturer
▁commerc
▁meticul
6.8
ynovitis
1-2
ephalex
▁epilepsy
▁PMS
▁taz
strate
▁Impres
otracheal
▁abstinence
▁nitrites
weats
proate
▁tinea
opment
aref
asized
▁nurs
▁(45
ulfon
▁treadmill
fortified
0.2%;
70;
▁paren
onide
plete
=1.24,
exCAP
▁statew
histamin
enolol
renat
91.
ensi
roly
▁triglycerides
▁pyoderma
Vistaril
▁0.14
ylophor
▁outnumbered
.7.
ellets
▁Assess
indol
▁Dried
▁unsuit
▁55%
10-
splitting
▁Allerg
editer
▁unsched
emati
ethoprim
▁0.47-0.6
▁0.7
▁33.3%
▁lacking
▁0.70-1.09);.
ecro
rter
ounder
5-1.0
articular
14;
.4
▁>45%)
▁eros
▁28)
▁antispasmodic
▁16.
▁83%
PaO
weighed
rites
▁unres
▁alcoholic
▁sleepin
=4060
=15).
▁onset
▁atorvastatin
▁murmurs
quires
1,
iplin
▁8116
▁Individuals
stem
=3.4,
iou
isus
▁antidepress
sive
tings
Wad
▁3;
▁uptake
7-2
totreat
omn
▁5608
▁Pharmacologic
ocat
▁licor
▁excr
▁acetyl
/344)
▁Hispan
▁rati
phic
▁strati
▁(0.9
▁nonasthmatic
=4.4).
▁1.56
acyclovir
▁becam
DAS
arret
amide
▁pioglitazone
ABAs
comitant
▁-0.5).
▁implying
▁29,133
ffexor
689,
,25
rhonchi
▁intrap
mentary
▁1.02-
▁automated
olving
6.2%
▁(45%);
eber
34;
ithd
▁simultaneous
▁Comb
difference
▁HDL
▁1.13-1.6
▁Engl
▁15,
sverse
opex
▁dental
▁genitour
dre
uberosity
ositive
ylit
ayed
0=
▁hyperandrogen
▁jeopard
tional
▁couples
▁1.18
▁identifying
CEL
▁anxiety
▁appraisal
tinom
ostom
inkles
▁stimul
aturation
orrhea
▁8
▁attainment
thro
▁ticlopidine
erti
epith
▁phon
▁expedited
=64.
ussi
-7.5
ulfidine
alance
▁1.47-2.9
ographies
potential
▁irritation
Du
▁tubercle
3%)
▁inflate
▁515
thre
iousness
ternational
rometry
echanism
<.005)
cessibility
2.0
▁reas
▁flun
▁(49%)
▁0.75-1.0
ichl
alian
▁DAS
▁44-8
=110),
creatinine
lytic
▁monitored
▁irbesartan
cobal
tender
unli
▁chronic
▁ipec
▁-3.54).
strab
▁0.09
adicated
olics
▁pantoprazole
▁Hyd
▁serotonergic
▁undetected
▁dyslipidemia
quenced
volol
eted
▁subfractions
rogenic
peri
]=1.2-10.9,
▁Prog
raphical
▁reco
000)
itin
atify
▁troglitazone
140
▁urg
78;
levation
=8;
▁ulcers
density
ulvov
▁olamine
▁specialist
aP
reasing
0.6
▁2611
-0.98).
oquinolone
crom
domy
ogens
=18,241),
▁cran
▁practic
Enbrel
▁apne
hosp
▁Gonen
wly
▁4.32-5
luconazole
uccess
agnose
dihydrop
entified
▁tac
▁Nutri
yptorchid
olytic
▁punch
▁1.13-1.66).
agia
axine
WEE
erac
▁encomp
-35;
arked
ifth
tiary
▁0.96%;
▁denser
8-
4-0.
▁Eight
weighing
▁hyperandrogenic
vulan
▁ASCCP
▁0.52-1.30).
anderbil
▁suction
▁neuropathic
2-8.4).
▁bronchitis
nP
▁potassium
munof
▁FD
▁facial
▁gri
▁transv
=34
▁favored
▁requi
▁77%
imaging
▁estimating
▁30/
Thor
resl
▁cerv
oling
▁DF
▁(35%-50%
▁evaluating
▁0.36-0.60).
.001).
oed
▁41.8
verif
▁(3%)
iptical
▁breastfe
.005).
▁proti
iov
ixth
imilar
vide
tenat
=0.36;
▁intake
▁arrhythmic
-2.38
sly
▁99.
▁biased
=1.33;
3057,
secondary
onstrating
▁aging
▁7
glycer
▁Twenty
]=77)
7-5.9
▁106.
▁0.63-1.01;
▁5%;
▁734
rof
=-13.9
olecule
▁0.7-0.9
▁11.3%
▁alopecia
▁oxymet
322),
ritical
axati
inuria
elves
lating
▁Genital
▁704
▁morbidity
▁16%,
44,
▁diverticul
CAP
spectrum
▁0.29-0.96;
▁explor
▁discomfort
▁classifications
pful
tioners
tle
-0.3
emorrh
▁pyrazin
tinoid
troban
▁beha
entric
ortem
3%);
▁1.0-12.
▁2.66
▁emergent
▁0.12-4.16)
romatosis
▁0.70-1.09);
productive
umati
▁loz
▁triathletes
▁mc
▁0.30
]=-20.43
▁embry
▁capill
▁2900
izanidine
tentionally
ongest
itrofurantoin
▁17%.
▁CDC
▁detrusor
▁galantamine
▁obes
azapine
ergot
ocaine
▁prescribing
-1.15),
▁(58%
iwe
▁PLP
-3.51).
.01
ricyc
▁variabl
otransfer
▁CABGs
44
▁33.
▁informal
▁Antagonist
▁quantitative
▁parathy
vely
52.66
▁RSA
▁hypot
ulence
51).
alopathy
afibrate
▁463
▁246
▁PSI
▁1)
▁0.33
▁2.0.
▁2.1-11.9
especi
=61%
eliver
0.7
▁Stroke
stati
.1%
3-0.74).
leic
=0.87;
▁cromoglyc
tifine
pir
▁suture
▁injected
cleared
valence
▁superiority
responders
▁903
▁psychi
inolones
Hys
ibit
luox
omograp
▁57.
48%
adion
▁Wen
8-1.54).
mates
timiz
9%.
▁exclud
▁Regular
elated
enograp
terle
tioned
▁ef
4-13.16
45)
▁27
▁0.14-0.52),
erases
gamm
▁(>100
▁Exercis
ovastatin
▁rhin
azep
worst
erape
▁heteroph
-0.
▁Hispanic
▁anhydrase
▁deem
▁<10-
▁alon
▁4500
LHAT
▁Antic
Azulfidine
boc
ylene
wake
▁ove
bilirubin
alamine
=23,
ressive
▁cultured
▁Tyloph
=12.
ethox
epend
▁skeletal
▁nonmelanotic
3.16
▁0.27
▁hemof
▁receptor
▁Clinic
▁(112
ialized
sychotherapy
▁0.64
eran
ergency
▁Clinician
actures
▁acetamin
▁Taiwanese
enography
▁255.2
diar
RAs
ipple
rimary
▁Statins
6,790
▁prog
▁overes
=0.30;
=0.13;
▁100-
▁immunization
=2.08;
tims
▁latex
▁4.3.
▁3.4%
▁Decreases
trical
▁ADHD
=210
▁dieticians
▁1.31-1.99),
Proz
▁thyroiditis
Evalu
12-
lye
AAL
imaz
2000.
▁prochlor
/188)
idants
unctioning
leos
▁lax
ROS
▁lisinopril
=0.53;
▁PG
▁200-6
respondence
24;
▁suggestive
adiologists
inistration
▁(4893
<.001
▁rickets
Naprosyn
yang
▁postinjury
cital
▁lidocaine
▁235
=1.77;
▁areata
▁Expressing
fraction
eve
llin
plication
89
2-41.
onogr
▁unopposed
plify
▁alcohol
utein
▁0.60-0.8
0.14
▁systolic
owest
ophon
igmentation
breas
Vistar
othal
▁274
stl
Gar
gree
▁simil
ussive
▁(62%
=13
rici
stratif
▁augmenting
▁Caroti
9%).
proven
▁529
▁piroxicam
vancing
55).
▁(50.
▁impairs
▁circumcision
▁0.52.
3-19
8%-3
Ea
=2.5).
▁knowledgeable
▁(61.2%
▁noct
=1.20
▁NCE
▁LIP
intestional
▁balanc
▁shorten
endem
miti
▁mI
=7.4%-14.
ecologists
▁bronchoscopy
369)
▁phosp
vided
▁risks
anazol
mature
▁9/1
▁1.9
▁thresholds
▁offs
▁nebivolol
▁undetermined
▁rotav
inence
trap
▁0.29-0.9
▁anatomic
▁methodological
=20;
ivy
▁146
mely
▁unstable
▁prospective
odil
oer
▁undershirts
▁12/1000
orsi
annan
▁ack
▁agonist
▁Unpubl
anin
vus
▁methimazole
▁excretion
▁3192
▁(1:1
ectasis
▁579
▁testicular
aminosalic
▁0.89-1.15),
▁Vitamin
ecology
▁tigh
▁constr
orman
▁endor
veys
▁warfarin
ospasm
▁colos
▁ator
20;
reatinine
eos
edip
Cs
▁immunoblot
formations
▁dermal
▁cef
▁1.8-4
▁1992,
▁neurot
irritant
▁188
▁2.06-6.29).
▁preser
ffects
▁decisions
aised
WEET
▁13,443
▁0.78-1.58).9
NAAL
vings
ventilation
▁incontin
▁1103
▁elic
▁curriculum
▁Nulliparous
▁hysterectom
▁tablets
▁pencicl
▁0.4-0.
andine
orou
▁focusing
5.5%).
enefits
pecac
hyl
urem
▁0.56);
▁retention
(0.
▁decad
ADCS
▁1.19
ticosteroid
eduling
OA
▁(0.9%)
▁polyp
weeks
nology
effects
enomegaly
4-9
-3.6
ecar
luding
8.7),
▁temafloxacin
▁predis
reser
▁Lifestyle
▁cooling
hene
2%.
▁loratadine
▁neutrophil
▁0.76-1.
▁bladders
▁5.8%
delaying
▁nursing
▁surgeons
▁Wisner
apsulated
▁Preliminary
trol
9.6
meg
<0.00
▁1210
okine
▁30.4
▁montel
▁orres
▁5
▁inhaler
roxicam
lebre
ephal
▁0.00
=.0043)
▁appendec
▁infancy
=1.37;
▁ester
gous
athologic
plicated
▁62%
ormo
▁disabl
odop
▁hereditary
ertility
▁midd
ceph
likows
=11;
olves
0%),
Eight
rinivil
erre
andards
▁quintile
Wi
laying
▁rifampin
=0.32;
bility
▁crur
▁pathology
ucational
.6,
▁-152.66
tiometry
▁0.58-0.9
assage
▁750
▁initiate
astroenter
▁compares
▁0.87-1.20).
44),
-15
▁husk
▁injuri
=0.67;
=-2.
Hashimoto
▁persistently
▁(8%),
FeSO
▁blister
880
ounc
arlic
▁14.8%
criptive
68%
▁endob
▁46%
1%)
▁<0.75
<.001).
ecture
flox
ingi
yearly
▁1.1-2
pou
ndf
▁carriers
onsystematic
gulate
204
▁deleteri
▁ofl
▁inflammation
inavi
▁47.4%
▁ergot
versely
onberry
▁pregnant
tuft
=6)
essar
romb
ticasone
▁spasm
▁assessments
▁preparation
▁heterosexual
00-2.
121
sychom
▁0.2-0.
5-2.
thromycin
Hg
▁Fluconazole
▁Paren
▁fatigued
▁tachypnea
chool
7.8
▁adipocyt
erosolized
▁sulf
ysterography
munic
▁monthly
▁DTS
▁normalized
▁insu
ocusate
▁1.1/
ewise
▁1.4-5.8).
TAB
tially
tionnai
▁21%;
ocin
▁PCR
▁inste
teinuria
-15.8).
▁17-
ectom
79).
eas
▁circumcis
anox
▁pyoderm
ronate
romyalg
1/367;
▁Endoscopy
tures
▁partn
▁1.06-1.
▁recurrenc
▁noncompar
tali
ermom
8.3)
cessive
erence
▁nonsmokers
▁Avoiding
▁emphasized
▁nonskeletal
ymptom
amethoxazole
plies
osures
▁absorbable
▁mening
-12.
assi
ractory
▁4)
embry
▁McB
valuation
▁1198
sth
738
▁superi
avirus
▁(19/10
]=1.71;
793
▁Cog
-24
andf
▁6.5%.
lacing
▁sponsored
▁239)
umon
ectoscop
▁3-
ulfis
▁(36.5
▁thir
▁conclusive
▁PPDs
0.9,
]=1.74;
etected
▁ezetimibe
mU
tazol
CAHT
▁pneum
▁flunar
▁Affec
3-0.7
▁0.22
▁brainst
406
ticenter
▁1996
755
.0-15.8).
ebo
▁97
ypers
▁1.15
▁decarboxylase
uprop
/0
ailability
aminosalicyl
▁surveill
luenced
olore
xac
▁ceph
ationsh
given
▁appra
-76%)
etician
▁hysterec
smokers
isal
▁RR
ean
▁Rayna
▁38
-6.9)
▁18.3-4
ermal
▁Regard
▁secrete
-85%),
esin
▁TIA
▁affecting
oidal
lamm
quar
▁tolm
adis
zheim
arotene
ubations
▁1.15-3.14)
PDR
essf
gM
▁paired
▁oti
4.1),
56;
▁biphas
▁explosive
▁1153
▁dairy
▁insidious
▁hypermenorrhea
undic
amazep
-7.41;
▁>7.5%
▁9%
▁enzyme
▁favoring
▁492
.0025.
▁carbonate
▁(2)
▁INH
▁(489
▁ulcer
▁ASCUS
▁bumetanide
▁0.2-
trogenic
asmin
▁VALU
▁5.4%
▁likeli
▁diagnos
vandia
▁attributable
▁10%-20%
Loven
▁delinquency
/109)
▁meniscal
ellb
▁metoc
ENA
▁(10%
breast
Hgb
cetyl
iagn
▁Cheil
ukast
otonic
tions
enla
ailure
▁Pea
▁expul
MSE
arcer
owl
inl
Ev
▁66
▁Stres
moking
-0.89),
▁3.9-10.7).
▁knee
▁30%.
ystitis
acyc
41.
▁Sleep
▁demen
restim
▁clinically
ifampin
=0.15;
▁2.5-4.
▁abr
▁betamethasone
▁unexpla
17),
=1.8).
effic
ority
▁IVCF
0%-
▁unop
▁hig
orkup
munization
▁plasminogen
Ib
icat
terim
ymmetric
vities
riment
▁overnight
▁antipyre
▁effusion
▁shamp
▁1.1-7.0;
▁retinoids
▁Murmur
Cou
▁0.55-0.8
tomy
305
=88%
irsu
▁dipyridam
▁-6.9).
▁antiseptic
▁21%
-8.
40).
▁quartile
ingococcal
ucral
ophilus
oxifen
▁endart
aminoph
ecdotally
ortu
▁sulfonylureas
angiotens
ticulocy
vascular
▁parathyroid
▁tonsillar
▁nonrandomized
▁(16.
▁400-800
▁ascorbic
lysate
amilies
▁5.6%;
arou
aried
oxicity
▁inflam
▁1.95-2.
courages
igment
vom
38,
▁<8
5429.
troam
▁neuropsych
proth
ociety
1-137.2
▁medrox
Singul
▁Exercise
▁Lut
,92
ibial
▁repa
ochran
olone
=27)
▁inhal
umulative
▁430
▁orresponding
▁intol
ikeli
22,0
olality
96
ularity
calcitonin
58
▁1/
udinal
▁cholest
azaro
▁noninflammatory
irment
ecia
▁sprains
▁transaminases
82
▁heelstick
▁mastoiditis
73)
▁(20%).
]=1.14;
astes
ENAAL
▁cyclical
▁fatigu
▁neurol
▁hyperac
▁atrial
▁polyethylene
5-0.7
▁persisted
]=11).
▁sonograms
lucan
xif
▁Bauer
lific
xer
▁fluticasone
▁0.24,
5.96;
entify
izu
obulin
▁(42/1
▁insuffici
▁1.
▁2005
▁sham
7%);
onadism
▁Silvadene
▁overuse
ochrom
▁unipolar
=1.8;
▁phritis
-41.4).
▁Nephropathy
=24-31).
vesti
▁caroti
▁glen
lammation
ochem
stimul
85,
.05)
41%
yq
▁examiners
▁1.07-1.86)
ndo
▁44-89).
eiz
▁STIs
▁gabap
80
<.001),
tally
▁irri
radiol
▁ACI
asiz
▁3.0-19.5])
telev
▁healthcare
▁uncl
luc
efloqu
5-0.71;
7-0.93)
=0.33,
▁reassess
ffex
▁comprised
7,
odest
▁Oxim
PCI
ifenes
▁untreat
liness
5-8
▁Richm
▁(0.6
veres
fied
iatrogen
-1.99
▁swit
estrogens
estional
▁5.1,
URB
opper
▁disseminated
▁antiretroviral
▁primar
RR
ongestant
▁(1408
mpan
onadotropin
ylp
omia
41)
iltration
▁conflicting
▁hyperm
onorgest
▁Terb
▁psychopath
▁elec
▁cellul
esults
ospasmolytic
▁longit
reatment
aiw
▁0.13
▁antifact
egist
rorrhagia
hec
▁overus
onab
daily
-97%,
58-
3.8)
▁109
nasal
erficial
▁sof
▁fecal
enomen
▁9.4%
asteric
▁migh
uestion
oches
▁nasoph
30-1.
▁provid
▁seroc
▁rhinorrhea
rofecoxib
▁ceftriaxone
balamin
▁20%-3
▁aden
phet
rimox
▁halves
▁Increas
▁incep
lamyd
xtensive
ynecological
amping
oar
▁miscar
▁sonohyster
=6).
-18.9).
▁<1.
verting
roidism
▁cantharidin
03
▁1.8-18.9).
▁adjustment
▁midwives
pressing
Tor
ucl
▁0.81
▁allergic
5.0
sthm
%]
▁nif
▁counsel
▁ablation
▁examinations
akf
inis
sies
osensitivity
ispanics
▁DMPA
▁1.35-1.78)
▁menorrh
▁tiz
▁decreasing
▁psychosocial
▁Epwor
-89%),
▁0.99
▁0.82-0.98)
▁attit
▁(90%-100
▁dropou
chemic
adycardia
glucosidase
<.07
cinol
imep
atigu
=2.7
ourth
inforce
peptide
▁quin
▁0.03
gha
▁Stimulants
▁stripe
priately
▁epidem
anide
▁antiar
epam
onist
5.
▁newb
▁50%,
brach
/0.96,
ostter
leag
▁drill
▁13.9-15.
erum
lomethasone
3.3;
doph
▁trunk
ortis
]=0.8
▁120
▁etiology
▁17,
▁2.9-6.
▁91,561
=136
▁herpes
▁60%.
▁intubations
▁pep
▁NDCAs
▁distorted
ainf
-33%).
amphen
▁99.5%
/34
enezuelan
▁2134
▁leukotriene
haviors
reactivity
▁manifestations
▁Markov
▁desm
nograp
elu
Ts
xiety
▁Pill
▁44-
▁fibul
ilization
gf
▁947
5-
-0.82).
entally
▁thist
ilden
▁1.12-1.86).
-2.42)
endaz
acerbate
▁preparticip
<.0007,
▁hyperven
ircul
knowledges
▁fixation
▁cortisol
▁exceptionally
rk
▁progestogens
▁dermatologist
5.22;
arated
dant
▁Terbin
=0.99;
4-0.99).
Lum
▁yielding
trasound
olum
▁misc
▁nevi
unched
itals
rang
▁6800
▁1.2-1.6)
osit
▁Malignancy
▁neuro
▁PSA
izure
ceo
mpty
▁hypox
jects
▁susceptib
▁nebul
produces
uspar
▁atropine
mom
enorrh
▁unip
▁symp
▁1999
adotrop
oplasia
8%;
iotropium
italop
ekend
ingin
▁hydrolys
▁0.93-1.00).
▁2.7-5.4)
▁carpal
etence
hap
utoantib
▁Efficacy
▁athlete
4-0.8
▁techniqu
emoral
▁(4.
49).
▁elevated
3.3%
▁adolescence
▁torsion
appropriate
=3.3
opec
cohol
olotrans
▁SABAs
ophi
▁costeffective
▁emul
-17.
opal
panic
icot
.3-4
▁maneuvers
▁itsel
=4091;
=12;
▁endogenous
▁1058
▁tracts
▁(81%
efin
▁asth
<8
▁0.09-0.3
▁hypergly
egard
▁1.33-1.
Lam
▁remo
▁32%
▁rehydrating
▁modalities
▁longus
▁spit
▁BMI
DAb
▁additionally
adotroph
▁volum
▁Oximetry
utoim
hibitive
alence
odic
66;
5-1.9
05)
terial
ocarcinoma
=10
]=10.
▁1993
▁coste
munized
unoc
itamin
▁thereafter
ysician
▁brev
▁neb
tinu
▁supple
moc
ipul
entilator
▁jus
7.
▁metatar
tition
]=5.3
calorie
enan
▁Artery
▁-20.70
▁4-
asci
cI
onvulsant
umcised
,000
▁194
ertion
=7370
=3715)
ricul
58)
sag
inated
▁nause
▁perip
IU
▁bowel
SBP
▁McIssac
ROSP
=3.4
▁identifiable
▁Delayed
▁naprosyn
▁2.12-2.67),
medic
esol
▁severity
▁suppor
arre
▁(36%
408
▁0.80-1.0
tervention
inalys
▁48-22
6,80
▁11-
tocervical
▁0.8
ometh
paren
▁insomnia
▁complication
=62%,
elog
▁OA
wic
tens
▁IgA
gagement
4-1.
▁stain
▁impractical
leosis
ysr
eer
▁LIPID
▁nonpro
▁inconclusive
trom
elecoxib
.0%
▁(16%
ictable
▁whey
▁varice
ERD
idly
etersb
ucer
nias
ntic
diagnosed
▁Gonadotropin
▁cetiriz
amid
▁1445
▁20%-33%).
▁substan
9.12
Pri
▁0.23-0.6
▁labeled
inergics
yclic
▁periop
30,000
ocial
▁Preg
▁1281
hts
8,7
SDS
19).
elic
cure
▁hypoallergenic
▁gums
tep
▁(88%)
ertension
teb
xacetonide
anese
▁infrared
ticle
gul
▁ASCU
▁-2.95
sgood
plific
▁77
▁90%,
=5
-0.60).
▁indur
▁scre
▁hemo
▁Eleven
solving
enign
-3.7;
▁amil
iterature
▁-1.58
▁1.04-1.
▁griseof
esion
▁Longer
=83%,
▁4.5%;
pects
▁SPLs
,60
tinuation
hrom
perin
▁serogroup
imodipine
▁synthetic
.0]).
throm
arboxyl
▁0.7-1.8).
upiro
▁whichever
kows
thmi
▁absorptiometry
▁advan
▁(16
riu
▁1.32-1.4
ounty
apac
▁amphetamine
achol
3-0.79);
chidism
55)
▁16,608
ticularly
andidates
HbA
efit
▁relapses
gus
-38%
▁tuboovarian
▁0.70;
achie
ialt
▁thi
ycy
Diflucan
▁NPV
26.5
▁Bayle
▁Mycological
curren
onine
▁0.10-0.34)
▁0.22.
onsi
▁bronchodilation
▁experiencing
timating
invol
rans
▁tymp
kinf
▁doxaz
-2.5
eam
=6.0).
,67
▁enterocolitis
4%-7
▁narrative
▁IVCFs
▁-1.0
▁choline
▁suspic
ercising
odological
▁Rul
opathological
▁aberrant
▁589
▁capsaicin
▁nicot
▁88%-93%
eine
▁crusted
▁referrals
▁>27.0
5/108)
▁initiated
36.
▁rash
▁antibiotics
estrogen
▁rotator
▁phenylpro
aggressive
▁8.1
=0.76;
thacin
▁suspec
efold
othyrox
▁hasten
▁25.
edication
▁lactobacilli
scarring
1-2.76;
▁biweek
▁>20
muno
▁DVT
▁superf
89).
▁-0.8
46;
ept
zard
▁1.32-1.44).
▁-0.1;
▁1.06
2),
▁graft
▁sneezing
analys
esic
zul
tinopathy
▁hydrochloride
HN
▁17,256
▁82
▁concussion
▁CAH
▁nonsteroidal
▁(72)
verit
5.93
▁probab
=.03;
▁coadminist
=2.1
revious
jac
ilvad
▁(>10,000
3-1.0
5%]
▁hepatomegaly
▁roughage
thion
ulfox
.08;
ooxygenase
>.05)
ansop
Bs
▁treatable
▁(25.5%).
▁thiaz
▁triazol
sation
▁(12/
▁ultrason
estly
▁Raloxifene
ococ
▁teratogens
▁misdi
26.
3-1.66).
▁nonr
▁reveal
▁273
ifty
▁banan
otox
▁aimed
-11.9]),
otom
▁residual
ocytes
30%
▁chall
areg
xor
glit
BVCA
zyme
iologists
4%-4
▁67%-98%),
▁6.
▁Imipramine
ryot
orsen
lowing
=96,19
enzaprine
=52%
▁amenorrheic
immun
bonic
▁damaging
osion
ccur
▁expe
xine
verv
=3)
▁undergoing
oquinolones
=39%
parathyroidism
▁Datab
▁introduc
▁posth
▁Rif
aminop
▁complications
▁Findings
pog
anical
riou
▁vertebral
feeding
gim
▁CB
terity
▁kit
prothrom
epithelial
▁diaries
xh
ronchoc
84
hoc
▁consen
Suc
ingh
▁caries
▁1078
▁Maddre
omiz
▁(12.6
thinning
▁aminotrans
linar
▁683
timated
▁3.1-10),
enafil
▁rubs
]=0.37;
ormally
▁Incon
50)
▁wards
▁Enal
▁2.72-41.8)
▁encompassing
ithelial
omeop
estern
eform
▁(3
▁tretin
zinc
▁uniquely
4%-81%).
▁1.02-1.94).
inflammatory
lacental
emol
▁antisecretory
▁serotyp
=-9.42;
estan
tort
utin
atolog
▁[95%
▁multin
▁substanti
3.54).
▁6.1
-]=0.06).
▁<.002)
▁(1%
▁<1.3.
harmac
dotally
▁diverg
▁viewing
▁acros
ocysteine
terus
orily
▁medications
▁nonpregnant
▁bioavailability
tin
ipolar
▁mcg
7-7.8
▁unrec
]=0.3;
▁nitrogen
gG
alist
▁88.1%;
mentar
ackl
ittaci
cervical
▁CAB
▁postc
ravach
ydial
▁nonins
ipation
inop
▁prognosis
iof
▁nons
=9%;
▁controlling
4.9
▁adjusting
▁1.44-2.99;
ciuria
▁-1)
=19).
▁ARR
▁regulations
hythmia
▁presoak
bacter
ioem
454;
▁analys
0%;
▁1.02-1.94).8
00-1
ransient
arged
murs
armacological
▁hernias
ropyr
oxazos
neez
▁syp
▁625
urious
received
▁consultant
30.
29.
▁205
lasia
epres
▁EIB
]=0.81;
▁glycoprotein
▁eighth
tricted
▁dysrhythm
complic
▁hirsutism
5-0.
eccent
laims
tracted
enectomy
12-0.7
Vent
ryotherapy
▁uncomfort
omoxetine
inag
3-1.7
▁1926
▁intraparen
prohibitive
lae
▁likelihood
=11).
▁(75-8
ffecti
irubinemia
▁electroac
orical
▁Depression
▁sebaceous
▁articl
▁0.04
▁nitro
Tolectin
▁5000
▁MDI
▁19.6,
▁0.98-1.54).
erectom
opidine
urv
▁(12.5
▁18,790
ioav
oen
hig
ouples
agul
▁hypercalcemia
eptin
▁25%.
▁angelic
formerly
citonin
scapular
▁0.36-10.
▁RCT
utum
▁grip
78/
▁nyl
▁postoperative
gluc
▁(83%;
▁(66.4%
▁8.2-23.5).
▁cardiomegaly
=.026
▁psychiat
▁milkbased
54).
▁fourteen
▁(500-1200
▁13.2
▁researcher
▁respirations
▁52%
▁excret
▁menstrual
atell
tense
erapeutic
nowled
-6
▁concludes
/36
▁benzodiazepines
osporine
ductor
comparison
▁inception
thosis
correc
▁0.07
,0
youn
adiness
▁1.2-8.0
▁infectious
ussing
astroin
unin
disciplin
:1
▁0.65
▁(9
86;
300
copically
▁obstr
vertic
orbent
▁1.86).
=1.67;
47.
▁cyclobenz
rase
▁8.15%
▁-1.21).
-93%
omalies
=1.38;
arting
earchers
erange
▁lup
▁cravings
cei
▁840
▁192,
tile
linting
toc
▁Abst
▁13.67
▁smears
▁cotrim
▁Doppler
▁11.6%,
▁endea
2/0.
▁16
▁0.5%
circumcised
▁Bangladesh
edtim
tainty
▁acquisition
49;
orations
▁gentamicin
▁-0.2
Ta
▁CBT
▁(0.92;
▁lunch
▁Likert
erning
ticaria
▁22.3%
▁11.6
rte
ucing
wals
▁37%-
▁0.20
ceive
lact
partum
▁Oth
opic
▁fibrill
▁placent
atot
DSR
onadal
1-3.3
ffairs
▁cryp
apam
Ten
▁AFFIRM
-54%;
▁expectations
usce
vulsive
contain
▁0.6;
▁deoxyrib
ioniti
▁(3.7%
tionat
▁Ancillary
Most
5-1.3
ecam
1.5%
rofen
5.7).
▁fasciitis
tinuing
ormin
atches
▁hypomagnesemia
copresis
essment
inders
▁bisoprolol
▁Subjec
ocer
03%
0-
▁blistering
▁cervical
▁electrodes
▁95%]
▁fec
▁reframing
▁interventions
edb
erular
ndom
ohumeral
roten
▁arres
▁bronchod
▁postd
acros
62%
▁1.9-4.
ulon
▁Affective
ceton
87)
erul
▁herb
asthm
roalbuminuria
▁(12.
ousness
methotrex
veloped
geal
ellbutrin
chizoph
▁daytim
▁conclusions
▁functioning
0%-1
▁200-
▁chast
scarr
▁immunocomp
Tol
▁physicians
▁ossicles
▁positively
-5.6),
569
ortance
▁Fewer
television
▁protracted
00-
▁nonresp
alating
curacy
▁aspir
tility
▁sumatriptan
=0.34;
elings
Sporanox
Rin
sweet
▁progressed
▁9086
▁challen
▁Coz
▁7.2,
sychiat
igra
ffin
cyt
<2.
trok
▁Beresford
atins
econds
▁prepr
pectancy
▁28%),
▁Cochrane
▁deemed
▁Disord
ecting
▁valve
4-1.74).
▁1.11-1.53).
=0.4
dlers
besity
aths
tigu
udied
ocated
▁neurocognitive
igher
jury
▁-9
▁discon
▁Antiseiz
ictions
6.1
aryngitis
▁synthes
ectable
▁Ventricular
onitor
▁torsemide
▁779
ticuloc
▁extracts
▁5.2-8.
▁>3.
▁ipratropium
8-1.26).
ceou
▁peritone
=2.6;
▁12-
acqui
▁pH
tents
verity
rbesartan
=16)
lassified
volve
unadjus
▁decong
,22
▁Fi
rivi
10)].
▁premenopausal
▁-12
isoning
ropathic
▁sulfameth
▁dropping
5%.
5%);
proe
▁0.34-0.53;
▁breakthrough
▁drugs
oing
esity
▁<6
▁(32%
2,012
1.6
ardy
90,
▁scarr
5-4.
etoc
igm
progest
▁3234
epressive
▁andro
▁(0.55
ysti
etop
▁felodipine
pharmacologic
garis
▁Achieving
unized
mmet
roerg
apri
9%
rely
zep
zit
▁ointment
osalic
▁>19.
omyces
educational
4.7%
▁arguably
▁0.04-0.74).
▁988
wheat
copies
andar
ibitor
▁asymm
probability
,233
▁thu
▁52.8
▁aP
-0.8).
▁honey
tigo
▁811
strict
edation
▁0.36-10.3
▁nonsol
▁tracked
▁intestinal
▁carr
tance
armacists
TABL
▁Diphen
hyth
ritic
▁viral
▁68.3
▁0.83-1.1
▁11.0
opust
=0.14
▁(46%
▁300-3600
▁therapeu
RBs
operatively
,75
argement
▁ral
663;
7-0.
ysp
eosp
▁5097
9%,
▁nonvertebral
▁-12.34
97
▁Rubber
amentous
roidis
▁ejection
raliz
▁1.1-6.4).
ostomies
ibrozil
▁clinical
sored
▁bup
▁1.29-1.5
=0.31;
amilt
0.1%
gist
ydamine
vaccin
▁adnex
▁<30
2.5;
▁routinely
▁81%;
/369)
]=25;
-66)
Amaryl
6-0.7
axim
▁Alar
=96%
butam
▁inhibitory
nj
timul
▁irrit
▁PE
ocorticoster
=2.26),
creased
tizer
▁1.32
▁284
onized
yri
▁1.41
▁(1.6%),
ablished
▁0.63/0.78,
▁135/
inamide
-0.79);
▁1.5-6.
▁10,00
▁17-23).
▁Incidence
▁malform
elex
apering
=24-3
1,561
poran
stic
▁3.7
▁anh
▁cardioembolic
upon
▁biphasic
▁healing
▁0.57
5-0.57).
6.2%,
6-0.
oderm
▁40%
▁lymphadenopathy
▁9,
apse
▁unv
▁1.62-2.
ereal
▁lipoprotein
Demerol
ithel
▁azithromycin
▁>20,000
▁anesthetic
tepartum
dds
9-0.2
▁0.72/0.8
▁172
▁psori
▁lactation
izability
▁Meperidine
yrib
osts
4%,
88
▁(74%-9
rati
95,
andages
viors
diab
remia
▁osteop
83
-90,
▁Limit
▁colec
erangement
▁(67%
▁midstage
▁postn
▁engagement
adily
▁diet
▁macroadenoma
iloride
▁untrained
▁inadvertent
▁unple
-91%
3.12
▁chan
etiri
▁PPD
agland
▁genitourinary
fle
▁noncom
udati
▁sinusitis
OPE
▁seropositive
.005)
yograp
irtaz
obronch
▁cutaneous
,300/
odilator
▁20%).
▁6.9%
▁29%;
▁cramping
▁percentages
▁gastroenteritis
ulous
LLHAT
▁0.83
ptim
▁benzyl
ontin
▁Acros
▁concom
atec
=.4
udg
▁anomalies
8.4).
▁Whereas
cidence
=1437)
-52
▁soy
▁1.72-2.19)
▁Traditional
inely
▁Available
▁endometrial
▁PTS
iazolidinediones
▁spacer
▁39,405
thyroid
▁jaundic
iodine
▁(2%)
▁3.3-8.0
▁Implementation
▁assays
▁1.5
▁reinf
▁anomal
ransfer
ethasone
▁estrogen
compar
gestim
tiol
atogens
ritis
nees
producible
▁hypoallerg
▁Obstetricians
▁18.5%
▁antihistamines
cussing
sit
▁preter
▁-0.0
▁discontinuation
orce
]=3.5
rhoid
osable
▁(76%
▁200
▁20,153
▁inconsistent
ayo
-7.86).
▁exploratory
cinyl
▁1.3-3.1).
estrel
ichm
48
▁lasted
▁Likewise
atings
▁Progression
▁uninter
edding
▁nonsign
ceous
▁5.2-
▁75%-89%),
ylitis
▁simv
▁0.60
endazol
-1.7).
ethyl
30-1.7
▁ferritin
▁Toddl
▁5,
▁subth
▁drainage
▁40.
▁McBride
rse
prand
▁socio
▁(74%
▁ramipril
ampaigns
▁choleste
▁0.94,
▁Severe
ormer
never
7.6
itral
▁airf
▁CAHT
▁acad
<.0001;
ilatation
6-1.44),
hypopnea
luded
▁Reflex
▁21
▁thickness
▁mupiro
.09;
fibrozil
▁0.01-2.9
6-0.96)
▁ispag
ainage
▁123
094
veno
erci
▁antimic
ificities
pated
arms
andomly
rhon
ulariz
▁electroconvul
▁(41.8
▁specifics
ecur
▁pigment
▁1.5-8.1).
rophil
▁3000
▁incom
▁Peak
ylpro
etone
▁Treatment
▁cohorts
]=1.4
eck
▁gastroplasty
▁relaxant
▁Mankop
▁replac
▁oint
▁surgically
upuncture
▁promptly
/0.83,
82%,
versi
itiv
▁concord
07;
veloc
examination
orty
▁calcification
=.027),
=12
PPP
▁flexor
▁acquiring
hetamine
omanic
▁ORs
]=0.06).
iad
▁compositions
▁logistic
alphen
ogm
3,613),
▁-0.
▁precursors
arous
▁acces
inked
256
achman
ROCA
=50).
reathing
onoscopy
3-1.00).
=2-3
vels
▁activi
opopl
arathy
▁anoth
7,000
sori
▁mononucleosis
▁0.79
▁pne
▁secreted
upro
▁0.63,
conc
78/43
▁5892
-6.2).
6-2.24)
▁>300
ffer
▁erythema
▁endomet
▁fasting
]=57%;
azol
▁Rifampin
▁lisuride
sicle
Ho
idazol
ardur
344)
▁punct
irthwe
rq
blems
phosph
erma
▁fibroids
icals
▁(36.
discip
fem
retion
3.5).
▁leakage
▁pharm
▁Holger
interpretable
opustular
idr
▁Pregabalin
▁insign
trason
elc
▁34
▁ahe
rolat
etection
terp
1,752
ramingh
0-1.
upr
▁antenatal
▁warmly
▁DMARD
▁uric
=2.07;
▁allele
▁syphilis
▁(2.6%
]=2.8
ictim
09
hexyp
orrheic
▁pai
infor
▁2%;
isim
▁hormone
▁lateral
▁970
ducible
umf
ocardi
-50
063;
]=0.56;
surg
>3
=.021;
Wis
▁exhaustion
titut
eref
levations
▁hypoventil
ureth
.3%
linder
andomiz
ynecologists
AH
ransform
▁cyclo
roscopic
47
▁0.5).
▁hospices
teron
7.2-9
etened
▁102
,001
entical
uritic
stanti
5-0.97;
▁>30
▁5%,
5;
deriv
▁0.55-0.9
reaten
thral
3-0.0
inete
ilver
▁1477)
enna
terpret
dL
▁7-
-7.8
▁revisions
onazol
umab
ifetim
asty
▁prescribed
ibrate
▁continuation
manic
▁3.80
▁antigliadin
zation
▁demonstrab
▁structural
▁GABHS
proxim
ylated
uride
▁2.21-14.5
creening
amox
▁endoscopy
ograp
clavulanate
▁84%-9
▁detects
▁(50%-95%),
▁fulfillment
▁wks
▁immed
vanc
▁Brev
▁1.19-2.
epw
ocyc
ucose
erenti
cycline
<.02
▁20
itrogen
pens
▁innercity
▁chill
urin
▁275
-0.97)
▁Aml
6.80)
▁transc
aintain
=30
▁-12.
presumed
Som
acer
=3-6
apl
reng
▁dicl
odolog
0.0%)
▁hemorrhagic
▁sulfisoxazole
▁>10
▁Bronchitis
eru
▁(50
3%
▁1600-
=2558)
▁LNG
▁unexp
bac
▁709
▁postp
▁3.2%
teria
▁Prevention
▁indication
8).
nz
italopram
▁Antimalar
ndef
bronchial
▁serocon
▁adher
4.6,
-99%
▁1.15-3.1
▁(0.61
trihexyphen
▁IELT
▁rais
▁holid
▁14-3
▁6.9
▁multisite
▁Silv
alH
Midrin
vior
,000)
positive
Lamisil
yor
▁guine
00-3
MG
▁NSA
NH
▁nonac
omal
▁SOA
arachn
▁Rochester
▁noninsertional
lects
otamine
▁553
▁amoun
▁0.95
DH
▁lor
109
inoc
tratter
▁1750
▁1,
timates
▁odds
okalemia
onylure
ceb
opramide
▁(278/438;
iline
-10.3
▁Euflex
assific
▁1564
,42
▁intense
▁accidents
▁mucate
ogenous
lol
▁diversity
ypom
▁1.57
▁mebend
▁metform
▁devic
▁(2.4%)
▁tympan
▁postcatar
acrine
roj
▁1.4-1.6.
-1.0
▁(77%
▁carbamazepine
fficacy
agulation
curac
hydram
idst
▁responsi
buliz
▁nocturnal
▁2.8%
▁peroneus
▁outp
▁deri
,3
▁1.1-2.7]),
▁0.0%-33.0%).
gation
7.2%
▁decongest
osomal
▁lutein
ivol
▁(1.3
▁variously
▁1.11-1.90).
lling
▁fluoroqu
▁2.35
]=3.11;
ollected
molecular
ndia
roti
gati
ioec
▁12.5.
4%-93%
▁concentrations
ectomy
▁wheezing
▁consisten
▁gonococcal
▁2.8%.
▁Dip
▁46,808
▁4.0%)
openia
lloc
yptorchidism
rolimus
▁blockers
roat
▁perim
enic
▁prodrome
▁Failure
▁radiological
▁stair
inan
idelines
inopril
▁0.75-1.05).
▁0.9-
thood
10-0.3
▁Taiw
tation
▁(49
▁blocker
efloxacin
onth
▁10%-54%;
▁43.8%
▁leukocytosis
ewes
▁unp
▁28
07
9.4)
▁genit
lactating
inod
omerul
mogr
▁methotrex
▁Endpoin
ycod
lamydophil
6.9)
▁lisur
▁11,427
▁Cyc
=7.4%-14.7%)
▁Sensi
▁occult
<.001]).
sion
▁21.4%
ziness
▁(40%
▁Approximately
bacteri
▁1.33-1.76)
4-0.99)
ffa
▁flour
otassium
▁85%,
▁hypercoagulable
syllium
abetes
omog
▁alcoholics
-1.21).
antibodies
bronch
▁79
▁Durad
▁(50%-9
▁-1.8
7%-8
▁Sleepiness
▁tobac
▁covert
barr
>1.
816
22.
3%,
▁75;
▁(500-1
▁biopsychosocial
icyl
46%
▁1.6-
▁Postm
rigation
▁Hyperactivity
llat
▁regim
▁induce
▁1991.
6%)
▁Rating
-95%),
▁(4.0,
▁revi
glucosid
yliti
▁Breast
▁labs
▁(1237
terqu
mone
rih
▁reti
▁thromboses
roce
ceived
▁carved
oxers
,500
Educ
]=3
ulc
▁wi
chiz
ommendation
▁esophageal
andardized
reement
▁levamisole
Ot
uptures
olam
30-63).
▁melanotic
uebec
iased
tise
4.3).
▁phosphate
-2.9
▁0.50
▁Increases
monitor
bohydr
sutis
▁chaste
▁Progest
▁gloves
orosis
▁normaliz
▁worsening
▁visualization
eridine
▁thyrox
erbal
▁7.3%
▁Pne
▁affec
aminos
ouraged
weightb
reduc
▁conjunc
/207
▁6.2%
raming
=.026),
aryngopal
eilitis
prox
orec
ture
orbidities
-4.4]).
umping
2%)
▁secretagog
▁32.
ricor
eation
tih
troly
-1.20).
53%
lative
▁>14
▁0.79-0.9
99;
▁1000-12
▁Varic
=3.7;
0.6%
reted
▁antithrombo
=1.50;
▁Ottaw
▁2.5-8.7),
attern
trasonography
▁reticulocyte
▁abbreviated
ontr
ostly
77;
iterat
lure
▁amenorrhea
▁0.98
pith
▁0.59-0.82).
▁subjective
-1.7
ISA
▁Antibiotics
iparous
=101)
-10
▁relieved
▁retinopathy
▁Symptom
oscl
▁pimecrolimus
▁113
=88%,
▁(12-18
▁iprat
acro
▁Organization
xin
retic
▁subclinical
8.5).
▁(8-1
mph
-0.23%
▁(0%
ataract
2.8
▁endemic
▁sedim
acin
istat
▁ciclop
stitution
▁Depres
=0.50
▁insignificant
hensi
ightly
.3.
▁amiloride
▁genotypes
▁1.05-1.79).
escent
-3.5).
▁disadvant
-0.98;
▁sulfadiaz
▁1
vaginal
▁diclof
icitis
▁GA
8-1.2
▁orlistat
IPO
abdominal
63)
▁creatinine
ysl
notic
▁93%
besartan
6).
▁articular
▁oxy
2%),
▁cautery
▁Prevalence
▁950
▁reflex
preh
arean
▁0.50-0.7
▁Breas
raphy
▁cefi
eF
93
▁fluorosis
▁surrou
▁91,
quid
therlands
▁(5.3
▁underly
▁appendectomies
athoph
▁arguing
-0.89
Pravach
eraz
▁(53%
acial
▁Bezafibrate
icacy
▁McMur
▁0.12-0.4
▁disturbance
Fol
▁monon
etirizine
posure
pectazole
9500
▁0.70-3.3
]=0.73;
angio
▁3.8
▁19,25
▁Gynec
▁resolving
▁bariatric
▁restenosis
▁1.48-2.0
67,
▁Ottawa
▁10%-2
=8),
▁0.23-1.76)
AID
specif
▁meditation
▁panc
cetamin
▁scabies
▁styl
▁Prevent
▁canc
▁Few
935
istal
Ster
▁0.77/0.89,
▁garlic
entoxifyll
quam
seiz
=0.89;
1%).
▁577
▁Gail
2-9.
▁biases
▁turbinate
atorvastatin
ortions
avity
▁strept
DHD
eight
▁2.03-2.74),
=10),
-2.54
ionized
eart
▁bandaging
ympan
▁52-144;
fax
gations
▁sensitizer
▁chlamyd
iopsy
nif
munities
anking
onsill
lent
▁(66.
eced
▁100,000.
▁refram
▁Tric
▁saphenous
hron
ydrox
=24%
itration
sychological
▁levodopa
=0.47;
▁lumb
=3-61).
▁164.4).
7).
-10.36).
itrac
▁Caucas
longs
▁<150
558)
▁Fibromyalgia
7)
=8
▁concussions
▁nasopharynx
▁59
▁refills
▁cystoscopy
▁0.1/
▁foods
=-57.93
▁gonad
▁5.6;
▁sore
2-1
utl
▁femor
ackg
▁indap
▁200,000
▁ery
ropout
menop
ostication
alatoplasty
▁lipoph
retation
.0-9.
▁29.4-57.
▁0.57-0.93)
89%
▁pell
67),
▁benz
quamous
uably
4)
▁60.4%
=125)
9.8
ALT
4-5
-80
ipants
▁biolog
▁orthop
1121
rescence
▁7.11).
▁168
roidec
xing
ongly
81)
▁glucosamine
ipramine
adruple
44;
eroth
▁30.4%
tard
tbo
tter
vothyroxine
onverted
▁35.8-7
agm
tic
▁3.4%;
▁confounders
92)
rombo
pidemi
▁ciclopirox
▁chorio
-2
▁cereal
▁0.51
-1.68),
▁electrical
existing
]=20)
▁0.99-1.3
▁0.12-0.7
ipan
ommit
onp
▁(32
BRCA
▁potenti
▁lith
▁Triage
▁278
▁freeze
meterol
scap
-3.9
▁hemog
▁feath
▁teleph
ffor
conventional
ulness
▁0.84-0.9
lly
roubl
acous
▁23/1000
cobalamin
▁stopp
▁vancom
▁rGH
▁congestion
32%
1-0.4
▁schedules
▁(36%)
sitivity
▁stu
2%).
otting
▁prostaglandin
bitis
uated
athioprine
continence
0.43
▁427
tav
=2.29).
▁preoper
▁Expect
61
=6.41;
▁gluten
asoc
=178)
titud
▁3.5
▁16/207
verti
chol
▁antiox
▁0.03-0.44;
▁intolerant
▁nond
alify
▁nore
▁Anoth
▁sustain
]=8),
atrial
▁26.7%,
▁abd
▁12/
▁restar
▁0.55-0.97;
sti
▁cartilage
6.6%
▁plann
rials
Lim
▁(15).
wis
ticip
thickness
tropin
▁elb
ecre
▁extrapolate
▁42.
isedron
oppl
▁necroti
▁imping
▁delaying
▁adenop
reatin
iogr
oxicillin
▁chloramphen
atoplasty
▁appeti
▁intermenstrual
1,7
acrificing
▁brad
ertr
excluding
▁carbohydrate
▁8/1
4.3;
▁divertic
▁sulbact
▁amlodipine
▁colleag
administ
▁80%.
ensitivity
▁>9.
itiating
imits
▁imip
▁15,880
atification
▁hepat
▁Secondary
8.3;
IH
osmol
bined
▁derangement
▁landmark
eon
protein
▁actinomyces
▁thermometers
▁fetal
▁Seventeen
lox
▁argu
ryotoxic
▁urin
romised
-1).
ertainty
denti
ancies
▁myomas
llit
▁cream
theroscler
inq
/0.89
▁unco
hydroergot
=1.44;
▁0.75-0.9
▁textural
ThinPrep
▁Prospective
40/
=514
▁steroid
imination
etabl
▁relieving
▁40).
]=1.15;
iazol
-0.99).
▁epidemiologic
=21.
▁procalcitonin
aceous
▁quantit
▁congestive
▁(23%
3-6
okl
tionally
lood
2%,
▁70.
▁quitter
Stro
▁incidence
▁5)
=93.8%
▁nonsyst
▁50
▁caregivers
31;
bronchodilator
veraging
ituit
▁-0.7).
▁receptive
03).
teris
▁1.61
ursing
▁hyperactivity
hth
lli
thlete
▁recurrent
▁metered
arynge
veill
adical
iliti
▁neph
-0.44).
▁(48
6;
▁adolescent
▁23%
▁34.
▁Examin
igarette
ptor
unad
▁arthritis
-1.98),
▁137
isn
▁bees
▁Caucasians
▁discharge
renter
▁mIU
▁Obst
arved
acq
▁transamin
▁4.4,
beral
5-1.7
▁nes
onst
Was
entl
ependently
VAS
▁quinine
dle
▁osteoar
▁(1.58-5.18)
]=0.23;
utom
▁Tis
injury
▁restud
uox
odific
asked
=61
▁polysacch
tiple
iclopi
▁Gluc
▁1.17-1.95)
▁durable
▁toothp
=2.93;
▁microbiologic
estionn
aight
erial
Ba
▁dysl
▁100,000
▁caref
tical
▁injuries
=.03,
=2.04;
],1
responding
▁ECG
▁doxycycline
▁endeavor
ataflam
▁1.4%;
itidine
86%
eking
0.9%
mear
inP
▁responsiveness
aryn
▁41.2%
▁(2.1%
lococ
oton
anism
▁162,000
identified
5%-50%
▁(45%).
▁140.
arrhythm
<.0007
79;
lification
odone
erapis
▁tooth
▁nosocomial
-14.58).
▁Optimal
2.6%
▁Clofibrate
▁salpingitis
opr
▁metast
izine
-=
tur
▁conduc
iconazole
xth
urvi
▁resour
-19.
getables
▁comprehensive
-1.07),
▁dipstick
▁tabular
concl
▁disclosed
▁reversed
food
utis
=93.8%.
▁alumin
zath
eregulate
orgest
ndpoin
=1363)
▁comparisons
▁recei
<.01),
▁Nugent
gestational
=6379;
▁testis
▁occurrences
eSO
orres
onsist
ondon
▁(-0.
asel
-]=0.0
=160),
▁maintaining
▁benzod
aflox
▁tenoxic
▁Hysteroscopy
▁miti
oiditi
arouse
allergenic
▁2.66-10.67)
▁mg
-24.
azil
-0
▁flexed
Buspar
▁myalg
dol
▁intraparench
6.6%;
▁<3.
4-3
generation
▁spon
7.09).
inquency
cce
▁ana
90)
▁-0.4
▁lumbosac
oconazole
▁tamox
riglycer
italiz
vitamin
=.02).
▁644
MAR
-5.8).
▁periph
uracy
glucos
▁prednisone
/3
endix
▁(81.
verw
tolytic
doster
hydrox
atched
inational
thp
▁31,567
▁255.22;
=.02)
inedion
44%
24.
▁>10%
▁oxyquin
Fou
idt
BT
▁eccentric
▁pressures
aturated
pber
▁0.03-0.
rocus
Tegison
▁agglutination
reter
defici
=5)
▁Consequent
▁contamin
tti
teros
▁sulfasal
▁sebace
langu
▁25.8
▁transferrin
▁35-66)-
▁76%
=-13.
6.7),
▁leas
rimazol
▁atelectasis
3.7;
ademy
▁28%;
]=57%
▁Identif
epp
▁plasm
acol
resent
revention
▁(0
rotide
thasone
ideal
▁outf
.5
▁0.59-0.82).1
▁0.34
onococcal
exyp
▁(28%),
▁Braz
rogate
▁MRF
efic
▁0.72-1.11).
qid
▁antec
▁Lorazepam
agonist
=0.30
=0.2
argets
▁resuscit
conclusive
▁clem
▁1.84-13.16
▁calorie
4.5.
▁statis
iphas
▁reliability
▁-0.6)
▁0.51-0.89),
openhag
▁structured
▁antagonists
▁0.23-0.74).
▁1.84-13.16),
▁gynecological
▁Abstin
▁cance
blinded
▁0.5-1.6;
▁2006
8-1.58).
Celebrex
▁590
iopsies
=5.6
Cut
ativus
▁pim
=1.80;
▁6.8%
▁supraclavicular
▁asymp
roxic
▁traumatic
▁16/20
▁hypoglycem
alidity
ghai
▁linearly
romis
HSIL
▁peop
▁pollicis
▁dipyridamole
▁shap
lyti
-0.70
eticians
▁positi
=2.26;
▁CURB
▁underst
rimental
▁scientif
erlikowske
▁SAB
kas
blocker
▁11
▁568
esophageal
ltras
▁giard
▁sprink
eS
608
-17
ceding
▁unblind
terven
pth
=0.80;
tif
-1200
tinued
▁unrestr
▁145,811
▁57,000
trihexyphenidyl
▁discretion
]=1.3
hter
▁>4
ticulosis
arge
1-0.75;
]=1.4;
▁osteoporosis
▁unli
Mis
ceptive
]=1.1
▁macros
▁attitudes
inot
]=1.8
▁orthostatic
ertile
4-2.9
▁ipr
▁nulliparous
1,567
▁atopy
=13.7
▁flourish
ruited
▁1429
kgo
▁Vaginal
▁1.04-3.3
calci
▁13
▁fluoxetine
idin
opharmac
▁91,5
opsi
]=15;
tisit
terir
▁4.32-526.
vag
▁reit
racture
tiati
▁trich
=0%;
]=0.08;
1);
bip
=4)
atosis
▁dih
PROCA
olick
Remic
ibroid
▁>16
▁dexterity
=140)
▁functionally
▁EG
reus
▁kits
-4.20).
amyc
▁Dos
▁Candida
enture
=.007
▁deca
odif
▁antifung
ingdom
WOS
cif
orting
▁electrom
▁(>10
▁urticaria
iciaries
=-1%;
▁Hamamelis
2,4
▁29
91).
enec
▁cara
▁pharmac
-81%).
▁0.75-0.94)
=8.3;
6-7
ochrane
reath
▁investigations
▁(33%
ytoc
uality
amag
▁sear
ymitis
survivors
▁(92
efor
1.4
intermenstrual
▁(500-12
▁gases
enad
tiation
▁puncture
aemic
linded
▁24
estational
▁reflux
ausea
-18.
▁sai
-1.44).
biph
omor
arder
▁lumbar
▁tetracycline
▁granul
atorenal
▁1.51
preventable
▁MRFIT
▁1.10-2.36;
individualized
▁cardiovascular
seled
▁nontra
omann
▁0.4-24.3).
Hyp
oriatic
▁0.07-1.4
-72
aim
aglandin
onvention
ayn
▁prevented
54;
xten
▁undiagnosed
60)
▁LT
ioids
▁tightness
ALLHAT
ourte
▁deficit
▁infertility
spar
rul
ontal
▁bullae
=3.38,
▁277
▁hypop
▁regur
olized
▁2.3
thn
iag
▁undeterm
▁brus
/85
▁(7%)
▁prepartic
▁TP
ercept
▁44
▁cysts
▁specificity
▁MRI
-15.
/32
▁neoplasm
gasm
▁predn
yzed
▁(84
deficiency
amati
63%
iazep
]=3.125;
▁postmenopausal
▁alw
▁17).
erec
▁uncommon
0.2%
miz
▁euth
opharynge
3.5%;
▁1.46-7.54)
▁allergies
▁1.05-1.28;
▁efficac
▁neopl
glycerin
▁arip
0%-9
emperature
sus
loram
90.
omot
▁iatrogenic
tivi
▁simvastatin
cortis
▁hyperco
siglitazone
arate
▁10.5
4-0.97).
ariates
▁singl
▁prophyl
/1000
▁(47/344)
▁dosage
▁hea
▁plateau
=5.1
=.004),
▁suspension
▁1.13
ransm
hool
-2.74),
fib
erent
▁4.91-137.26).
▁100
ispan
▁Tramadol
EST
▁5.0-15.8).
▁Unf
▁13.0%).
▁biochemical
▁Inconclusive
▁algor
▁0.01-0.42).
▁1.1-6.
▁drip
▁acnes
▁cheil
=40
▁Nine
▁9/100,000),
ulox
urad
1-14.
mopressin
/10
▁1098
10)]
endog
icyc
<6
5);
esalamine
atible
3.2).
sely
▁injections
▁BCG
▁DASH
▁adap
▁noting
▁marginally
▁<90
9%),
otherapeutics
ulop
ygiene
▁celand
aflam
enicity
itocin
ophar
▁seri
=1.8
osol
▁emissions
▁9473
▁respiratory
▁caro
▁gels
▁polyc
▁(1.25
▁angio
▁Azasan
▁intra
ynv
COPS
10.2%
▁consensus
thesized
aminated
▁untreated
-19
metin
▁1.2
▁Subc
▁incompetence
▁occl
ndrom
gestogens
).9
▁(<1
elis
oping
▁2.7-5.
▁transverse
ocys
▁dose
terone
ritain
▁142
▁relaxants
▁sco
▁perit
▁homew
▁circulatory
viewed
▁discontinuing
chang
▁DV
▁encopresis
.9
entable
estri
erven
▁microb
▁Atypical
▁Nitrofurantoin
sionals
vating
5.3
endr
▁prematur
▁0.08-1.3
▁magne
▁Elimin
odine
bran
/12
Gor
rogression
▁nonri
▁screening
▁venla
-7.6
mend
▁suspici
edl
Iss
▁harmful
Vist
hythmias
inom
riniv
▁diary
▁0.66
BH
▁Bayley
MRA
-220).
-38%).
▁0.19-0.67.
▁microbi
▁2742
orsion
tiom
▁ankle
▁-0.28;
▁0.9-1.
.08
▁Unus
igaret
argine
17%,
ilob
▁2.1-1
=1.39;
16-1.
arations
-70%)
=.36;
iotic
▁continuously
ipocyt
,000.
iazide
opnea
▁rhabdomy
hist
▁incision
=1.9
▁warts
=4.6),
▁1.72
▁amniotic
61).
Wors
OSP
▁mef
propanol
ocri
▁dosages
idebo
▁pyrid
afib
gias
▁compliance
▁MEDLINE
riax
▁condensed
=90%;
tend
▁carob
▁embolisms
9.4-5
olesterolemia
mnipaque
eneity
▁duloxetine
▁Projec
▁20,751
<.05),
▁exh
upirocin
riages
▁deo
=15
uad
iable
▁prolactin
▁Thoracic
roxine
▁0.75
ultr
28).
ROSPER
alved
<.002)
ndividual
went
pH
▁venti
▁64-99%),
▁LM
▁hypoven
▁dyspep
containing
6-6.
zyg
cessi
ropou
▁consti
▁Smoking
=603),
▁Attribut
,805
▁prophylactic
▁adenoc
▁adhesi
▁digoxigen
renal
-17.10)].
reams
▁nonst
mox
ornia
0.4
▁potent
titis
▁fluids
orar
=1663;
10-3.
eec
▁anembryonic
wak
ROC
chitecture
lof
bosis
pectations
hary
▁dullness
egison
▁CNBS
▁tripled
▁sulfon
▁4582
▁halved
-16.0]).
▁1.2-8
▁smokers
erge
imod
▁vaccinated
ubles
▁eczema
ughly
itc
ogies
-35
othia
▁sedation
ypical
▁stricter
etan
▁99
957
2-14.5
Mes
phil
▁550
▁(0.05%);
▁conservative
iosus
-33%
iciti
alization
onon
etec
compliance
gil
▁700
▁bypass
▁Randomized
ibros
▁Secretory
▁Haemophilus
▁FDA
▁ventilator
▁cen
▁mesalamine
Thorazine
▁congenital
=55).
eo
▁1.0-2.7
▁Lactobacillus
zuelan
▁68.3-90.9)
52),
▁hematuria
Pu
▁cohort
dition
▁1333
▁dexamethasone
xation
6.2;
vati
▁rebound
▁hemofil
wee
iton
▁1.4%
isoprolol
▁beclomethasone
phenidate
▁thiazide
pharm
farction
conduc
<.001;
▁96%;
=13).
▁84
-144;
rosom
▁uln
▁Comparing
itnesses
<.01
▁cyclob
arbohyd
erebral
razolam
00-12
▁abor
mpa
enr
▁hir
munoc
dered
dyn
▁1464
▁55.06).
▁EMA
rimip
nion
whey
achm
▁hyperg
osalicyl
apal
-0.61).
▁(6/10
▁1250
ptive
▁recr
8-1.5
=.042).
IPOD
▁3.5-4.3)
▁constituted
▁medicin
▁workp
-3
▁333
▁52.
▁exacerbating
▁threef
-13
acok
horm
7.10)
▁acro
=13.
ureus
aiting
rater
▁vascular
▁marginal
ophony
CBT
parathy
-81
thmia
▁consens
Ham
ificiti
▁venlafaxine
idat
cemic
▁VALUE
33;
▁Thyroid
▁Schizophrenia
inovir
ulvovag
▁Epidem
3,6
establ
▁statistically
HOP
▁contracep
dance
▁Thei
-50%)
ecul
alphenazone
sequences
▁refusal
PDS
▁hypertrophy
isd
-10.9,
availability
acture
ractic
.03)
ticulously
▁0.56
erate
dial
lows
ailab
▁ketorol
▁Banglad
=140
▁0.38/0.8
-1.86)
▁70
▁drilling
▁satur
bber
tication
ioplasty
▁2.7%
chers
ndat
▁ultrasound
▁renin
eppermint
▁3.5-4.
vidence
oub
▁tricep
=0.60;
ibup
IgM
▁weightbearing
▁abou
heren
▁vegetables
▁AFFI
copical
▁intracere
yrox
▁venography
acids
▁couns
▁Serum
▁70-1
.000
▁indoor
inical
timulus
uci
▁Families
▁supr
Lef
,-1.3
▁>24
▁1096
▁HBsA
▁judg
ocar
▁aure
▁nonpre
26.17),
90%,
▁carbonic
11-21.2
▁47%.
▁scann
pli
▁8.28
omogr
▁dressing
gestation
nologies
udoephedrine
oprostol
▁digoxig
boo
overall
▁0.77-1.
dus
creatitis
25),
▁2973
ographically
▁1.38-3.
▁Staphyl
essing
actro
▁immunoglob
sid
viate
▁nerve
▁192
▁averaging
raisal
▁triazolam
0-0.
▁cyt
▁minimally
▁clears
▁maternal
▁Inj
=2.0-2.
interqu
▁0.55-1.3
▁126
▁14%,
releas
▁reversible
▁Framingham
▁(1.4
▁1.87
▁estrogenic
▁retardation
epezil
▁(98%
▁(4%
▁0.12-0.44).
▁unilateral
rihex
=.004
PRAISE
▁0.25.
onsens
▁visiting
▁(175
▁babies
=7.6
▁PI
0%-33.
▁acknowledges
oprolol
44)
▁917
2-0.98)
Eval
jur
Ele
habil
▁2.26-5.85).
xone
▁prolongs
4-4.
ecommend
atriptan
efer
▁Wals
▁90%.
▁concurrently
7%-4
matic
▁177
▁Unfort
▁213
mI
esize
▁raniti
▁lessons
▁glomerul
proach
▁45%-4
9/
▁10-31;
6,22
▁Exc
▁approp
scer
▁abo
ffair
.2).
▁(<
ribonuc
luid
▁0.48-0.94;
▁2570
▁benefited
▁fluoridated
raspinatus
emiological
icine
ulg
▁hyster
Bac
idymitis
=14).
▁(266,
ysterec
▁enteric
]=5.0
▁(545
=44)
▁menstr
unsc
enges
asin
▁1992
ultured
▁preec
▁hysteroscopy
▁ASCC
▁mala
▁Finkel
eleb
▁1.25-1.6
sively
usting
▁>2
▁histological
77).
kotriene
▁1.3-5.
hydroxyp
7]
>9
▁>9
▁clon
1/
▁74.
▁relaxation
]=1.0
inati
▁addressing
▁(<150
▁Ischaemic
erat
ortant
eraliz
ipment
athing
▁NNT
alox
33
hie
▁phoned
▁356,
quen
within
▁1.7%
,300
neumon
WB
]=13.
tichol
tiliz
▁serologically
▁apprais
▁(22%
00-1.4
3-0.6
erived
antag
▁acetaminophen
▁adipon
plied
▁laxatives
sponsored
▁supervised
erfici
▁MIs
▁dehydrated
alazine
amage
▁enrolling
determ
ophyll
ermy
cyclic
▁curric
30;
▁Dut
▁0.013-0.0
▁Wound
ungal
5,811
▁morphine
iron
▁stratified
ffinities
ationship
▁argues
imesul
ounted
nally
alos
▁nonsm
inor
▁misadvent
▁uprigh
3-0.44;
71%
ildly
reatine
▁lemon
207
▁glut
onserv
▁(33.
▁Glucosamine
naud
6,2
iagnosed
(8
tural
ranuloma
liz
leed
▁biopsied
ndre
icien
atoma
71)
ACAP
▁withdra
arj
thoracic
▁(700
▁gynec
▁309
▁basing
▁SNRIs
tator
3.4
tig
iazolid
▁soluble
▁141.71.
▁Nystag
▁biph
▁eradicating
xyt
ortable
▁tha
orptiometry
-1.58).
igation
▁Patients
zhe
▁analges
▁-2
▁1986.
▁(3.0
=.051).
▁chorionic
▁(-0.2
▁glucocor
Prozac
▁0.99-1.34).
rime
7-1.20).
plos
▁shave
thod
6.7).
▁depression
▁hexacet
oprazole
70),
=1%
anderb
=23
▁(68%
▁820
▁0.98-1.2
▁9454
veness
▁inap
operative
ylcysteine
ffere
qued
choscopy
▁norf
1.23).
>10
▁discontin
esop
,443
▁25.84).
▁dementia
EEP
▁surgery
▁Sodium
▁Pregnancies
umans
▁(25.8)
ikelihood
thmias
pazine
▁glucocorticoids
uprofen
▁Thre
olysis
ithm
▁backg
eases
▁dorsal
inediones
ticulitis
onephritis
-66
▁Litt
▁classify
▁exams
▁15.8
cough
]=0.72;
7.26).
▁<85
▁hepato
uab
igran
ologists
▁adequ
▁coagulation
▁1.01
▁unti
▁5.8
edical
.".
minent
28-20.
▁stenting
glycop
▁(18.
trach
asonale
Colace
▁pef
▁serog
69)
valuat
▁Diabetic
kely
▁mEq
▁0.56-0.92;
▁aureus
▁triceps
asmoly
▁ramip
▁1708
=.9
ortripty
24%
▁hyperth
▁TI
▁hepatocellular
domyolysis
3.7%)
euver
guinal
7/
oretical
emper
80%
▁insti
▁269
antop
bladder
arat
armac
lucom
sychos
▁glyb
▁blot
ultim
pared
ndr
▁correlated
ytoch
▁sour
opping
▁retinal
▁trichloroace
▁controver
ternating
tscreening
▁analyses
▁pean
opl
▁bipolar
▁ligation
▁traum
▁addres
▁302
▁(62%)
rosemide
arkov
▁tube
▁hypn
=375)
tein
▁0.72
▁percep
etran
Amary
trov
wice
itiation
epati
<0
erien
proved
▁mono
▁2
▁nominal
▁parox
everal
▁(13%
Sys
utation
tide
quir
▁8/
▁Overall
orption
▁deleterious
▁duct
albuminuria
9-3.
▁45
▁FE
ainly
▁noctur
ersensitivity
parenter
likelihood
WTM
▁500
▁Apg
=.05)
laxants
Tapazole
Teg
gressive
emic
▁-0.17%,
ericans
lend
▁129
boemb
▁exac
enderness
▁Iranian
6.7
erran
▁38%
thalid
epatitis
▁-0.7)
▁0.13-0.26).
▁weakness
0.89
keletal
▁iso
▁86.5
▁persisting
otro
▁answ
unop
headache
Its
▁Outcom
-4.1
▁66%.
biphas
agrap
imenopausal
▁suffers
therl
▁Holter
▁Diagn
ainten
omography
▁reviparin
opat
turb
▁meetings
,82
▁0.23-0.
▁Professionals
=2.9%).
▁pregnancy
oglitazone
otential
▁nonf
anad
ioid
psy
▁levon
Pain
lates
RIPOD
▁enal
▁Thin
▁67%,
▁friction
▁bivariate
▁100=
=1.47).
lactam
▁-0.4;
minist
ecc
asb
▁hypotonia
oner
94;
rex
8),
▁Centers
biphasic
teric
retics
enterolog
▁eliminated
enohum
hirts
▁Brevoxyl
bulation
▁fati
ropium
maryl
rimethop
6/
ervices
▁exposures
WMD
▁CRB
ofulv
▁42
-15.0%
▁benzyd
alv
rion
CHD
astolic
▁aPL
<.01);
elp
▁thicken
esw
▁clinic
xact
▁2002,
HIT
=.94
▁66;
uciating
omprom
8%.
dihyd
anual
08),
studied
toac
▁3%.
NRIs
▁generalizable
▁ossicle
epines
planned
▁1.45-4.98).
▁166
99)
rousal
▁CAL
mediately
▁donepezil
orbable
▁Adipocytes
▁airw
▁bilirub
▁97.2-9
fro
08
▁8.4%
▁90
▁recordings
▁microwa
▁summarized
alment
Revised
▁1034
▁inflamed
-2.1)
Gib
▁rised
2.9%
xam
ulfate
▁victims
onorrhea
7%-9
▁liver
▁DEET
▁cholinester
Hb
▁targeting
eflox
▁streptococcus
▁0.0-0.
etopro
▁sple
▁affinities
▁Avoid
▁folate
ecaus
▁nonstress
▁acce
idine
▁Epidemi
=.002)
▁hypoall
▁rehabilitation
▁amnes
▁(1.9
-5.28).
tist
Ds
7.67;
pharmac
▁resting
CVD
▁18.2%
▁Fetters
-1.08).
▁mammography
uction
▁fibromy
ightb
▁unab
]=0.6
64)
▁biweekly
▁0.3).
entifi
▁75%-8
ially
▁Nimodipine
▁neutro
Lif
▁170.
▁involvement
▁terb
NHA
76
▁Osteopor
Lit
19)
]=1.50;
▁560
▁40,00
1.00
TSH
▁(9.
▁inhaled
rography
5-1.
reward
LN
chiop
oods
▁albumin
▁establishing
▁ori
oxyrib
▁familial
vant
▁7%
alam
ogue
lowed
ALU
avis
▁hepatome
/0.8
▁0.17-1.0
encephal
1.0
▁whic
olycys
=3.77;
▁abl
▁SPL
▁albuterol
insulin
arental
▁78.3
▁fibroid
▁syndrom
ergent
ognition
isease
▁0.96%
▁analgesics
Silv
818),
▁bony
illin
▁52.9
790
eci
▁immunocomprom
▁carcinom
▁alleviate
▁clinician
▁vitamins
29%
▁voluntary
▁10-
▁14.5
eterious
▁<9
pep
=.003
▁mann
▁orc
-56.
▁remaind
▁practi
▁constell
▁peers
enge
▁hemoch
▁preop
▁appl
concentration
▁135%
caus
apiti
ipa
▁5.7%
onfatal
▁TC
7.7%
urro
uliz
▁26.7
7.6%
idu
▁neuroimaging
▁subtherapeutic
onex
▁(16%),
=3.17;
▁electrosurgical
=0.185).
▁spurious
=2.1;
▁980
▁>1.4,
alsy
ervis
igital
▁cholesterol
9),
timod
enin
stitutes
▁patella
▁-1.9
ughter
▁carc
eof
iminated
umul
▁metronidazoleor
umet
rment
aphen
ranberry
▁1.46
▁heartbur
eric
▁239
atesticular
tiap
▁needing
▁(85.1%
bohy
apro
erp
▁19,257
▁defecations
▁Cut
idney
▁solitary
gasmic
elst
]=5.2;
-2.58-
kot
▁prednisolone
ixime
▁dres
hythmic
3-1.
0/30
orv
-90%,
▁>30%
ransb
antrums
cale
▁polymy
aflex
▁endogen
▁desmopressin
▁96%,
upi
▁ovulated
▁Banglades
rocin
cedures
▁60%
NHAN
▁1.5)
▁Transbronch
teriz
Spectazole
ipid
ultant
melan
▁balloon
▁postcoital
icin
8-5.
]=1.44%;
nons
6-7.5
▁ODD
SIL
estol
Gh
ltr
▁carvedilol
▁comparable
sro
rti
igl
▁precur
▁docusate
ioglitazone
▁physiology
Mul
▁Recommend
▁Interr
oglob
-800
retag
▁obstruction
▁mood
▁1.9%
▁STI
▁vesicles
adrup
.0-2.
efa
▁Bariatric
▁awakenings
▁disability
▁aceton
4.2
conver
ewest
▁scars
▁55.0
▁postnatal
▁premature
▁staple
▁0.46
orw
oan
▁0.82
-0.2
tors
xical
anan
eco
▁7.5%
edist
utw
-6.
=10,000/
▁enrolle
emically
▁247
restimate
oplasm
hich
chlor
▁8.8.
▁Educ
▁neonates
]=-
]=3.1
=121)
chop
▁imple
inistered
aratriptan
iclopidine
oklet
▁Conservative
ocalcemic
sectional
▁rhinovirus
onate
fusion
-1.63)
0.67;
eplace
lve
▁aro
46).
iolog
▁0.56-0.94).4
ingle
19%
esem
ulting
timally
rates
ymptoms
▁radicular
▁8%
Eigh
gage
atent
orsem
6,0
riculum
▁reliab
73
▁Improve
▁0.99),
-34
.007).
▁trichloroacetic
▁embolism
▁0.3
55
▁1966
▁7.6
▁Preven
▁ineffective
-2.7
▁creams
▁muscul
accinated
▁0.01).
▁abduc
adox
▁criterion
▁2.26
▁presenting
▁2004.
ardation
▁Closure
▁antac
bok
▁cong
ilat
ndar
ranas
▁ipratrop
▁noninvas
▁intermen
▁manu
-0.77)
▁borage
▁donep
=1265).
▁0.34-0.7
▁101
▁substances
bup
▁hypothyroidism
valuate
▁infarction
▁anovulation
72;
=1.3-1.9
▁trimethoprim
▁socioeconomic
▁116,094
=0.58).
leural
▁anomaly
isph
expos
.0-9.4)
▁heels
-98%
cording
▁(42/170
olig
uvaRing
▁9014
-60
▁subg
=10,828).
▁complaint
▁<25),
▁hospitalized
▁brom
<.0
▁203
▁0.70/0.95,
▁47,
hiz
ocytopenia
▁(30/30)
4%-93%)
▁naratriptan
erythromycin
▁1555
2-1.44).
valences
▁intravenous
opausal
uniz
▁PHN
▁paroxys
▁pseudoephed
egis
02;
▁1.04-4.
▁penicillin
utritive
numbered
▁excessive
.9%)
chosp
▁etiolog
sA
arbohydrate
FeS
bste
▁-1.
▁4.46).
▁432
▁0.51-0.8
roxyp
enings
▁0.23-0.4
▁equate
▁hyst
▁betwe
11
ogon
apies
▁0.17
▁cetirizine
▁palsy
centrations
▁sugars
▁-7
=23,613),
▁targ
▁biloba
▁GADA
▁hysteroscop
izan
kert
▁Sixteen
ecol
retage
0/0.96,
arity
21)
fate
]=142
-0.98)
50);
▁inhib
▁68%-7
▁-2.7
▁phenotype
oracic
ocardial
▁celecoxib
atrop
▁(19%
tained
75)
intensive
tagonist
Lymp
endec
vical
ocalcem
=1.5;
▁sometim
Dip
▁9
7]),
ymphoc
counseling
igricans
▁0.03-0.19)
opamine
sitive
ncop
▁rele
atestic
elih
.2%
▁16.0%
▁crom
▁menopause
-4.3)
▁heterozygous
▁ecz
duc
viparin
ralf
▁emo
haved
▁Viral
▁(1:1:
▁>6.0
▁Thia
▁caution
bese
omethacin
▁(18%
3-4.
▁(<2
4.7;
ilarly
mega
regate
▁experts
▁somewh
lexor
▁Bric
ospas
▁Cryotherapy
81,
papulopust
▁nonfasting
4.7
▁microh
▁710
suming
-7.0;
nowledges
▁thromboemb
▁1239
elecox
odiazep
▁oxytoc
▁(15%)
64
▁slowed
▁(20%
Rim
▁20.2%;
lovir
▁0.013-0.063;
▁147
▁endos
,2
7-0.8
espir
▁neutroph
ysms
=.02,
▁disadv
ycl
▁0.4-1.6
etere
=19)
titr
▁demise
▁peripartum
positi
▁adi
232
78/438;
▁86%,
▁Recent
▁saiboku
imot
vasion
▁standardiz
oyment
▁80
▁prednis
▁obesity
▁bans
▁achievement
▁equivocal
▁technologies
adjus
▁spleens
steop
sitiv
▁mellitus
]=5.
calcemia
▁compressive
erns
▁chl
urses
▁equiv
ipidemic
▁resten
▁2.7-5.7).
4%)
puted
icensed
▁overl
▁vulvov
▁electrosurgery
onsyst
=25;
▁Pregn
ubg
▁mycop
aigh
heral
inten
▁30%
]=0.78;
sequent
onsillectomy
▁63
▁1980
▁eligible
2-1.4
eteen
Altace
▁ane
yte
hically
▁lifetim
Remicade
andinavian
▁defic
▁rhythm
▁confine
▁tolerance
TEs
-1.07
omatosis
bod
ationships
▁macrocyt
urid
inotrans
▁endometri
levision
▁worksite
eterans
timib
▁51.7%
cessful
oiter
physicians
RF
-61).
uscular
▁malignant
▁postural
▁ruling
▁Factors
▁autosomal
▁dermatologists
▁tes
-98%),
earched
ALLHA
Eb
▁94%
erfen
▁SID
qually
yses
xime
enal
▁Eradication
estations
cand
▁mE
▁MEDL
▁vein
enzyme
▁STOP
exCA
▁SMR
▁35-6
-1.40
thmic
▁Localization
-1.05).
▁abbrevi
▁transcer
▁5.11-21.2
8-1.3
▁hydroc
▁1.3-1.6).
hemat
▁multist
▁crosssectional
-22
thritis
bodies
frequency
osensi
▁946
▁1.18-4.20).
ripping
iovascular
▁serotypes
▁misopro
oxig
-6.7).
▁oxytocic
bances
▁Phase
Tricor
▁unbi
▁1.80-5.37),
termenstrual
iogram
▁overused
560
233
▁mononucle
▁1.68
xercis
ugmentation
▁1.00
9-4.
enot
avent
▁(33.2%
▁88.
▁comor
▁0.72-1.0
▁emulsion
▁Transient
▁chor
ochrome
vulation
).1
pulsion
▁terbinafine
▁blinded
▁nebulizers
ransmission
▁endometrium
hyperten
entou
amam
▁nonmelan
▁Cognitive
]=0.62;
▁mania
▁1.02),
▁1.2-8.0]),
egular
myx
osm
▁-0.84).
▁Hg
otropin
▁63-99;
uretics
ysical
▁glim
etat
athem
▁crossover
▁comorbid
13
▁rats
creat
▁Penh
▁Madd
▁healthy
▁0.10-0.3
versy
siz
▁0.65-1.0
lind
itus
▁2.14
Ur
.."
98
▁melan
▁misdiagnosis
7-2.3
ypos
vile
echni
▁1.63
alifying
ouraging
ffective
▁7,
▁nonor
▁psychom
ommends
comy
▁concomit
etine
▁journals
▁stairs
ndomet
▁Colle
trin
▁(20/32
▁lapa
▁clopidogrel
pleas
▁acrom
▁quadruple
▁(1.2%
▁3.0-19.5
▁PT
ronoun
.0]
Issac
tituted
▁McIs
otient
hilic
5.6
Garamycin
=10.
▁unresp
▁Bisphosphon
asalazine
7-
▁Ultrasonography
urric
84).
orrheal
▁2.82
▁Referral
▁296
Naftin
▁19%.
▁skel
▁1.0-2.
952
-1.51).
echocard
atisfact
poscopy
▁rhab
endos
8%-
▁Tonglulo
▁malarial
voth
▁buck
ermin
itaz
▁celandine
▁30).
4-1.6
udden
Ve
olpidem
ritive
-0.78
imvastatin
▁intere
▁demonstrating
▁256
troes
1,75
osac
▁<70
▁HbA
▁characteris
▁defec
▁(7697
▁8.3-9.4
▁1995.
▁4907
▁infliximab
Nit
▁psoriasis
tidepress
masteric
atarsal
=1162;
▁(1%)
-1.02).
▁americ
▁nitrit
▁levothyroxine
uic
▁reviewing
propri
ffered
ogical
▁8.8%)
▁68,
vulsants
omag
▁494
▁hazel
ophys
▁5.4
▁1.3-3.
rickner
▁restudied
▁541
▁validity
ylphen
▁myom
▁6.7%
▁(94
▁<.00
naus
▁proton
▁ottorh
ilial
▁dehiscence
itourinary
▁warrant
utam
]=2.17;
romise
rief
▁outlined
456
▁tomography
▁-1%
▁sativus
resenting
linary
ocalized
erive
elay
amicin
plenic
irte
owske
aniz
▁rearrest
nolog
▁1.66-1.88;
▁18,
▁leptin
=.04.
thesia
6.1%
ograms
resum
onos
▁SNR
▁40-80
▁osteopor
ureas
▁salmeterol
▁2.7%,
estab
iatric
▁oth
▁RAS
metazol
▁Likelihood
methylphenidate
Related
▁ulc
▁hered
thwe
▁intest
▁salp
8-1.34).
78%
-6.2
edback
inatal
-95%).
ediat
10-0.52;
porary
▁gentamic
omotor
=4.6
]=-20.
▁0.35
▁3.79,
6.
▁angel
▁(8%
▁sprue
picillin
arithromycin
tensive
8.4%)
▁tumors
▁sonography
▁effec
eswax
▁decade
astrophic
=.034).
▁atopic
-18
rener
timation
▁grocery
▁hypernatremia
reatitis
▁IgM
▁analgesia
▁amox
retest
▁tech
Eg
▁AFP
ittac
▁0.83-1.19).
▁Elevated
entually
thysterec
▁undef
▁0.6
▁diclofenac
atript
azard
quately
identify
▁6.3-4
onaz
ioth
ffec
orating
ylm
iolytic
carr
▁nonph
=.031;
▁incomp
▁Thy
paz
rillation
6%;
hydr
▁Opioid
90%
-3.1
urtic
▁psy
▁invasiven
otherapists
▁thrombo
allerg
▁ureter
5-1.2
stit
▁1.2%
lamydia
Foll
ronchod
▁kneading
▁18,500
▁inducing
xually
inester
iprazole
ondence
ransc
79.
▁Paragraph
tho
ygen
▁566
ichom
hase
▁Rised
odul
▁Neurop
]=8).
▁juic
▁24.
iformly
ittent
ucasian
cataract
ilify
isner
tionists
idable
-32.
ankle
bam
paring
▁ruptured
▁regain
agmus
▁Bec
▁-0.03
oids
▁2.0
ubc
▁biopsi
▁AO
▁Treating
45%)
▁hemorrhoid
etuses
▁(892
olos
apid
yel
▁(5%)
▁civilian
▁Bacter
▁determining
coat
=6.96%
uban
▁Esophageal
▁cardiologists
Fo
ostd
alloon
idemic
Dou
anl
▁190%
▁Medications
/8
▁0
vam
oscop
▁specialized
ipating
▁-0.33).
95.9
]=0.54;
▁peroxide
=135),
-1.94).8
▁0.66,
nonsystematic
SAID
ividu
▁ons
▁Prel
orward
▁(10
▁64-9
▁5646
▁20%,
partate
AO
▁mitigate
▁833),
▁=.0025.
▁endometritis
ectional
25%
tinuous
▁23/1
ypt
▁multicenter
thyst
▁Cozaar
crim
enl
rexate
oscopy
▁nystatin
udit
5%,
cooling
etronidazole
▁antimicrobial
-25
▁77%-9
-1.30
otional
ycop
0.00
aryl
bop
ypertension
ydrogesterone
▁756
▁(24%)
▁enrollees
▁0.59-1.6
▁0%,
organisms
respondingly
METS
anaf
▁Strept
ilic
reo
teroid
reak
▁savings
▁300-
arrh
▁uro
compr
▁giardiasis
stitch
▁Impression
uliti
▁PTSD
▁(16.6%
▁Survival
▁19,000
▁antidepressants
▁escal
▁Maximum
▁171
valuates
▁antioxidants
▁surge
erral
perazine
oxac
▁outn
▁HL
▁Azas
▁adver
▁4.3%
calating
-1.73).
rhythmic
Mid
▁lowere
sulfameth
▁meal
▁5.6
▁(2300
]=25
32-5
▁adhered
▁Responders
aclor
]=2.72;
▁unsel
▁gastroenter
▁actin
▁haz
utery
estrogenic
ablet
▁mam
Vit
▁evaluat
▁receiv
▁sunl
▁(20/
athop
▁recor
isters
asteberry
epat
▁disposable
▁10.5-18.5).
▁12,5
▁chlorth
ditioning
▁asymptomatic
▁phosph
ephritis
Lis
Lip
▁1.09-3.
pion
▁aerobic
▁74
▁practitioners
▁ThinPrep
ROCAM
ipulative
▁2/
▁1.00).
=.49).
bace
gement
.7
esigned
tact
rofurant
ormed
▁Danazol
▁allergen
▁dexter
8.9%;
▁dyslipid
=0.
iab
ription
ienti
ifor
-0.5).
▁antagon
93.
ardiasis
autery
=14
fes
lamptic
ymp
▁econazole
▁300-3
▁(6/30
uthors
atien
,0.
▁zinc
▁78
iitis
▁nonsteroid
=180
1.4%
▁Ini
uteal
▁0.15
▁ongoing
1.7;
▁1.2-3.7;
argins
58%
▁accessibility
randial
iterrane
▁tape
Hypertension
▁0.12
OSC
▁subar
▁servings
ribut
▁METS
4).4
oupl
▁1000
onvuls
▁encourages
▁MMSE
▁azoles
▁(9.9%
▁phenyl
▁17-2
xtr
▁benefici
▁calciton
▁27,456
/4
▁ulnar
terolem
expec
couraged
aising
nexal
adone
stet
▁duke
ogonadism
▁anecdot
24
▁-23.2
▁CAD
▁intact
▁88%).
CAH
elae
▁Sucralfate
▁NCEP
▁pea
predominantly
=.50
adictory
▁antipy
▁splenic
rimo
▁attending
-92%).
▁absorp
TOR
▁covariates
casein
9.1
▁substantially
▁terbin
orther
14,3
▁neon
bacco
acerbation
▁Eff
atified
▁sulfonylurea
heumat
▁histology
ademic
▁infrequently
eparin
▁prela
▁traz
lya
▁ceti
Few
▁Sys
▁0.00-1.4
▁naproxen
orpor
96;
▁seaf
verap
Ny
▁Theoretically
▁dull
▁lef
atab
itec
4]
▁10-3
▁orthoped
▁pyod
▁Forty
▁(3)
▁Calc
▁assoc
hydrating
▁intraepith
ackles
▁(8.8
etings
sart
ulopustular
8-0.8
▁abscesses
226
▁538
75%
ifedipine
omenon
▁polysomnograph
▁ferrous
44).
otransco
etazol
pectr
onam
▁5.0
ofemoral
▁592
Pen
0-0.9
ondy
traline
ervic
erfenadine
▁suspected
▁1983
ucted
01).
▁Erad
▁desmop
▁1720
▁indeterm
▁(4.8
▁acarb
azoles
▁suppres
▁aml
▁azath
11%
enile
ertil
-0.97;
landin
▁838
▁respec
.4;
issing
▁(54
▁compounds
▁0.70-1.0
▁herbal
fuss
Sid
▁3.7%,
dwelling
▁2.9.
▁carcinoma
obin
▁VTEs
STAR
anaz
CGs
=1%;
-86%
▁Tender
▁postm
▁3)
▁18.3-42.
▁0.54
eriority
=935)
otab
▁0.4-0.8])
facturing
▁810
▁12.4%
pointments
▁troublesome
▁2-
▁53%
▁stratifies
8-0.7
sternally
-0.73)
▁shaf
▁adequately
▁111
▁antico
turban
▁10.4
▁placement
placebo
▁tiotropium
▁HAM
▁nontreatment
▁lidoca
nthes
omeg
elong
▁bedtime
erose
▁fru
▁0.4-0.9
dverse
erosol
▁-10
▁29.4-57.6).
ropion
▁Euflexxa
▁contradictory
▁susceptibility
14.4%
=4.5
PROCAM
▁hypoc
tich
=2.2;
-20.0
▁1.1-
entar
7.8,
▁lability
-85%
▁subcut
amined
echanical
8-3.
▁Tyl
ibitive
▁polyethyl
ervative
▁616
▁amnestic
/204
itively
▁bic
▁(>3
▁probes
▁antifactor
orl
ctioning
▁prenatal
,15
enaz
▁norgestimate
inforcement
oephed
asein
ticipation
1.2
rts
▁(1127
ogrel
OAP
▁(63%
imab
▁Chlamydia
▁secretolytic
32;
adach
icycl
=0.99
=160
▁ultrasonography
27).
hypop
▁Atlay
▁Impact
▁normotensive
▁describ
alents
troc
▁vigor
▁emotions
▁heterogeneity
▁72
-7.54)
ternally
afti
<.002).
▁Thou
acri
▁inver
urrenc
▁82%
wk
His
▁inad
▁14,
berr
▁triglycerid
▁71
ovascular
ocalization
meth
▁attemp
▁indicat
5,
mec
uish
=4.9
ucated
6.80
oselective
▁0.09-0.29).
▁worsen
zine
▁antig
52%
Fort
ionitis
6);
▁calf
▁67%-9
▁0.43-1.
▁TRIPOD
▁complicates
gian
(4
sific
▁offsp
▁immunosup
fidence
▁Classen
eig
▁thyroid
plast
▁1000-1
eterminate
]=1.01;
obacill
▁nonoperative
▁-0.3
ptors
leph
▁fallopian
▁outb
35
▁correlates
▁Specificity
▁cephalosporins
▁rehyd
Ei
arolin
▁Surgical
▁McM
▁urea
▁utilizing
gerated
▁0.9
/15)
▁0.91
roxyprog
vein
▁CIN
uffici
=1.5);
4%-9
▁naf
▁prochlorper
▁strengthening
▁benzo
ohyster
▁nausea
antoin
▁43,738
udents
▁0.67-5.
▁exudative
▁sonoh
oramoxicillin
▁Levothyroxine
terine
therm
▁salbutam
pworth
olest
9.5),
▁zaleplon
oft
pidem
etar
tene
scheduled
▁1.2-2.
sumura
uence
]=0.7
]=3.7).
▁outl
ymal
▁52-1
robial
4-2.
▁dihyd
ocon
-2.67),
erop
▁demonstrates
-13.9
▁montgomery
0%-2
9-15.
▁smoking
▁71.5%
=55)
=.043
mulation
athiop
atiti
atistically
▁bilir
▁bioav
▁10%,
ensiti
▁Inten
▁-7%
vestigated
resents
▁49,
▁cotrimoxazole
▁reno
▁0.94
inology
iant
venience
▁Dental
▁1.1-2.
▁interventional
▁angina
ectin
▁tumor
▁1.04-3.34)
▁0.20-23.2
▁urography
tending
▁adol
72
▁comparative
▁0.4-1.6),
ransit
ortun
▁(>5%)
oplac
▁0.02-0.2
sors
▁recept
66-10.
▁restl
▁(31%
tior
omew
ffeine
▁ionizers
▁lactobacill
2.9
▁comorb
▁xyl
▁endocrine
ixty
nding
omagn
▁97%
▁cephal
5.1%)
▁mirtaz
▁rigorous
▁adhering
assif
idic
histology
▁coor
sophageal
▁1.01-2.7
▁RCTs
▁hypog
▁straining
cursors
▁yearly
3-3.
uminuria
▁histop
99.
▁Tiss
ovag
.4).
ositi
=.045;
▁0.13-0.
▁gestation
▁Combinations
2,47
▁filtration
▁2.12
]=4.5)
▁Duradrin
▁milnacipran
▁(55.7%
lamin
edure
=44
▁rup
91)
renatal
▁methyld
-0.91).
▁contraceptives
andia
▁calcif
80).
▁tow
=10,000
▁intram
eut
9%-
coated
4%-81%
▁inhibitors
▁bri
3.2
timulation
▁Manufact
counsel
amus
▁fluox
▁3.4
ifes
21).
▁0.13-0.6
▁(65%
lamine
▁smokeless
▁postprandial
▁categorized
Bay
▁optimis
ffr
▁>1-4
onado
▁805
parity
osmolar
▁<23
reliminary
▁desi
national
▁exaggerated
tec
▁80%-9
58-5.
▁mineral
unp
sill
-526.
▁114
onstrab
▁(64%
Lowering
monitored
lixim
9,405
mptom
ecreases
▁lorat
placement
▁78%)
ractical
97%
cause
▁salmeter
portant
=4).
▁unrespon
vigorating
ipram
vaccinated
▁179
enital
itonsill
▁infarctions
roxys
nep
crib
▁HBsAg
▁Twel
eclampsia
▁loos
riazol
esear
thisterone
▁bum
▁anaerobic
▁constellation
▁neurobi
6-1.2
laf
▁uncompl
▁interim
▁improving
opposed
ormiti
poscop
▁(-0.0
▁audited
Nin
orid
upus
awb
▁8.3%,
mf
contrast
trihexyp
biotic
antit
anid
▁3500
▁(266,0
corn
▁concus
▁ovul
couragement
▁Anc
sensi
▁jaund
▁Lipid
ndin
adequ
▁jeopardy
ereb
▁0.13-0.31;
▁50,000
resis
▁abruptly
osag
icid
uaifenesin
▁0.20%
▁fumar
▁182
chloroth
▁abortion
▁Shanghai
▁unpred
▁1%-3%;
roor
▁phlebographic
xyl
omogeneity
▁antihyp
▁1.89
▁nonop
▁hemorrhage
▁predisposition
▁77.
NSA
Gy
tative
▁rehabil
▁stratification
▁75-
▁7.84
▁0.34-0.54).
verl
▁miln
▁Diagnostic
wm
cys
▁serolog
▁estradiol
atry
95
3-4.5
▁bananas
▁antibio
eou
-0.94;
rthovisc
▁(87%
Very
▁mefloqu
ewh
enat
idam
▁Adequate
hexidine
andag
STOR
▁helical
▁0.8%
▁Norvasc
racycline
59;
▁ketoacid
▁inversion
▁0.19.
ardized
▁cardiome
00),
▁influential
▁90-
▁sampled
▁5.5%
▁Eighty
iox
▁acn
▁midtrimester
.3
7-2.91;
ycardia
azepines
▁chorioam
oital
ournals
onesian
▁metabolic
-0.79)
▁intrace
32
00)
romet
inem
▁0.75-0.99;
▁arter
▁hydroxyzine
vides
▁lesions
▁nights
erest
▁57-2454;
▁(1),
ipran
▁resus
▁cardioem
▁hypothetic
▁ison
ubber
olyc
wl
▁yielded
▁(40
5-1.05).
erati
▁tendencies
mog
ilit
▁(97%);
▁inspiratory
7%
etim
oidectomy
▁356
aminase
tment
▁1.09-3.51).
acquired
▁690
▁Physical
▁trends
fetoprotein
=4.5),
7.1
xo
alli
]=1.8;
atistic
5-0.5
▁Staphy
▁(64%-81%).
▁nimesulide
therw
ripp
aced
▁paroxysms
▁inac
▁hypothetical
ylamine
3%;
▁beeswax
regulation
▁scab
onding
▁scrotal
▁6%).
▁0.0%
ufacturer
▁1.03-1.40).
aucasians
erestim
azoline
▁numerousreinf
▁53.
▁Magnetic
▁blis
henhyd
▁brevis
tution
▁Subsequent
lul
▁IUDs
▁468
ibiting
▁maneu
unus
▁58%
▁tolerability
arely
▁immunocompet
ifel
meprazole
50;
▁(3.7%)
▁secondh
▁(42.
EDL
iffus
poor
entam
▁Expert
isit
▁vertic
29
▁0.25
depressant
unf
▁gonado
▁1.24-1.74).
=-0.38
▁unsweetened
427
▁adhes
.07)
▁postur
▁297
06
▁1.2-3.
sre
neel
hyro
▁unexplained
queous
acet
junction
▁heterogene
▁0.06
▁impair
onh
=9.0;
▁9/100
▁deregulate
verages
sear
trospective
ealth
.10
mum
▁5721
▁Cameron
=78.8%
▁0.23-0.43).
enteritis
-10.9).
tedly
lobin
▁249
▁retard
=0.58;
aculation
rotec
esterone
-0.28).
▁1.33-2.42)
elayed
=555);
▁Improvements
064
.009
<2
▁eradication
▁strategies
▁Inves
▁hydrolysate
▁0.28
▁gastroint
▁stools
itons
▁granuloma
RAISE
▁estol
]=0.60
ectr
▁233
▁singlet
-3.4
ricans
▁Caro
ecation
amines
▁Corticoster
▁90.
▁hydrop
Dent
▁53
achn
onid
(0.65%
rolin
confirmed
▁(448
▁outcom
▁premise
▁nondiuretic
▁compromise
▁PEF
sium
rofessionals
timat
ocyst
ETS
=1.95,
olved
opw
▁(1406
glucomann
efits
▁145
-49%).
▁Alz
▁multistate
rovascular
amycin
illar
▁refus
▁balm
isual
7)],
sional
opalatoplasty
▁heparin
▁801
▁onetim
▁neurole
▁lep
-14.7%)
8.0
▁whos
▁564
iltr
euk
TDI
▁1.31-1.9
onists
0-1
eriti
▁cardioemb
mesal
▁reproductive
▁risedronate
▁salbutamol
merci
▁192,47
9.5%
curred
▁pound
▁antifract
orning
ematical
▁0.0-0.8).
▁2.61-26.97).
▁vacc
]=25.
anat
tionnaire
Ra
▁amo
=11)
▁749
ussions
▁carb
oronto
▁endorse
=.03
radication
▁obstetric
bilirubinemia
▁10.1%
▁198
damycin
5.5).
aif
▁glargine
verely
▁distal
zetim
ipen
rovas
▁methot
▁4.5%
▁14.
▁wrist
oulder
stinence
itonin
▁coad
▁Researchers
▁hone
=3.72;
lusion
timi
▁adapalene
9/18
▁<85,
7-7.
-40%
7.5
terogr
▁consis
6.2
udy
essive
viral
ximately
cholesterolemia
▁Copenhag
▁alan
bA
itrit
microbial
▁normalization
tronic
earcher
efici
esm
▁goiters
atad
lion
urate
▁9.9
orine
▁intrapartum
fatal
-0.4;
ocu
▁pefloxacin
▁crac
▁Feeding
incidence
▁polys
=2.09;
enadine
=.001,
,9
munog
hibited
-7.
▁insoluble
genation
-72)
kic
▁unch
▁cromog
anul
▁antepartum
▁1.42-
orough
osom
bohyd
▁buckwhe
▁sten
▁emesis
relaxing
▁(1.0
=18,
▁hydrogen
Wom
nin
▁benzoyl
apride
▁nonblinded
/70).
5-3.
▁warr
llium
1%.
▁Adolesc
ramine
▁codeine
ehavior
vitis
ourag
idity
▁concurren
▁immunobl
▁expectantly
llitus
▁pathophys
▁surgeries
ducer
=1.87;
▁28%,
ihy
▁readings
▁artery
▁218
8.1;
▁arrhythmia
▁undere
▁-5.
▁cholines
assical
veter
dull
troa
abumetone
zoster
ockers
cise
▁schooling
▁psychiatric
onents
▁0.59-0.8
▁soldi
▁neuroleptic
▁Chlamydophil
▁rhy
▁>38.9
<.14).
econdary
▁reinforcement
33),
openhagen
70).
iprof
amipril
hinP
tage
▁cuff
▁beliefs
mentou
▁Douching
▁=.00
yper
27),
apsaicin
▁serotoninergic
▁HP
itriptyline
▁otherw
0.6).
▁0.9-3.6).
▁Cream
yclosp
indings
▁1.30
-1.2).
=9.0
▁1.3-
-97%
uscep
usi
▁Mediterranean
7-5.96)
▁Copenhagen
thor
xameth
▁spontaneous
-5.2
75
▁valproic
▁27%
▁0.62
oung
8.7
▁Sched
▁Murmurs
▁vaccine
emerg
▁Injection
▁cholinesterase
icens
hine
arach
▁micros
▁acidic
asop
▁Older
Gastro
26
apulopust
▁hygiene
erness
▁appropriately
ropp
▁anox
▁alcoh
▁20,226
▁Gav
=.26)
▁(5.1%)
resc
▁hysterectomy
▁calcitonin
▁52%,
▁(89%)
ulfad
▁immunog
).7
Hig
▁Grade
▁chewed
msel
aprosyn
▁unwanted
▁nonc
dop
▁-3.
vestigations
eletal
▁localized
▁(122,
5)..
reened
eze
itam
irom
osclerotic
HRT
HDRS
asalaz
▁multic
▁adiponectin
strual
cyte
▁104
▁serone
▁Tramad
rective
ichia
inur
emoph
▁(72%
▁wee
▁nonver
idati
wat
-81%
gitis
▁193
▁traction
icates
47;
▁physioth
▁0.70-1.2
onset
paghula
66.
▁0.43-5)
vente
rre
▁0.71-1.08).
▁cotin
lary
▁netw
yom
▁81
▁2.26-5.
▁impul
▁MRFI
tropium
Vet
▁ischemic
97).
▁3.
▁Geor
▁adenot
▁hepatot
Ai
alanced
▁Extensive
abolism
troent
▁Neither
▁duve
▁foll
=1.22;
=480
▁Sims
yalg
▁audit
oace
▁20,536
▁13,
▁(20/68)
▁Gonad
tient
▁720
▁0.5-0.
▁intravaginal
▁confers
chill
kbased
ysteine
▁tablet
osyn
2.4
corbic
▁fluoro
azos
imitation
▁concer
▁prescriptions
▁antih
Eu
ecific
zol
▁acupuncture
▁1.45;
▁hirsu
▁angioedema
▁penciclovir
▁nurses
750
voc
vian
52
▁20%-
tivari
▁0.67-5.96)
ithe
▁heterozyg
xper
▁scalpel
▁malignancies
▁differed
▁(3.8
=5.7).
erch
ailures
otent
▁95%-
.02
ractice
▁cyclooxy
▁chemotherap
▁acetylcysteine
Ton
razol
specified
▁Antidepress
onstrated
imesulide
▁2.10-3.77).
azoleor
02).
oclopram
umeral
▁initiating
▁(75
▁3.2
]=0.82;
▁docu
▁unaffected
▁muc
iseof
▁PCI
2,
hexyphenid
▁discrim
=2.
▁42)
▁paradox
▁exhaus
▁intrav
Morb
▁concor
hop
▁beginn
yocard
▁asy
▁chil
▁ate
lopram
65)
xan
doles
0.0%
oratory
ischemic
eak
▁detecting
▁migraine
2-1.8
42)
neumococcal
▁seque
▁2.6;
▁119
▁whol
utritional
7-0.6
64;
/0.81,
yuri
veal
9,40
hydrase
▁cystic
▁portends
▁NN
▁(69%).
ricycl
▁pathoph
▁0.72-1.
-2.05).
▁56%,
troenter
▁relied
▁Iberogast
▁weighted
▁tripl
▁pyuria
▁(1.6%
.001)
-76%
▁youn
sar
unctional
cerv
▁multimodal
▁Enalapril
▁industr
Ru
▁1970
nip
veget
▁779,
ulmin
laxing
▁coniz
lthough
▁islet
fici
▁(24.
▁sonograph
plification
0-1.0
▁manifested
▁pollic
▁IVP
▁endoscopic
▁adh
nized
▁Valproate
Seven
xacet
▁implicated
▁1.21
▁535
▁excessively
▁prognos
imil
▁quanti
▁subgroups
ogl
icco
▁omega
waves
=.009).
▁infor
▁unn
-0.52;
ampo
urea
enzodiazep
▁sequenti
screened
▁pancreatitis
ycard
2-1.9
ectious
▁histolog
justed
▁3/
onit
]=0.99)
▁Screener
▁70-100
▁colonic
lf
▁sunsc
▁(1.2%)
reported
▁predictors
▁autoantibody
etermin
coag
mL
occal
recep
etin
▁corticosteroid
PPV
▁509
▁bupropri
▁Gord
▁alendronate
istently
8%)
arench
▁cramp
acologic
▁dipy
asthmatic
-88
epsis
▁seborrheic
▁soiling
63,
iazepine
▁(1000
▁murmur
▁daltep
tico
uresis
rogest
ilitis
▁bacteria
▁1.62
remaster
]=2.7
cyst
olun
▁0.54-0.8
000.
▁vaccination
▁pyraz
▁Screens
▁Interrater
BMI
▁1.01-2.76;
fants
▁somew
▁0.34-0.
timalarials
4.8),
=100)
Although
atea
▁glutamic
ustular
angiotensin
-1.6),
▁dipyr
▁somatic
odies
▁tonsillectomy
▁montg
▁Scor
endp
vidual
eity
▁ei
▁childhood
Soc
▁prescription
=4.6;
phary
Rat
▁4-5
▁1998
imethyl
▁anteri
▁Manip
▁Triaz
▁unpredictable
▁multidisc
▁microhematuria
▁xylitol
▁antihist
▁transmitted
2,471
9;
-1.6
sives
▁27,
ibs
▁>10,
▁Varicoceles
▁valpro
▁bathroom
-90%
perts
illec
onec
mmetric
▁(1:1:1)
▁nontraumatic
▁0.35-0.57).
istered
▁(97
viti
Sti
rheal
▁saffron
ignificantly
▁HPV
▁mandatory
▁coworkers
illment
▁etretinate
linic
aminas
strates
MH
urysms
▁0.72-1.01).
chid
eartb
traumatic
ateau
▁(3.8%
9-1
nerc
=0.6
▁recurred
olescent
aise
errane
ravastatin
2-0.23).
▁translum
LISA
ibo
▁delin
<.03
▁pho
tly
concent
▁flunarizine
ipar
hula
▁atro
]=8.
gnant
▁pyelography
initiated
ylin
=-0.98;
▁headach
NPH
vestigators
▁(16.7),
/30
▁metoclopramide
adiaz
▁24.6%,
ogis
▁heterog
-600
▁Phen
▁Grover
vuls
▁ketor
6-2.2
racti
9.6%);
▁underp
▁enteral
yline
oq
anis
glycoprotein
▁CNBSS
atc
▁3.26
udited
ecal
▁Reoperation
▁31%
▁Losartan
opopliteal
▁objec
arbox
<.02).
odal
▁sexually
riminate
▁nadir
▁0.48-3.0
inantly
lyte
▁acetate
▁skinfold
bations
▁thia
▁hypom
▁expelled
broad
▁1.05-1.69).
▁Pneumococcal
24)
8.9).
▁Varice
▁ferrit
edem
erior
ophren
1-0.9
soph
▁neurop
roids
▁deficiency
sychoph
▁31;
]=2)
▁developmental
tassium
▁dysr
<.071)
imed
▁indo
▁compa
▁0.79-5.28).
▁outbreaks
3.1,
▁HB
▁56%)
pile
phin
raditional
resch
imu
accur
▁aten
▁(33%).
▁effecti
▁ranitid
▁antipyretic
5.8
▁281
▁ampicillin
ricular
▁AOM
arenchymal
▁(>14,300/
ransbronch
▁decongestants
injection
▁regulation
▁agg
=85%
▁ValHeF
▁5.9%
Silvadene
▁cleanlin
juri
antial
▁demis
▁durations
onvul
cIs
gm
uptured
▁muscle
iterranean
xers
▁(26
oprol
llation
6.9).
▁Norther
scherichia
EET
▁sumatript
▁posttreatment
▁Ace
▁12.1%
▁decayed
▁misclassified
▁(17
▁37%.
iograp
▁14,881
▁sepsis
▁59%-76%),
▁exploration
▁hyperl
▁(14
rednis
▁carbohydr
▁rasp
▁(16%)
▁pharmacologic
▁precord
13;
1.4,
timulants
raclavicular
reptococcus
5.1),
redn
tral
▁hs
▁1998.
4%-1
0.8),
ogu
▁5.9%;
lude
▁diminished
▁37.5
.6%
▁4.0%
▁knead
35%
007
galy
▁specificities
mitis
ullae
▁(70
▁(56%
▁42%
2.7
]=13-1
▁fracture
▁unusually
=1.47;
ofil
▁oxygenation
-0.93
▁scheduling
▁interpretations
53).
▁visi
tioner
▁excre
▁conveni
osclerosis
urrently
▁resul
-24).
ilure
eliac
0%)
▁doubling
greater
▁pituitary
▁homeopathic
ropean
▁histopath
▁1010
▁nutri
ginal
1-2.7
pted
umetanide
▁0.04-0.13).
▁2.1-11.9]),
apar
=.04).
ejection
lees
13-0.
▁2.3%
▁microinvasive
▁childh
-100%
=0.23;
gred
▁(39/188)
]=0.27;
ecti
tassi
iminate
▁theor
alies
▁reviewer
ophile
▁Nit
▁dilatation
-100
▁1.62-2.22),
▁nonoperatively
erth
▁VV
▁autoimmune
classified
▁pem
27;
ostility
orpti
▁LMW
▁induration
-60)
▁cuts
fiber
oF
36).
▁dalt
▁melanomas
▁multimod
aditional
▁procalc
▁rosig
▁antich
▁modif
▁1.36-2.2
9.4
ococc
perature
/110
▁Consequently
▁0.90
▁spu
ronic
mography
/7
xud
-14.56)
umerous
▁hyperb
=409
iterion
▁908
▁preinjury
siti
Confusion
82%
▁kinases
mise
▁biop
thysterectomy
reti
▁tach
rill
▁TVS
▁throat
pregn
▁lozenges
errant
▁3.8%
▁89
flamm
NIDD
-1.74).
nalysis
▁leukoc
▁1.19-7.
▁decarbo
▁assessment
-1)
▁Resolution
▁-20.0
▁21%.
14.
▁199
▁HBs
lut
ocycline
▁770
▁suban
▁98%.
tyyear
▁PID
▁(2%
oronary
-1.20
▁preventive
▁39.6%
60),
▁68%-76%)
▁anxio
promoting
pium
▁oxyt
culariz
▁antisec
-0.34)
▁ancestry
38;
heav
acked
▁47.
propriate
3.8%
thesize
=.50).
3,61
.04;
tyl
▁Melan
ignan
-1.38),
▁trials
PDRS
▁Sevente
-1.6;
▁mycoplasma
▁proce
esoph
onsive
aphy
>6
rovement
Sin
▁0.6/
▁favo
Ti
Ace
epressants
yroxine
hematuria
-0.77;
▁0.35-0.97;
-0.88).
erob
▁cerebral
▁twofold
ofulvin
ubit
ustained
▁80%,
cine
HAT
▁patches
plemented
▁diuretics
hydrop
▁anhyd
▁12.5
▁incis
97-0.9
onduc
erit
▁calor
▁inhibit
448
tinues
▁adjusted
▁deterioration
▁fing
0.1
ronical
liminating
9.4%
▁inflamm
etrac
onstrate
ificity
llment
▁108
▁2003,
PEG
Rul
▁specificiti
▁(2.1%)
▁atyp
▁neutropen
convul
▁tTG
ligh
ociation
direc
sity
ticas
▁Atla
loxacin
quences
0.7).
0-23.21)
erou
volved
entor
▁tubercul
ongus
▁Compared
andial
=6
▁ultras
19.4%
=.001)
▁generalize
▁cromoglycate
amoxifen
orad
▁tricyclic
▁10%.
▁intensive
=.001).
osses
/0.9
hexyphen
▁39.
▁0.6%
▁fetuses
TCA
▁80-84).
/18
▁31%;
▁1.10
ternate
45
Bow
gated
4.5)
oore
▁Nut
ADA
ceti
▁CRC
429.
▁Perception
acitracin
=3
▁atrop
ecomm
57
▁(400
▁valac
ifican
enopaus
▁10.5-18.
orkers
anderbilt
ubate
idrin
1.3
edati
▁ingestion
▁DBP
▁1.00-2.8)
▁fulminant
-6,
▁endoscop
▁Benz
terest
.07;
abits
18)
91%
▁pathophysiology
butrin
▁wors
▁calculi
▁ranged
▁vertig
▁471
cycl
▁4.8%
yldopa
▁confirmation
=125),
=10,8
alsh
jected
▁lessened
orias
weighted
▁observational
▁incid
arid
▁alleviating
3-2.
-1.95)
Ls
llowed
tiguous
onmental
zema
eavor
5.2
▁Cogn
▁recur
28
=-9.4
▁saphen
▁epidemi
<.05)
▁factorial
]=1.87;
omaly
▁stimulants
▁overestimate
ylen
▁indig
▁relaps
-1.33).
uptly
2.3;
glitazone
<15
▁pronounced
▁contig
▁buckwheat
▁multiv
▁montelukast
▁4.3
icially
▁noncan
atologists
11.
▁disturban
▁intran
▁CVD
]=0.4
/70
utralizing
▁EB
ioten
pw
apamil
torch
89),
83%
▁imi
surgical
▁smok
TSD
▁MEDLI
inine
unlikely
ESTOR
▁previ
▁methylm
▁ranging
1035
-1.6.
▁572
▁Adherence
orks
▁Ninete
arro
vast
ractures
▁1.35
alon
25
6-1.30
▁tizan
▁Screening
3).
▁Prav
roughout
]=40
asmace
▁unb
▁physiological
esal
▁(45%)
▁Farnett
fortif
rous
▁(<6
▁0.57-0.82).
▁stent
▁propranolol
▁naus
Nim
▁pharmacists
7.10)]
▁urodyn
▁appetite
▁dietic
Tan
<.004,
Avandia
▁5.2),
▁0.4-0.9),
▁461
▁0.45
▁0.86;
▁informational
▁bucindolol
▁digoxigenin
empts
ostt
▁Wad
▁curett
ypop
elaf
opped
pout
▁markedly
▁polyeth
abapentin
-1995
trihexyphenid
>0
▁corpuscular
onsumption
exid
▁benzodi
▁LV
▁cicl
icotine
acla
idase
▁Helical
ortion
ocrine
▁valer
alab
▁rigorously
ricter
Fs
▁Suc
▁Stap
▁inta
▁>7
40-2
emoth
illness
hate
▁1.8-45.
▁100%
ividuals
exual
irocin
▁antigliad
▁electromyograph
▁modestly
▁antith
▁(3/15)
2]=
afe
xist
▁erythem
▁excretory
inoma
arax
cour
▁LEE
omain
▁unscreen
▁Vag
igrans
lora
▁saliv
▁physician
▁tuber
gulation
ynovi
idstage
▁isolates
tinent
▁1.5-8.
▁241
▁chol
ourteen
tatis
-4.94).
▁celi
oste
ilin
frequ
Lopid
▁17.3
▁classified
▁vomiting
▁lengthiness
ochester
adict
▁83
▁asymmetric
▁elimination
▁10%-
23).
bron
▁nonmilk
▁stopw
▁(5.1
inolog
▁hyperp
ventricular
achieve
onres
=16,
uinal
=-6.
13).
lavic
▁<2
owered
etron
▁meals
atios
ydroxyzine
▁pyelogram
▁8.3%
bstein
▁Punch
oreo
▁91.8%).
▁9.
acr
▁Optim
ctom
ashes
▁healthc
280
verestim
Sel
▁1.61-3.
▁succes
yph
adren
-1.57;
tifact
lebrex
indolol
=31).
gesic
▁presumed
▁TSH
yop
arac
ticulocytosis
vering
800
chlorperazine
94),
▁7.2%
eterogeneity
▁7.5
vulsant
struation
iography
▁microen
▁reactions
▁200-4
epsia
▁enz
▁Epworth
▁686
onged
aerob
▁(400-800
terf
ysts
▁funded
ritin
unadjusted
utral
▁corres
▁Tiotropium
▁isc
comprising
arker
▁sonograp
reef
spon
▁pyelone
▁circu
▁1.66%
yroiditi
isdi
▁contiguous
▁9.5
▁analgesic
▁oximetry
▁11.8
pirin
▁<90,
98)
inning
tually
▁Sensitivity
▁HERS
siven
▁alen
alep
erce
.002;
layed
▁14.8
]=1.50
thrombo
uminum
▁numb
toch
osporin
▁6
inogen
▁73%)
alosp
them
osacral
▁hyperpar
▁emis
genital
▁1.48
rasp
▁abn
▁3.3
▁embol
▁0.26
eluk
▁Prep
▁coenzyme
stric
ocortic
aminations
▁york
▁revised
▁physiotherapy
▁underes
hydrochlor
=78%
-0.60
▁postinjection
▁vigorous
-1.40)
▁(41.
excell
▁sodium
rocery
yoly
reth
olle
rogram
▁33
vertig
▁podophyll
coagul
▁Intention
▁diabetes
mittent
▁classif
ummarized
69%
yroiditis
6,193)
▁plaqu
38.
▁adults
romoc
portance
▁hazard
▁meticulously
▁1.0).
ogel
revalence
-23.
cepted
Risk
▁0.34;
▁indurations
▁clopid
44%;
47).
▁inconcl
kend
ometim
▁usu
hieve
▁survived
verbal
rosyn
▁Initi
ildren
684
wanese
ingon
etamine
benefit
mostly
oflox
▁glucos
-2.3
▁(7%
▁mU
▁laser
▁vesicle
6)
andida
allowing
epsi
▁Benefits
6-0.9
▁stinging
tace
oat
▁egoph
▁glucose
▁0.42
80-1.
essm
omegaly
▁stom
ytocin
▁antim
uctus
apalene
idities
1-1.
steoporotic
▁otoacoustic
▁aggressively
othiazide
amamelis
▁noc
▁tendon
=0.49;
▁1.2-14.7)
▁Institutes
-0.5
increased
▁1.11-1.40)
▁0%;
▁benzydamine
CAM
▁spasmodic
▁0.70-1.23),
▁0.45-0.79)
1.4).
unoth
ttaw
▁Furtherm
▁inappro
enafine
▁93.
▁blin
▁Achie
▁Pooling
40/90
andard
anati
▁nontreat
icen
yocardial
ofl
▁(19
choles
LH
gnancies
reaths
=71)
▁bouts
thinn
ecom
tT
istology
pensity
4).8
▁2.6-4.9]),
Bacitracin
]=20
ectant
▁2.5
▁radiograp
▁intrauterine
:30
▁assessing
▁82%,
▁dextrose
tiqued
idual
▁44%
▁orrespond
▁prox
onucleic
9-1.5
=2.3
▁fatty
-2.09);
ulcer
▁nonspecific
▁Incision
reop
Pati
=.045).
▁SSRIs
▁accounted
▁emotional
NIH
reinforcement
ifested
8.5%
▁Respond
▁78.
astroint
▁165
thot
SCS
▁Sevent
▁264
▁549
▁48%;
andmark
]=12.
hensive
ecklist
Viox
▁quotients
▁1.1-1.9).
lingonberry
ulom
achnoid
▁12.2%
▁414
=.09
▁antibod
elow
▁quoti
odeine
▁400
▁eryth
▁surveyed
62).
9-2.
▁congen
▁experim
▁atti
▁extrap
▁39,40
▁malignancy
sweetened
▁1.1-2.4),
▁0.43
▁0.40
▁confirmatory
▁25.3
Effec
▁abdom
absor
4.1
hep
▁audiological
]=3.
▁133
-4.16)
oniaz
-0.85).
-0.99
arl
eptic
armacology
alic
risks
-1.6).
enaf
zati
opause
▁lumbos
▁clind
ulose
▁therea
ardl
▁carbam
etoprotein
▁ketoacidosis
llerg
9]),
▁limbs
apab
▁volun
▁bleed
ticulous
▁gynecology
▁36.4%
:3
▁awake
▁(8%)
▁unad
DCAs
▁603
eedback
<.00
8-1.
iru
▁Acetaminophen
▁Newly
▁postoperatively
tial
▁melanoma
efinite
▁Chlamyd
ranasal
promised
▁belts
▁ABR
▁uni
acute
ralgias
▁succin
▁suspicion
▁DEE
ormaliti
elg
514
▁nonsmoking
▁diz
▁emboli
eftri
xpect
ersensi
51%
idone
asur
erant
upunct
▁methylphen
▁(38%
▁eac
▁antiather
cepti
eature
▁scler
glycerid
▁immunity
]=0.60;
▁uncer
ndid
3.2%
irin
Ce
▁chemotherapy
=12.3;
▁disad
▁inqui
nigh
ogeneity
7-1.
▁lipophilic
5.4)
brachial
▁excoriation
mpl
▁suppositor
▁Escher
▁40.4%
tomies
▁weaknesses
▁Neuro
▁43,7
▁33%
xylitol
▁220
inbur
697
▁98%
▁349
adism
idaz
▁(25.
▁ince
▁Propioni
usat
▁standardizes
xet
=91)
/99)
▁Oral
▁(21%).
▁Parameters
▁whee
degree
xyc
▁Systematic
▁lowering
▁attrib
strain
▁Individual
▁cytoch
▁0.28-0.
tenc
▁11,000
Gs
xants
ightforward
-0.1
dosterone
-97
▁TS
▁emerg
rolatum
012
▁sulfonamide
▁validated
▁diets
▁secondhand
▁164.
ostatic
▁compre
erectomy
lness
▁lessen
▁76
ndos
=7;
▁(792
▁methodology
▁1.2,
▁2.6-4.
▁glarg
▁0.47-0.61).
<.0001)
▁43,
gestrel
▁Manipulative
▁440
wax
▁thrombus
ilirub
▁1364
▁venlaf
▁spirom
ococcus
3.9;
-2.58
6)-
▁65%;
ioam
▁tenosynovitis
▁Detectable
ioa
opidog
LVD
▁acycl
▁presum
prohib
esson
▁reinforce
-13.16
Aer
▁assessors
8.3
ophyllin
▁29%
omogene
saicin
▁699)
oplasty
-23.21)
ditions
9);.
onger
mentous
▁21,752
73;
dural
7-5.4)
▁2002.
▁elbow
CMT
=0.39;
ibbs
▁261
IVP
acerv
ooling
efol
▁reiter
uspirone
▁wou
▁stabilizers
▁0.93
▁1.5-
hydropyridine
oided
▁3.0
oyl
aryng
▁RS
charged
▁sucr
proximately
-6.2).7
▁795
▁1.7
▁acetylc
rigid
hul
urren
=0.5
5.8;
ultu
73).
▁Invigor
Fine
.0-
▁critically
▁treata
owes
ulia
locker
-40%).
xu
▁22
neys
dver
▁Apgar
▁analogue
ferr
esquam
00%
▁Antidepressants
▁311
ualiz
(7
uterized
=15.
▁ascertain
▁metastatic
alcem
upture
oxyl
ephedrine
▁medroxyp
▁scans
asthma
trob
efib
rover
-7
inally
fractions
ardiovascular
▁-4.52
ioch
lipid
50/85
weekly
▁(1.39)
weightbearing
▁enro
▁cylinder
▁transthoracic
▁glenohum
▁recep
▁Hypertension
troac
▁benign
rosomia
▁3.85%
▁0.74-0.99)
0%,
▁indigent
94).
givers
endron
sif
▁simplification
afle
83,
accuracies
leens
irubin
▁interac
▁12.
▁antif
▁verification
Cataflam
inac
▁aggl
NBSS
▁20-57).
▁backgrounds
isad
▁2.26%
▁abil
▁Combin
ingonberry
specificity
▁Austr
bance
0).
-2.0)
▁detectable
-33.0%).
thin
<.
yloph
91;
ytes
▁unclassified
isabling
Hal
arthritis
▁thes
▁Nuv
▁doubl
▁10%-5
teroscopy
▁losartan
HERS
ystematic
IRR
ependent
16
▁326
▁varicella
▁microorganisms
rosis
tish
▁nebuliz
▁ingredients
▁overlapped
eterose
69).
ounders
5-0.94)
Fac
erestimated
elts
▁lavage
aproxen
,880
oscopic
-12
▁carbohydrates
▁1.3-5.3).
▁2994
ivilian
▁AACAP
▁PP
iplinary
▁myal
=0.17;
2.7;
49
icad
bef
-1.8).
▁bac
=2
eclamp
▁otoac
epl
▁adulth
olv
3.67,
▁nontoxic
▁Insulin
-70%
nisone
inqu
ressi
enstrual
▁Effic
0%-3
55;
▁2.9-1
00
▁1.5;
▁enrollment
rologic
▁restr
iacin
loramp
-92%
bab
▁45%-48%
thad
▁Scandinavian
riat
▁Insu
ostm
utan
pecial
orectal
▁cromogly
uror
▁vasoc
azap
▁covari
9.5%.
▁323
▁sickness
▁Doppl
=1.5)
▁insurance
▁(88%
4-1.69)
=3.9;
▁psychop
erapies
▁audiometry
ygi
ytology
▁electrolytes
▁surgical
osartan
▁CIs
▁Recently
▁(63
vements
-0.71;
▁Lamisil
=1.5
▁posttest
ometheptene
-7.0).
▁antiatherogenic
10-3.77).
▁79.6%
arynx
otl
▁nonb
▁sorb
reatly
▁defecation
alteparin
<7
▁Phenytoin
neezing
▁(15%),
9.1).
▁Bisphosphonates
HB
ferrin
=338)
▁0.21-0.85)
artm
▁estro
4.9)
tiapine
▁asymptom
bumin
osy
5,8
▁<3
▁Aid
=4060),
trast
itly
2,60
▁uninterpretable
▁1.1-2.8)
▁SIDS
▁curet
were
▁adipos
-1.9).
akth
▁demonstrable
▁58
3.6
=-57.9
▁Odds
▁chemoth
▁menop
▁transluminal
▁56%.
havioral
-69.6%);
lys
▁urethritis
hered
izab
dration
ulariti
▁(0.4
restricted
▁Atrial
ideation
▁apnea
▁compli
34-6.07)
osab
=17),
▁sulfox
Ae
oxycyc
-220
tiate
10,000
Bri
ithi
-5.85).
▁hypercoagul
tillate
▁hepatoxicity
unate
=.001
1.5
▁juven
chloride
Mild
rements
▁217
ourescence
▁Shorter
prothromb
▁Curettage
predic
▁ston
iates
▁23,130
/90
▁74%
tive
linical
-5.8
ulopathy
8-1
▁mech
oxazosin
▁2.03
actere
0.2
▁attenuation
▁MI
.8%
=2.9
pecifically
▁ech
▁servic
ronchoscopy
IPID
▁magnitud
▁6.41
▁eradicated
▁nondepress
▁Synvisc
Hashimot
anif
acies
06).
▁150,
▁135/85
lodipine
▁<25%.
treat
apartum
▁tio
▁choos
errit
▁5.2%
ognize
9-1.6
assessed
ifene
▁expressing
=165)
RCA
atoxic
published
▁16.1
▁(93
6-1
34.
osive
▁meticulous
-4.9
istle
ergies
-99.
▁Eye
▁0.77
56.
rouped
2-41.8)
0/
raclavic
eoper
▁targeted
erus
ecule
2]=57%;
<.05;
.0]),
6-0.94).
llees
4).
▁150
=9
▁OBP
▁(60%
▁otoacous
▁nutrition
▁0.41
▁radiography
▁Divalproex
erapist
nionitis
domen
=.023;
▁presc
▁metoprolol
EPDS
atology
▁exag
▁hazards
▁acup
ALM
▁restric
ecome
3.0
amc
▁9%;
Ir
gents
=.02),
imecrolimus
▁vancomycin
▁hemofiltration
asth
=.0015).
265).
thly
emoc
emicals
▁unswe
▁mep
▁>6
=4;
▁jeop
▁homeopathy
▁decline
▁(478)
▁dermatological
arcin
▁gradual
▁0.497-0.97)
▁(>10,000)
rro
▁dye
▁Omnipa
▁Tongl
omerular
osamine
▁(34%
ysterectomy
HDL
admill
▁Escherichia
▁manag
-4.1),
22,
plo
▁1204
tio
▁citations
DNT
trati
▁-4.
anometry
▁parenting
evi
naires
carbohydrate
=2-
urves
▁212
ulable
mace
intestinal
inavian
endoc
ekly
▁Tong
▁degre
]=7
▁CBC
▁diagnoses
amn
▁interf
ritant
▁Unfortun
4;
▁survi
reakf
olisms
8.9%
▁inadequately
predominant
entax
▁0.12-0.77;
▁seroton
▁1.52-9.12),
ysterectom
▁60.
▁-6.
-2.22
rolim
▁18
▁headaches
▁perforation
0%-100
pite
lep
▁73
▁Beres
ergens
uag
▁75
esium
23%
00,
▁outflow
▁detec
tically
orps
-1.01;
▁1.1-2.0
iopsi
USPST
ully
bact
▁deat
icati
▁insufficiency
OAPP
3.67
▁conjun
uniti
heavy
▁universally
1-0.8
ormance
▁serop
oard
▁0.59-1.63)
reatm
itig
1.3.
▁anesthes
▁anticoagulant
▁Subjective
ibrillation
utics
▁abscess
alid
▁restless
▁switches
uide
erties
oxazol
etiriz
nowl
]=0.63,
▁1.5%
=5.7
▁Interpretation
efaz
▁(10/120
▁suppressed
zide
=94
imally
=55
▁exis
▁aty
▁0.016
Wal
iotro
Motr
▁MH
▁chann
affec
struction
lls
7.9
▁(43
▁0.12-0.71,
ysuria
irical
aline
=1.18,
reating
eralized
fed
nbrel
▁Antiseizure
alding
etimibe
▁30/70).
▁reactive
yclov
▁reiterated
rected
tent
2500
▁(0.5
20.
▁empirically
▁insomn
▁leu
ormaliz
▁Thir
▁PDSR
ctivi
ilirubin
etrial
▁93
▁inhalations
-9.4
Ment
▁>7.5%,
hies
otably
-50%
▁isome
ipr
Morbid
anom
▁14-35;
nate
menstrual
▁(9%),
▁Estrogen
mput
▁lowered
730
▁acut
▁ect
▁Adh
▁0.19
▁verapamil
▁influenza
ximetry
▁Epidemiological
seling
ylase
▁Barrett
-11.9
▁balding
▁738
▁visits
45%
▁tors
Veter
=0.54;
▁0.56-0.9
▁0.016-1.
roxyprogesterone
▁whoop
ventric
▁mastoid
▁<.001)
timate
edipine
▁39%,
cified
▁Therap
particular
▁38.0
▁50-79
opid
stetric
combination
=.04),
▁Ralox
ossi
▁bismuth
▁cough
▁Belc
▁boxers
etoconazole
▁hypoman
eutics
▁-2.
▁methim
805
ternet
sulfonylure
▁0.04-0.20).
▁1.52
oacetic
▁Mankopf
▁25%;
55);
▁underestimated
▁presumably
oful
▁0.35-0.5
ephrop
▁allevi
▁1600
addell
-2.20
▁Antepartum
▁terti
▁Otherw
▁Insoluble
hys
ourin
gold
▁Invigorating
▁reh
esemia
=7).
▁TM
ustralian
roidectomy
roscopically
ividually
▁(24.3
bonate
/108)
▁pig
▁tibia
inations
troke
▁introd
-65,
RCT
▁interfer
▁unblinded
▁8.6%)
ecutive
iabl
allergen
rast
▁daytime
vival
▁270
emain
▁unrestricted
amaging
OMM
cinated
=0.7
=40),
▁41%
ublication
▁hemorrhoids
essionals
▁Ramipril
▁0.75,
▁perioper
tisite
30-1.73).
gone
otranscobalamin
▁doxazos
▁nonsel
uvaR
▁fluoride
limin
▁Carotid
atients
▁15.47
▁contraceptive
gou
▁irritable
▁antifungal
▁0.45-2.20).
▁aggressive
▁antiseizure
phoric
45;
ugment
plenectomy
▁genot
plen
=1.51;
▁CST
ixt
Pn
▁1.07-1.8
Ven
▁petrolat
poc
converting
▁somnolence
▁strain
tiz
=0.29;
▁5%
drom
ucle
trates
▁Expectant
▁nonexper
▁tuberc
illion
reit
▁(97%)
12-0.9
Mast
]=1.8).
ransition
itr
450
▁55.8%
▁Catastrophic
88)
▁usag
bj
▁Diets
▁0.8.
▁sulbactam
9/188)
Tric
▁monteluk
▁0.87
berc
ltrasonography
▁proges
-1.9
25).
-99;
verific
atherogenic
▁fourths
Gyn
▁Replacement
sartan
ephalosporin
alc
▁2.2
▁50-72)
▁reviewed
▁accounting
▁seronegative
▁4.9
-0.6
ensitive
omit
▁aggre
<4
▁0.19-2.33).
▁extre
etail
elective
▁bronchodilator
airment
oriz
-0.87)
▁unadjus
encep
-10.6
1])
▁pn
▁(77%)
-1.68)
vative
mati
ialist
rear
▁(5.0
-1.09).
-7.0
]=14.3).
▁Cough
ipidemia
▁0.5-1.
1.9]),
▁10%-50%).
]=3.12
apart
ghts
▁labo
tested
thrography
3.
RIs
sover
▁toil
▁-0.1
acou
irid
▁3.6%
▁desat
ticon
,536
-2.7]),
elding
atty
ometrial
▁hou
hances
▁stren
organic
▁nonin
▁13%),
▁abnormalities
ribon
2).
lter
acrolimus
▁clothing
followed
-1.09)
▁lymp
toler
ullip
upraspin
isap
itudinal
=2.67;
]=13-17)
opos
▁simplex
▁tiotrop
▁hypo
ravachol
▁polycystic
ighty
sychop
embol
Ef
plications
▁hemochrom
▁Endpoints
▁9.0-9.4)
▁6.3-41.4).
-0.57).
<.0001,
eflex
▁94
▁ceft
▁4000
▁HI
▁66%
GIC
▁regulating
mE
-2.91;
▁peritonsillar
▁thems
▁12-80
▁0.10-0.28).
▁stool
▁diverticular
▁61
▁ong
▁propionate
ompazine
▁0.44
▁lowmolecular
,133
3-0.88).
actorily
▁birthweight
▁Changing
▁CAP
-42.
ightfor
▁sunlight
thw
▁Adverse
31).
▁Blin
▁Centor
aril
amcinolone
weat
▁29,13
▁stercul
ipro
▁97%,
▁inade
▁etanercept
▁occupational
wives
▁thrombosed
eclam
eph
rimester
▁methotrexate
▁Consumption
5-0.79;
▁intratesticular
laxation
=90
iability
eled
▁OCs
andidiasis
▁anhydr
restr
▁1.26
NES
volving
-21.2
quently
06;
inid
13.
▁37
waren
veries
arameters
respective
omized
WO
=8.
-2.1
=4.3;
nation
76;
proac
istamin
▁impingement
▁undi
vestigat
▁2.9
▁SSR
]=0.5
▁TD
duces
▁orre
▁0.3/
▁autos
olism
▁186
67;
▁Disorders
gative
153
pital
erts
33.
▁creat
linding
gine
26;
inim
▁pretreat
▁specialists
6-0.92;
-99.6%
ranb
ndred
itol
▁mast
verted
▁outlet
CNBS
▁carti
▁obstetr
▁nonproteinuric
arction
▁nonres
erythem
elograp
▁exagger
-0.96
▁deliveries
umatic
▁1.15-1.98),
lycemia
▁semen
ranber
asmic
▁verbal
neumoc
henaz
57%
etoprolol
▁VT
▁outpati
proex
eosporin
tiven
▁Chec
ondh
,24
onsm
Cylert
▁65
omorbid
-7.1
valents
-2.8),
▁Antico
7-1.47).
0.9).
▁strangulation
▁0.5
4%;
agnos
▁neurogenic
=.000
titrated
▁70.7%
igible
titutes
verall
economic
8-1.11),
athematic
econ
▁preschool
laq
intest
▁palpable
▁sterc
2)
6.).
8-10.
▁81).
▁theo
▁Dri
peraz
-2.99;
ndic
▁earli
olpos
ommending
DCS
▁1986
30
▁reinfection
ogniz
▁carcinomas
identif
▁dehy
omatic
valp
ourages
cemia
▁flutic
▁nec
▁tamoxifen
▁(54%
-]=0.
NSAIDs
tud
▁asplenic
▁Coc
▁POCkit
kotri
▁magnit
373)
▁5.11
.7%
utcom
000/
enog
ewhat
emid
(0
centric
missed
22,012
ailu
osage
effective
=1.1
abiliz
20,000
itain
▁intraparenchy
▁decarbox
▁(61%
icter
▁prescrib
▁weighing
▁ivy
iscence
valuations
nres
▁margins
urmur
▁Parag
6-7.54)
▁triamcinolone
▁synovi
alonic
mitus
nography
▁Recurrent
clavulan
ximet
onsum
tory
acl
▁Curren
▁causation
nish
-5.37),
agulated
xce
scha
▁refle
▁intermed
athyroidectomy
oxifene
▁subf
▁managing
▁7.1
improved
/0.89,
5%-5
▁medro
ismu
▁319
onance
▁guaifenesin
2-14.
andm
▁399
gery
epez
orking
iclovir
BV
artile
igor
romes
odiazepine
enzac
▁7.5%.
01,
-4.8)
-3.8,
▁Nex
▁Coronary
▁(250
▁2.5-5.
itially
ripl
,23
toin
▁cram
▁systol
▁trichomoniasis
apled
6.2).
ureter
▁cere
▁10,
leges
▁Guidelines
ormalized
38)
RRR
9.4;
▁digox
coronary
chondro
antrum
enol
68),
algia
enteral
▁5.2-8.4).
▁cytology
permint
osphon
tussive
▁nedocromil
venture
▁inversely
▁42.1%-69.6%);
▁strok
ersome
aterials
lorp
▁(1/1
opian
▁acetic
▁1.1-1.5)
osel
adyc
novi
▁dysphoric
relates
achial
ocol
-1.88;
othi
ulth
volum
unately
=0.86;
-56.89
omnograph
3%).
▁0.13-0.88).
▁neonatal
▁adn
▁bolus
▁18,816
▁>64
▁purulence
▁Opinion
▁prognostication
ortab
▁transcription
▁42.1%-69.6%
▁42.8%
unre
▁IVC
apr
ublications
1-0.7
inki
▁acqui
▁sensitiz
▁0.59
ogenic
▁6.3
istolog
riaz
▁nort
▁excruciating
enicil
▁3165
8-1.33).
valency
Ul
84%
▁6%
▁DSM
arachnoid
▁2.5,
▁toxicity
▁wea
15),
▁indom
couraging
.3-42.4)
mok
▁intercourse
armf
▁Foll
▁56,
▁86.6%,
complicated
exposed
usions
abdom
▁incar
▁thic
▁6-36),
▁0.63;
amet
atological
ranean
▁pyrazinamide
▁pregn
ighes
Sy
biti
acorpore
▁bladd
openh
ayna
▁oral
▁strate
▁infar
eving
3%.
erin
genism
▁encouraged
98.
tices
Oth
eek
isone
munotherapy
erf
▁flunariz
▁ALLHAT
▁20,
adycard
SOAPP
8-4.
▁decongestant
seud
▁CHF
▁outweighed
alysis
CAs
▁0.11-0.
▁brisk
ientif
=1.2
FIRM
▁100,00
▁Urine
0.4%
ipat
petence
sists
▁3.0-19.
▁atop
mpiric
▁sunburn
05%
Rs
sant
,00
▁unwant
▁paracervical
-2.1).
▁cortis
▁ICU
▁(84%)
22),
▁200-600
▁isonia
ported
emin
▁140
▁balancing
otriene
▁344
inol
2-2.19)
henop
rengthening
4-0.73)
▁impaired
▁255
otreat
▁chlorhex
▁filtr
▁mortality
2.
▁artic
▁abnorm
▁macroaden
▁ethnic
▁rheumat
▁tric
▁unaffec
]=1.23;
▁quinacrine
esig
▁amenorrh
▁hemat
50,000
▁0.79-5.
negatives
VCA
▁gyn
32).
ylure
▁antigli
elial
▁SOLVD
eat
urys
ionally
>95
▁atomoxetine
▁acanthosis
▁wound
▁154
▁aerosolized
▁enterocol
rani
▁methylp
=1.41;
▁unreport
▁Afric
▁fulf
▁580
▁enceph
uelan
76%
▁=.002
▁2.
▁4%
▁chemically
▁hypnotic
oporosis
athroom
▁antic
yers
arfarin
4.6).
▁130
▁ome
▁11-2
▁1.48-2.05).
ndp
▁surro
isuse
enos
nonfatal
tiq
convention
ransbronchial
▁Authors
▁dichloral
28-20.6).
aspin
acil
irox
▁midwife
Til
▁TCA
▁1501
▁stepwise
=8.3)
▁identically
▁tretinoin
obron
▁pneumoc
▁1.40-2.09);
▁Leuk
▁misoprostol
=0.60
▁latency
▁pref
needle
depressed
▁disabling
nals
▁84%
▁laparoscop
RB
▁arrhythm
roin
40-2.0
reastfed
▁amitriptyline
▁98.
,40
cros
relim
8%).
eop
-8.0
orenal
▁Maddrey
▁Aerob
▁selegiline
earan
=16
samin
4-6
ilator
▁enemas
▁3350
-69.
yrid
urgit
▁bumetan
▁(12
▁441
▁ejac
▁57%.
▁stratify
yld
▁unmetabolized
verticular
▁1.29-1.54).
ecological
tracorporeal
ouns
esonide
▁315
ibromy
=1.1;
lome
<0.0
87
zac
▁hypermen
▁pneumoniae
▁sequenced
▁challenges
ompl
▁(1.58-5.1
ughters
▁fractures
▁(2.4%
▁Trial
▁0.1%
▁lowers
▁glucocortic
50.89
▁Leukotriene
compared
▁radic
▁(32%)
▁0.98-1.5
▁bathing
=60
▁0.43-2.1)
psia
arrative
-12.8)
atient
▁unex
▁urologic
▁avoiding
▁45%
▁explorations
timibe
▁critiqued
=.00
alepl
▁PH
▁gua
uret
throg
llate
603
▁sali
▁nonoper
▁antib
FIR
▁1.4-1.6.).
Sod
cebo
▁dysrhythmias
vul
▁Bacit
nalapril
orpore
etas
▁Fren
▁monit
▁coordination
▁elemental
rthov
specifically
▁8.5
▁279
▁derm
riaxone
▁fract
Dy
▁Outcomes
illus
-1.5
attera
▁1.16
rograp
▁dias
ylophora
▁lymphocytosis
lyc
adir
14
avast
▁8-12
enism
74;
▁0.81-2.
▁questionnaires
▁alpr
▁Excluding
▁excis
▁characterized
uffered
sycho
▁deaths
culation
agiti
reni
edg
▁intracran
opn
▁cortic
▁worsened
proteinuric
▁alternating
▁47%
bearing
.0-15.
▁Breslow
hieved
▁revacc
encom
▁proch
▁quo
-1.06).
▁miscarriage
▁(55%
onary
▁methy
▁>40
▁0.52
enzy
▁acetonide
ipine
▁sterculia
=7.8,
ecad
ghing
tensin
▁Hamil
ongl
▁digoxin
▁0.23-0.79);
ews
9.3%
▁14%
aroti
▁acarbose
17,80
econdh
elive
cati
▁1030
▁invasiveness
pretable
aftif
▁-1.5
▁cranberry
ocio
=.81
▁detri
imited
▁62
lometh
▁adenocarcinoma
etect
osar
▁127
▁discontinued
tizing
▁drain
▁1.17-1.9
▁Venezuelan
▁obstet
agnit
erapy
nment
atastro
oron
▁Reviews
=.26.
▁17.6%
Depakote
▁anticoagulated
ukoc
Rus
▁unavoid
strati
▁Concent
▁hairs
uces
3.3).
-0.96),
▁ELISA
arenter
▁Pravastatin
▁promin
ecif
▁cach
ylic
▁Veter
adine
▁Tylophor
▁0.28-0.8
onep
-4.
▁1.35-7.
giene
unctionally
▁lesson
OCA
▁19.
phetamine
ransamin
Mep
▁sulfas
yroidism
▁regist
▁35.8
=1.
▁4.2%.
aridin
▁PCOS
▁10,001
▁>0.
icis
lity
urac
▁-15
▁cognitive
ransverse
02)
▁lupus
=3).
▁awaren
▁Histologic
TNT
▁tis
71
▁psychophysical
kelihood
3-4
positional
▁30
▁arth
▁resou
▁dermat
rope
viating
ethylene
▁breastfeeding
▁lasting
ortri
▁SSE
=1.82.
04
lysis
▁glycosylated
▁32.7
osterone
]=2
96)
▁Conventional
arred
idias
34
ormational
▁lovastatin
listat
▁0.9;
▁plantar
rebral
▁(0.9%
▁cotinine
▁mmol
▁(80%
▁88%
▁diathermy
methyl
▁whoops
kast
=3.7)
-1.54).
plic
imul
ortends
hout
edrine
urat
rean
aturi
grou
▁symptomat
▁1.10-2.3
Af
▁(0.7%
flam
▁24%
calce
-70
▁adhesive
isord
olof
stro
▁surrogate
hea
2.4;
creas
4-1.5
urnal
▁mainst
▁0.18
▁945
actur
ewing
▁nasopharynge
▁postop
▁Reduction
▁critiqu
▁spasmod
▁diu
▁Sulf
85;
fluoride
▁Finkelstein
-78
▁cure
ifical
▁0.55
▁alth
lc
sulated
aturity
▁multivariate
▁cryog
opard
▁quotient
▁2003
pirone
oxib
odip
obronchial
▁epile
boh
▁nondis
/68)
<9
tiology
7.5%
rini
etam
▁intrac
tatistic
▁2.82-14.5
▁guaifen
892
▁purp
infants
▁1.61-3.41)
▁reactivity
▁veterans
▁arthrography
eum
▁64;
27.6
inland
▁malformations
cinom
▁nonselective
]=0.59;
▁LMWH
▁Adip
ralg
▁Preventive
▁pulse
]=19).
tivitis
bry
▁Pentox
ipril
▁unavoidable
54)
otb
▁meningitis
azepam
7.1).
▁glycol
etform
15%
▁(251/367;
aryngeal
orol
▁heartburn
ergo
5.9
86
entati
ormation
ectas
▁essenti
▁neomycin
▁0.78-1.5
▁1.30-1.7
Mono
▁4.7
intestion
izop
116
involving
▁clotrimazole
emaining
▁27,45
▁1.63-4.
▁68,297
ypog
▁>10,000
modified
3.7%
oints
urti
nead
acip
tomat
▁diuretic
enstr
▁(9.9%)
ework
▁headache
▁confirming
=96,
asotec
▁cephalosporin
astrointestinal
▁Cros
▁sero
cholog
bilify
▁derange
▁Dysfunction
Blin
lal
▁squam
▁expectancy
▁autoantib
ermati
goph
18
▁indications
=5;
3/0.
▁0.14-0.5
▁consul
▁1.02-1.9
▁horm
rhy
astati
▁Parental
strac
Nul
▁eld
▁Cardio
assified
tomized
levating
nalizing
supraspinatus
valen
▁(7.2
jum
▁baths
ARR
=126
▁terat
▁9031
▁adversely
antity
1-0.
▁trimethop
▁witho
▁stringent
displacement
ortality
osal
chlorper
thr
iuri
nus
▁95%,
.45
▁Generaliz
unres
-125,
▁>50
trophy
▁tympanos
eteri
▁influenti
▁abnormally
-]=0.02)
▁sulfoxide
▁dysfunction
▁resonance
▁1.04
ealand
▁dips
▁dyspl
loid
▁sput
31
▁clemastine
▁hose
▁vulnerable
▁beneficiaries
0,000
▁posttus
▁correspondence
depres
ergonomic
enoterol
12-0.
odular
▁orthost
-1.01).
▁stokes
atogenic
▁60
pri
=9),
▁atheroscler
eterol
▁0.08
tla
arent
▁heigh
hexyphenidyl
2-0.2
4.0
▁percentag
essary
▁dela
enofibrate
▁postpr
▁(0.44;
imv
▁casein
ulb
▁2.66-10.
▁prophylaxis
icated
▁taper
riptine
oxetine
reases
▁1.5-7.
▁91%
osyl
▁footb
caro
icac
▁instrum
ucat
Gl
eteroph
▁saphenop
▁13-20
oxaparin
ylphenidate
▁frem
▁cisapride
=110
ercis
▁1154
thletes
▁primro
isop
-1.1
▁1.2-1.
=0.3
seve
otypes
Myc
▁Cancer
▁wom
▁ches
▁declined
▁antio
▁Nul
▁reproduc
Wes
astroph
atric
>14
▁Expulsion
▁pregnancies
41
▁0.36-0.7
▁25.1%
▁Intensive
▁Stress
timately
athi
▁inadver
▁ovar
1-1.0
amom
finding
emal
-10.7).
3-2.74),
progestin
-0.42).
900
2-7
▁0.69
▁cephalex
▁Additional
▁Iber
▁thrush
▁77%-85%),
Lipitor
STF
▁overview
wb
onyl
Rand
23
250
05
▁0.67;
▁(4.0
ocalcemia
emergent
▁(18%)
▁4.8-13.7),
significantly
iric
yla
idely
Nap
▁60.5%
arob
ranes
▁uncom
▁340
▁15%
▁10.2
▁acyclovir
atoid
,88
turned
▁ThinP
▁ligamentous
inorrh
▁Likew
96,
▁99.5%.
=7370),
▁assay
▁furosemide
ereditary
]=1.6
▁117
010
orazep
=1.21;
▁nonrig
oneus
▁nightly
▁0.06-0.29).
ielded
74)
109)
xte
-1.2
▁contraception
▁colpos
sulfonylurea
▁ARB
-14.7)
▁vulvovaginitis
-3.35)
arette
ducted
▁Americ
Mos
efec
▁Ey
Crocus
▁distillate
▁0.81-1.07),
oxidants
▁PPV
=50
-0.97),
8).9
lyt
▁systematically
▁possi
2/
=5).
somn
iminating
-1.5)
oniae
▁autoim
isoxazole
nause
hyla
-0.7).
▁diab
yre
▁exhibiting
-=0.14
erbilt
7.5%,
▁herp
onucleosis
32.
iiti
yro
▁meth
oxi
opted
othyroid
▁wash
respec
earc
tir
9500/
▁peron
▁1.24
▁57
6.0
▁embryoplacental
atement
▁20-35
iatry
▁229
▁bedroom
uver
▁0.78-1.58).
Dri
=0%
ransec
6-5
resectoscopic
enil
25,
▁Treat
▁schiz
▁tertiary
-0.99)
iatro
▁5.2
▁(47/34
arenchy
▁6%)
gesting
▁substit
▁SPF
antar
▁uteri
Benzac
.09).
▁theore
▁>140/90
justing
ventive
seizure
avail
eprazole
▁5353
▁infrequent
▁basal
exc
▁196
ioc
▁unsch
allium
▁anxiolytic
apable
▁uncirc
▁1.36-2.24)
rangulation
<0.05)
▁dehyd
ucasians
▁66-7
09).
▁stratif
topril
pti
▁tenosynovi
eson
menting
iap
yster
▁0.88-1.11),
▁athletes
ococcal
▁neuror
rove
=46
]=4.
cents
opical
08;
average
roo
dti
owering
▁irrigation
-0.96;
▁disturbances
6.0%
▁problematic
4-2
▁73%
ooxy
▁Tran
itou
tress
,816
▁luteinizing
▁interacted
alex
arri
▁identif
8%),
▁88%),
=0.56;
▁2001,
itrofur
89;
▁protective
-6.29).
▁dopamine
▁assa
assium
▁1731
olamine
▁0.12-0.
ipoc
outine
▁anticoagulation
3),
▁androgenic
rur
ocytopen
pharmacological
▁subjec
onerg
rared
uar
pecified
▁recurren
8/0.8
bulating
▁behavi
xed
-16
estation
▁72%
